# Guidelines for the Management of Conditions Specifically Related to Stress

mhGAP

World Health Organization

# Acknowledgements

# Table of content

# Glossary

**Acute traumatic stress symptoms:** Symptoms of intrusion, avoidance and hyperarousal in the first month after exposure to potentially traumatic events.

**Cognitive-behavioural therapy (CBT) with a trauma focus:** This therapy (CBT) is based on the idea that people with posttraumatic stress disorder (PTSD) and acute traumatic stress symptoms have unhelpful thoughts and beliefs related to a traumatic event and its consequences. These thoughts and beliefs result in unhelpful avoidance of reminders of the event(s) and maintain a sense of current threat. Cognitive-behavioural interventions with a trauma focus usually include (imaginal and/or in vivo) exposure treatment and/or direct challenging of unhelpful trauma-related thoughts and beliefs.

*The term cognitive-behavioural therapy (CBT) with a trauma focus is synonymous with the term trauma-focused CBT (TF-CBT), as used in the National Institute for Clinical Evidence (NCCMH, 2005) Guidelines and in Cochrane reviews (e.g. Bisson & Andrew 2005). It is noted that in the traumatic stress literature the latter term also has a more narrow definition for a very specific and widely disseminated multi-component CBT protocol for children and adolescents developed by Cohen and colleagues (2000).*

**Early psychological interventions:** Psychological intervention delivered in the first month after exposure to a potentially traumatic event.

**Eye movement desensitization and reprocessing (EMDR):** This therapy is based on the idea that negative thoughts, feelings and behaviours are the result of unprocessed memories. The treatment involves standardized procedures that include focusing simultaneously on (a) spontaneous associations of traumatic images, thoughts, emotions and bodily sensations and (b) bilateral stimulation that is most commonly in the form of repeated eye movements.

*Like CBT with a trauma focus, EMDR aims to reduce subjective distress and strengthen adaptive beliefs related to the traumatic event. Unlike CBT with a trauma focus, EMDR does not involve (a) detailed descriptions of the event, (b) direct challenging of beliefs, (c) extended exposure, or (d) homework.*

**mental health Gap Action Programme (mhGAP):** The mental health Gap Action Programme was launched by the World Health Organization in 2008 to address the lack of mental health care for people especially in low- and middle-income countries. This program included the formulation of evidence-based guidelines for use in non-specialized (e.g. primary care) settings.

**Problems and disorders specifically related to stress:** These problems include posttraumatic stress disorder, acute stress reaction and bereavement reactions.

*There are numerous other stress-related disorders and problems (e.g. depression, behavioural disorders, alcohol/substance use problems, self-harm/suicide, medically unexplained somatic complaints), but these are not specifically related to stress (i.e. they also occur in the absence of identifiable stressful life events) and these have been covered previously in WHO mhGAP Guidelines.*
*It is anticipated that acute stress reaction will no longer be classified as a mental disorder in ICD-11 and, accordingly, the current guidelines make recommendations for symptoms of acute (traumatic) stress rather than for acute stress reaction.*

**Psycho-education:** The provision of information about the nature of a mental disorder and its symptoms, and what to do about them (Wessely et al., 2008).

**Psychological debriefing:** The promotion of ventilation by encouraging the person to briefly but systematically recount perceptions, thoughts and emotional reactions experienced during a recent, stressful event (WHO, 2010).

**Psychological first aid (PFA):** Humane, supportive response to a fellow human being who is suffering and who may need support. It entails basic, non-intrusive pragmatic care with a focus on listening but not forcing talk, assessing needs and concerns, ensuring that basic needs are met, encouraging social support from significant others and protecting from further harm (WHO, 2010).

**Stress management:** Psychological treatments that use cognitive or behavioural techniques (e.g. relaxation, stress inoculation training) that do not focus on the traumatic event (Bisson & Andrew, 2007).

**Structured psychological interventions:** Psychological interventions that go beyond general application of psychological principles of care that are part of health and social care. Examples of such principles of care are good communication and mobilizing and providing social support (cf. the mhGAP Intervention Guide, p.6, WHO, 2010).

**Symptoms of acute stress:** Psychological symptoms in the first month after exposure to potentially traumatic events.

*Examples of such symptoms include:*
- *Acute traumatic stress symptoms (defined above)*
- *Dissociative symptoms, including somatoform conversion*
- *Enuresis (bedwetting)*
- *Hyperventilation*
- *Insomnia.*

**Universally applied bereavement interventions:** Interventions that are offered to all people who have experienced bereavement, regardless of whether bereaved people are experiencing symptoms of mental disorder.

# Executive summary

## Why these guidelines were developed

There are currently no suitable, evidence-based guidelines for managing problems and disorders related to stress in primary health care and other non-specialized health-care settings. Agencies working in post-conflict and natural disaster settings are increasingly interested in mental health care. This requires the development and testing of a module on the management of problems and disorders specifically related to stress.

## Objectives and scope of the document

This document was developed to provide recommended management strategies for problems and disorders that are specifically related to the occurrence of a major stressful event. The recommended strategies will form the basis of a new module to be added to the WHO (2010) mhGAP Intervention Guide for use in non-specialized specialized health-care settings.

The scope of the problems covered by these guidelines is:

- symptoms of acute stress in the first month after a potentially traumatic event, with the following subtypes:
  - symptoms of acute traumatic stress (intrusion, avoidance and hyperarousal) in the first month after a potentially traumatic event;
  - symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event;
  - non-organic (secondary) enuresis in the first month after a potentially traumatic event (in children);
  - hyperventilation in the first month after a potentially traumatic event;
  - insomnia in the first month after a potentially traumatic event;
- posttraumatic stress disorder (PTSD);
- bereavement in the absence of a mental disorder.

## Who should use these guidelines

The primary audience is non-specialized specialized health-care providers working at first- and second-level health-care facilities. They include general physicians, family physicians, nurses and clinical officers. They also include those specialist medical doctors who work in areas other than mental health and substance abuse, such as paediatricians, emergency medicine physicians, obstetricians, gynaecologists and internists. A secondary audience is those tasked with the organization of health care at the district or sub-district level, including programme managers responsible for primary or non-mental health secondary care services.

## How these guidelines were developed

*Guideline groups:* A WHO steering group comprising members from relevant WHO departments (see Annex 1) was set up in May 2011. This group established the provisional scope and selected members of the Guideline Development Group (GDG) to reflect all regions and appropriate expertise and to achieve a gender balance (see Annex 2). A larger group of external reviewers (see Annex 3) commented on the evidence profiles, draft recommendations and final documents. Their comments were considered by the GDG.

*Evidence search and retrieval:* The WHO Secretariat initially proposed scoping questions that were modified and agreed upon during three rounds of electronic consultation with the GDG. Further consultations with the GDG involved review of scoping questions phrased using the PICO (Population, Intervention, Comparison, Outcomes) format. Outcomes of interest were listed and the GDG voted to rank them according to importance.

By the end of July 2011 a set of scoping questions had been finalized. These were then used to guide searches for relevant systematic reviews that had been performed within the last two years and met inclusion criteria (see evidence profiles 1–21 in Annex 5 for specific inclusion and exclusion criteria). Where relevant systematic reviews (a) did not exist, (b) were not recent (had not been done within the last two years) or (c) were not of suitable quality or applicability, new systematic reviews were commissioned. For the new commissioned systematic review on medicines for PTSD, specific additional searches were carried out to identify studies in Japanese, Chinese, French, Portuguese, Russian and Spanish.

*Evidence to recommendations:* The *WHO Handbook for Guideline Development* was followed and the GRADE system for assessing quality of evidence and using evidence to inform decisions was applied to inform drafting of recommendations. For each question, an evidence profile was developed summarizing the evidence retrieved, including discussion of values, preferences, benefits, harms and feasibility. Wherever possible, the evidence retrieved was graded and GRADE tables provided. A decision table was used by the GDG during a recommendation drafting meeting in Amman, Jordan (July 2012) to agree on the quality of evidence and certainty about harms and benefits, values and preferences, feasibility and resource implications (see Annex 5 for details of each decision). The strength of the recommendation was set as either:

> "Strong": meaning that the GDG agreed that the quality of the evidence combined with certainty about the values, preferences, benefits and feasibility of this recommendation meant it should be followed in all or almost all circumstances;

> *or*

> "Standard": meaning that there was less certainty about the combined quality of evidence and values, preferences, benefits and feasibility of this recommendation, thus there may be circumstances in which it will not apply. The word "standard" (rather than "weak" or "conditional") was chosen to be in line with earlier WHO mhGAP guidelines and to avoid the negative connotations of the word "weak", which could have risked biasing GDG members towards "strong" recommendations.

4

# Recommendations

The guidelines have separate recommendations for children, adolescents and adults. For the purpose of these guidelines, adolescents are 10–19 years old while children are younger than 10 years old.

All recommendations come with remarks (see main body of this report). For example, the remarks note that even in instances where there is no recommendation for treatment, all individuals presenting with a potential mental health problem should be fully assessed to exclude physical causes of the problem. Similarly, the remarks refer to previous WHO mhGAP Guidelines (2010) recommendations, such as the recommendation to make available psychological first aid to people who have recently been exposed to a potentially traumatic event. Also, the remarks emphasize applying mhGAP general principles of care, such as good communication and mobilizing social support.

Overall, these remarks help communicate that people who suffer mental health problems should not be ignored and that certain practical steps can be taken, even in cases when there are no (new) recommendations for the management of problems and disorders specifically related to stress.

## Acute traumatic stress symptoms (re-experiencing, avoidance, hyperarousal) after a potentially traumatic recent event (recommendations 1–4)

### Recommendation 1

**(i) Cognitive-behavioural therapy (CBT) with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning.**

*Strength of recommendation: standard*
*Quality of evidence: moderate*

**(ii) On the basis of available evidence, no specific recommendation can be made about stand-alone problem-solving counselling, eye movement desensitization and reprocessing (EMDR), relaxation or psycho-education for adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

### Recommendation 2

**On the basis of available evidence, no specific recommendation can be made on early psychological interventions (covering problem-solving counselling, relaxation, psycho-education, eye movement desensitization and reprocessing (EMDR) and cognitive-behavioural therapy (CBT)) for children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

5

### Recommendation 3
**Benzodiazepines and antidepressants should not be offered to adults to reduce acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.**

*Strength of recommendation*:
  *For benzodiazepines: strong*
  *For antidepressants: standard*
 *Quality of evidence: very low*

### Recommendation 4
**Benzodiazepines and antidepressants should not be offered to reduce acute traumatic stress symptoms associated with significant impairment in daily functioning in children and adolescents.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

## Insomnia after a potentially traumatic recent event (recommendations 5–8)

### Recommendation 5
**Relaxation techniques (e.g. progressive muscle relaxation or cultural equivalents) and advice about sleep hygiene (including advice about psychostimulants, such as coffee, nicotine and alcohol) should be considered for adults with acute (secondary) insomnia in the first month after exposure to a potentially traumatic event.**

*Strength of recommendation: standard*
*Quality of evidence: very low*

### Recommendation 6
**On the basis of available evidence, no specific recommendation can be made for early psychological interventions in children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: low*

## Recommendation 7
**Benzodiazepines should not be offered to adults with insomnia within the first month after a potentially traumatic event.**

*Strength of recommendation: standard*
*Quality of evidence: moderate*

## Recommendation 8
**Benzodiazepines should not be offered to children and adolescents with acute (secondary) insomnia within the first month after a potentially traumatic event.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

## Enuresis after a potentially traumatic recent event (recommendation 9)

## Recommendation 9
**(i) Psycho-education about the negative effects of punitive responses should be given to caregivers of children with secondary non-organic enuresis in the first month after a potentially traumatic event.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**(ii) Parenting skills training and the use of simple behavioural interventions (i.e. star charts, toileting before sleep and rewarding having nights without wetting the bed) should be considered. Where resources permit, alarms should be considered.**

*Strength of recommendation: standard*
*Quality of evidence: moderate for alarms, low or very low for other behavioural interventions*

## Dissociative (conversion) disorders after a potentially traumatic recent event (recommendations 10–11)

## Recommendation 10
**On the basis of available evidence, no specific recommendation can be made on psychological interventions for adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

### Recommendation 11
**On the basis of available evidence, no specific recommendation can be made for children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

## Hyperventilation after a potentially traumatic recent event (recommendations 12–13)

### Recommendation 12
**No specific recommendation can be made on the basis of available evidence on rebreathing into a paper bag for adolescents and adults with hyperventilation in the first month after exposure to a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

### Recommendation 13
**Rebreathing into a paper bag should not be considered for children with hyperventilation in the first month after a potentially traumatic event.**

*Strength of recommendation: standard*
*Quality of evidence*: very low

## Posttraumatic stress disorder (recommendations 14–17)

### Recommendation 14
**Individual or group cognitive-behavioural therapy (CBT) with a trauma focus, eye movement desensitization and reprocessing (EMDR) or stress management should be considered for adults with posttraumatic stress disorder (PTSD).**

*Strength of recommendation: standard*
*Quality of evidence: moderate for individual CBT, EMDR; low for group CBT, stress management*

### Recommendation 15
**Individual or group cognitive-behavioural therapy (CBT) with a trauma focus or eye movement desensitization and reprocessing (EMDR) should be considered for children and adolescents with posttraumatic stress disorder (PTSD).**

*Strength of recommendation: standard*
*Quality of evidence: moderate for individual CBT, low for EMDR, very low for group CBT*

### Recommendation 16
**Selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) should not be offered as the first line of treatment for posttraumatic stress disorder (PTSD) in adults. SSRIs and TCAs should be considered if (a) stress management, cognitive-behavioural therapy (CBT) with a trauma focus and/or eye movement desensitization and reprocessing (EMDR) have failed or are not available or (b) if there is concurrent moderate–severe depression.**

*Strength of recommendation: standard*
*Quality of evidence: low*

### Recommendation 17
**Antidepressants should not be used to manage posttraumatic stress disorder (PTSD) in children and adolescents.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

## Bereavement in the absence of mental disorder (recommendations 18–21)

### Recommendation 18
**Structured psychological interventions should not be offered universally to (all) bereaved adults who do not meet the criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: moderate*

## Recommendation 19
**Structured psychological interventions should not be offered universally to (all) bereaved children and adolescents who do not meet the criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

## Recommendation 20
**Benzodiazepines should not be offered to bereaved adults who do not meet criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

## Recommendation 21
**Benzodiazepines should not be offered to bereaved children and adolescents who do not meet criteria for a mental disorder**.

*Strength of recommendation: strong*
*Quality of evidence: very low*

# Introduction

Traumatic events are common in people's lives. In a WHO study of 21 countries, more than 10% of respondents reported witnessing violence (21.8%) or experiencing interpersonal violence (18.8%), accidents (17.7%), exposure to war (16.2%) or trauma to a loved one (12.5%) (Stein et al., 2009). Stress-related problems and disorders are also common. A meta-analysis of post-conflict studies using representative samples and full diagnostic assessment found that 15.4% of people reported posttraumatic stress disorder (PTSD) and 17.3% reported depression (Steel et al., 2009).

The WHO (2010) mhGAP Intervention Guide (v. 1.0, http://www.who.int/mental_health/evidence/ mhGAP_intervention_guide/en/index.html) provides clinical protocols for non-specialized health care for a range of mental, neurological and substance use disorders, but does not currently provide clinical protocols for problems and disorders specifically related to stress. The latter set of disorders and problems include PTSD, acute stress reaction/acute symptoms of stress, and bereavement reactions.

In May 2011, WHO and the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA) signed an agreement to implement the WHO (2010) mhGAP Intervention Guide in UNRWA health services in Gaza, West Bank, Lebanon, Syria and Jordan. Agencies working in post-conflict and natural disaster settings are increasingly interested in mental health care. This requires the development and testing of a new mhGAP module on the management of problems and disorders specifically related to stress.

The term problems and disorders specifically related to stress refers here to problems such as PTSD, acute stress reaction and bereavement reactions that require an exposure to a defined stressor as a precursor. There are numerous other stress-related disorders and problems (e.g. depression, behavioural disorders, alcohol/substance use problems, self-harm/suicide, medically unexplained somatic complaints), but these are not specifically related to stress (i.e. they may also occur in the absence of identifiable stressful life events) and these have already been covered through the mhGAP 2010 Guidelines and the mhGAP Intervention Guide (WHO, 2010).

## Existing guidelines on stress-related problems and disorders

There are currently no suitable, evidence-based guidelines for managing, in non-specialized settings, problems and disorders related to stress. Existing guidelines do not meet these conditions because they:

- have been developed for high-income country health systems (e.g. National Institute for Clinical Excellence, 2005);
- are for use in specialized care (e.g. American Psychiatric Association, 2004);
- are not based on a systematic review of evidence (e.g. Patel, 2003);
- focus mainly on policy and systems issues (e.g. Inter-Agency Standing Committee, 2007)
- focus on primary health care *training* only (Eisenmann et al., 2006).

Recent WHO guidelines for mental, neurological and substance use conditions are available online through the mhGAP Evidence Resource Centre (http://www.who.int/entity/mental_health/mhgap/evidence/en), which includes evidence profiles on a range of conditions (Barbui et al., 2010; Dua et al., 2011). The guidelines form the backbone of the WHO (2010) mhGAP Intervention Guide (1.0), which contains modules with assessment and management algorithms for different conditions.

## Objectives

The present project addresses the development of guidelines for the management strategies for problems and disorders that are specific to the occurrence of a major stressful event, such as PTSD. These guidelines will form the backbone of a corresponding module that will be added to the mhGAP Intervention Guide for use in non-specialized health-care settings.

WHO guidelines on the health sector response to violence against women are also currently under development and will include recommendations on mental health. To avoid overlap and contradictions between these two guidelines, a colleague from the WHO Department of Reproductive Health and Research joined the project steering group.

## Who should use these guidelines

The primary audience is non-specialized health-care providers working at first- and second-level facilities. They include general physicians, family physicians, nurses and clinical officers. They also include those specialist medical doctors who work in areas other than mental health and substance abuse, such as paediatricians, emergency medicine physicians, obstetricians, gynaecologists and internists. A secondary audience is those tasked with the organization of health-care at the district or sub-district level, including programme managers responsible for primary or non-mental health secondary care services.

# Individuals and partners involved in development of the guidelines

## WHO steering group

An internal steering group drawn from the WHO Departments of Mental Health and Substance Abuse (MSD), Reproductive Health and Research (RHR) and Violence and Injury Prevention and Disability (VIP), and the Eastern Mediterranean Regional Office (EMRO) was set up in May 2011 to support development of these guidelines. The full list of names and affiliations is provided in Annex 1.

## Guideline Development Group (GDG)

The GDG was made up of people with content expertise (non-specialized health care, child and adult mental health, bereavement and traumatic stress, cultural psychiatry and humanitarian response), relevant experience in low- and middle-income countries, and expertise in evidence-based guideline methodology. GDG member selection included concern for gender balance (six of 12 members were female). Members were drawn from all WHO regions and included people from international organizations (International Committee of the Red Cross, International Medical Corps) as well as universities.

Consultants with high-level expertise in evidence review and GRADE methodology supported the GDG. The full list of GDG members and consultants along with their expertise, affiliations and geographical base is provided in Annex 2 and their declarations of interest are summarized in Annex 4.

## External review group

External reviewers were drawn from end-users/partners working in the subject area of the guidelines, such as Disaster Action (a charity run by people directly affected by disasters), Global Initiative on Psychiatry, Médicos del Mundo (Doctors of the World, Spain), United Nations High Commissioner for Refugees (UNHCR), War Trauma Foundation and World Vision International, universities and national institutions (e.g. National Institute of Mental Health (NIMH), Japan; National Health Service (NHS),

United Kingdom). In total 78 people (from all six WHO regions) were contacted to review evidence profiles with draft recommendations, and 22 people responded within the time allotted (two weeks). Their names, affiliations and geographical base are given in Annex 3 and their declarations of interest are summarized in Annex 4. Unfortunately, there was no peer reviewer from the Eastern Mediterranean Region (EMRO).[1]

External reviewer responses were compiled and comments used to inform the GDG meeting discussion of the evidence profiles and draft recommendations.

In November 2012, selected external reviewers were also asked to review an early version of this final guideline document. Their compiled and processed responses should help to ensure that the document is understandable. A limitation of the process was that peer reviewers were not asked to comment early in the process on scoping questions and outcomes.

## Management of conflicts of interest

All nominated GDG members, external reviewers and consultants completed WHO declaration of interest forms. Several GDG members declared interests at the time of their nomination. These were then reviewed by the WHO Secretariat for potential conflicts of interest (see summary in Annex 4). It was decided that none of the nominated GDG members had a conflict of interest that would preclude their participation.

At the beginning of the recommendation drafting meeting (Amman, July 2012), the natures of all types of conflict of interest – financial, academic/intellectual, non-academic – were explained by WHO consultants with substantial experience in WHO guideline development. Each participant then described in detail the areas where they had potentially real or perceived conflicts of interest, including intellectual conflicts of interest. The session took about one hour. At this time, all participants were asked to review and, if necessary, update their declaration of interest forms.

Upon review of the declaration of interest forms, the WHO Secretariat and one GDG member (Dr Seedat) agreed that Dr Seedat may have a perceived conflict of interest on decisions related to pharmacological treatment of PTSD, because she had received financial support to attend conferences (total limited to  $5000 over nine years) from pharmaceutical companies. She recused herself from decision-making and drafting of recommendations involving pharmacological management of PTSD. Dr Cohen, a GDG member who according to her form may have had a perceived conflict of interest related to psychological treatment of PTSD did not attend the meeting.

---

[1] The lack of a peer reviewer from EMRO was compensated by the presence of four Jordanian colleagues (from Ministry of Health, International Medical Corps and the Jordanian Nursing Council) who participated as special invitees in the Guidelines meeting in Amman. The four colleagues were two family physicians, a psychologist and a nurse. All four completed the declaration of interest form, and none expressed a conflict of interest.

# How the guidelines were developed

The guidelines were developed according to the *WHO Handbook for Guideline Development*. For a detailed discussion on the merits and challenges of applying the WHO process of guideline development to the domain of mental, neurological and substance use disorders, please see Barbui et al. (2010).

## The scope

The WHO Secretariat initially proposed scoping questions. These questions included interventions for PTSD, bereavement and a range of symptoms that can occur in the first month after a potentially traumatic event. The questions did not focus on the *acute stress reaction* concept, as it is anticipated that this will no longer be classified as a mental disorder in ICD-11. Similarly, the questions did not focus on the *acute stress disorder* concept (which is not in the ICD), as this concept has poor predictive validity and its utility may depend on the need to have a diagnosis for making health insurance payments (Bryant et al., 2011). After three rounds of electronic consultation with the GDG, it was agreed that the guidelines should cover the management of the following problems in adults and children:

- symptoms of acute stress in the first month after a potentially traumatic event, with the following subtypes:
    - symptoms of acute traumatic stress (intrusion, avoidance and hyperarousal) in the first month after a potentially traumatic event;
    - symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event;
    - non-organic (secondary) enuresis in the first month after a potentially traumatic event (in children);
    - hyperventilation in the first month after a potentially traumatic event;
    - insomnia in the first month after a potentially traumatic event;
- posttraumatic stress disorder (PTSD);
- bereavement in the absence of mental disorder.

Further consultations with the GDG involved review of scoping questions phrased using the PICO (Population, Intervention, Comparison, Outcomes) format. Outcomes were listed, and the GDG voted to rank them according to importance using three levels (critical, important, not important). Individual scores were converted into a 9-point scale (critical = 8; important = 5; not important = 2), which were then averaged, and rounded off to obtain average levels of importance on a 9-point scale consistent with GRADE methodology.[2]

The process of drafting, reviewing and revising PICO questions occurred during June–July 2011, while the priority ranking of outcomes occurred in November 2011. One hundred percent of GDG members rated the outcomes.

---

[2] The spreadsheet files used to collect and analyse these data are available upon request, and we believe that these may be a slight improvement on the traditional GRADE method of asking people to rate the importance of scoping questions. A possible problem with the traditional way of rating is that many respondents who consider a question as important may have difficulties assigning it a 4, 5 or 6 rating if they have been conditioned (though their school grading system) that the values of 4, 5 or 6 are low and thus do not correspond to an "important" rating. The GRADE way of asking participants to rate outcomes on a 9-point scale may create a bias towards rating outcomes higher than intended. This problem may be overcome by asking people to rate using three levels (critical, important, not important) only and then convert these to a 9-point scale.

## Evidence search and retrieval

By the end of July 2011 a set of scoping questions had been finalized. These were then used to guide searches for relevant systematic reviews that had been performed within the last two years and met inclusion criteria (see evidence profiles 1–21 in Annex 5 for specific inclusion and exclusion criteria).

While only systematic reviews less than two years old at the time of the search were included, there were no age limitations on individual studies within those reviews. Although the same interventions were considered for adults and children, separate reviews were done. Evidence from the adult literature was not generalized to children.

Where relevant systematic reviews did not exist, were not recent (had not been done within the last two years) or were not of suitable quality or applicability, new systematic reviews were commissioned. Databases searched include MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. For the commissioned systematic review on medicines for PTSD, specific additional searches were carried out to identify international studies in Japanese, Chinese, French, Portuguese, Russian and Spanish (see evidence profiles in Annex 5 for more detail on search terms, databases searched).

## Evidence to recommendations

While keeping in mind the strengths (transparency) and limitations (low inter-rater reliability) of GRADE, the *WHO Handbook for Guideline Development* was followed. The GRADE system, created to enable explicit assessment of the quality of evidence and use of evidence for developing recommendations, was used. When assessing the evidence base, methodologists (consultants supporting the GDG) summarized the evidence extracted from systematic reviews and meta-analyses into "Summary of findings" tables and graded the quality of evidence summarized in the tables (see Annex 5).

In the GRADE system, the "Quality of the evidence" is defined as the level of confidence that the estimate of the effect of an intervention is correct. The quality of evidence is rated as high, moderate, low or very low quality, as detailed in the table below.

| Quality level | Definition |
|---|---|
| High | High confidence that the true effect lies close to that of the estimate of the effect |
| Moderate | Moderate confidence in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different |
| Low | Limited confidence in the effect estimate: the true effect may be substantially different from the estimate of the true effect |
| Very low | Very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of the effect |

During grading, evidence from randomized controlled trials (RCTs) begins as high quality, while that from observational study designs (e.g. non-randomized or quasi-randomized intervention studies, cohort studies, case control studies and other correlational study designs) begins as low quality. The quality of the evidence is then further assessed. Five criteria can be used to downgrade the evidence. These are:

- **Risk of bias:** limitations in the study design that may bias the overall estimates of the treatment effect;
- **Inconsistency:** unexplained differing estimates of the treatment effect (i.e. heterogeneity or variability in results) across studies;
- **Indirectness:** the question being addressed by the guideline panel is different from the available evidence regarding the population, intervention, comparator or outcome;
- **Imprecision:** results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of the effect;
- **Publication bias:** systematic underestimate or overestimate of the underlying beneficial or harmful effect due to the selective publication (or reporting) of studies.

Three other criteria may be used to upgrade the quality of evidence rating: a strong association, a dose-response gradient and plausible confounding.

During the guideline development meeting in Amman, Jordan, the GDG was provided with evidence profiles summarizing the evidence retrieved, including evidence on values, preferences, benefits, harms and feasibility for 21 questions on specific interventions. Wherever possible, the evidence retrieved was graded and GRADE tables provided. A decision table was used by the GDG during the meeting to agree on the quality of evidence and certainty about harms and benefits, values and preferences, feasibility and resource implications (see Annex 5 for details of each question, evidence search, inclusion and exclusion criteria, decision tables). In several instances the group decided that the lack of randomized evidence on the effect of proposed interventions, coupled with uncertainty about harms and benefits, values and preferences, feasibility and resource implications, meant that no recommendation could be made at this time. This has been indicated in the list of recommendations.

The **strength of the recommendation** was set as either:

**"Strong":** meaning that the GDG members agreed that the quality of the evidence combined with certainty about the values, preferences, benefits and feasibility of this recommendation meant that it should be followed in all or almost all circumstances;

or

**"Standard":** meaning that there was less certainty about the combined quality of evidence and values, preferences, benefits and feasibility of this recommendation. Hence there may be circumstances in which it will not apply. The word "standard" (rather than "weak" or "conditional") was chosen to be in line with earlier WHO mhGAP guidelines and also to avoid the negative connotations of the word "weak", which could have risked biasing GDG members towards strong recommendations.

On the basis of summary text in the evidence profiles on quality of evidence, benefits versus harms, values and preferences (from an end-user perspective) and resource consumption (from a health services perspective), the following **decision table** was completed by the GDG to come to a decision on a strong versus a standard recommendation.

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?** *The higher the quality of evidence, the more likely is a strong recommendation.* | Yes No |
| **Is there certainty about the balance of benefits versus harms and burdens?** *In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?* *In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes No |
| **Is there certainty about the balance between benefits and resources being consumed?** *In the case of positive recommendations (recommending to do something), is there certainty that the benefits are worth the costs of the resources being consumed?* *In the case of negative recommendations (recommending not to do something), is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes No |

On a number of occasions, the GDG decided to give a strong recommendation despite a GRADE assessment of the available evidence on effect as being of "very low quality". This occurred only when the following conditions applied: (a) there was certainty about the balance of benefits versus harms and burdens; (b) the expected values and preferences were clearly in favour of the recommendation; and (c) there was certainty about the balance between benefits and resources being consumed. Occasionally it was not necessary to complete the table entirely when a partially filled table already indicated that the recommendation would have to be standard (e.g. if GDG members agreed that the answer was "No" to two questions, there was no need to ask the other two questions to decide on the strength of the recommendation as it would have to be standard). This saved scarce time during the meeting, given that discussions on the questions for each of the decision tables were often lengthy.

## Group process

During the GDG meeting in Amman, decisions were usually made by consensus, but where there was disagreement a vote was taken and a two thirds majority was required for a decision to be carried. After any vote, GDG members who were in the minority were asked if they would want to reconsider their position. In all cases, this led to at least a two thirds majority.

# Recommendations

The guidelines have separate recommendations for children, adolescents and adults. For the purpose of these guidelines, adolescents are 10–19 years old while children are younger than 10 years old.

It was noted by the GDG that certain remarks apply to implementing all recommendations described below. These are:

**Assessment:** Even in instances where there is no recommendation for treatment, all individuals presenting with a potential mental health problem should be fully assessed to exclude physical causes of the problem.

**Children:** Children's disorders and problems can involve complex interactions between child and parents/other carers of children. It is therefore essential that carers be assessed and educated to manage the child's problem in a positive way.

**Context:** Much of the evidence on which these recommendations are based comes from high-income settings where different sociocultural forces apply. Understanding of context should be recognized as a source to identify people's specific sociocultural coping strategies and resources that can be relevant when implementing the recommendations.

# Specific recommendations

The following text provides the scoping questions used, the recommendations agreed after examination of the evidence, including evidence on harms, benefits, values, preferences, cost-effectiveness and feasibility, and qualifying remarks. For full details of the evidence used and the decision-making process, please consult the evidence profile for each numbered recommendation provided in Annex 5.

## Acute traumatic stress symptoms after a potentially traumatic recent event (recommendations 1–4)

Acute traumatic stress symptoms refer to symptoms of intrusion, avoidance and hyperarousal – associated with significant impairment in daily functioning – in the first month after a potentially traumatic event. Other symptoms of acute stress, including hyperventilation, conversion and dissociative symptoms, and secondary non-organic nocturnal enuresis in children, are dealt with in other recommendations in these guidelines.

Psychological interventions and pharmacological treatments, especially benzodiazepines, have been used to manage people suffering symptoms of acute distress. There is currently no consensus on the effectiveness of such management. The GDG examined the evidence on use of early psychological and pharmacological interventions in adults and in children and adolescents with symptoms of acute traumatic stress syndrome, and made the following recommendations.

# 1. Acute traumatic stress symptoms (first month): early psychological interventions – adults

*Scoping question 1:* For adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in a reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### Recommendation 1
> **(i) Cognitive-behavioural therapy (CBT) with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning.**
>
> *Strength of recommendation: standard*
> *Quality of evidence: moderate*
>
> **(ii) On the basis of available evidence, no specific recommendation can be made about stand-alone problem-solving counselling, eye movement desensitization and reprocessing (EMDR), relaxation or psycho-education for adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: not applicable*
> *Quality of evidence: very low*

**Remarks**
*CBT with a trauma focus should only be offered in those contexts where individuals are competent (trained and supervised) to provide the therapy.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. When combined, these recommendations imply that psychological first aid should be considered in all adults with acute traumatic stress symptoms; and, where competent staff are available, CBT with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event. In situations without sufficient resources to provide CBT with a trauma focus, other interventions such as stress management may be considered in addition to psychological first aid.*

## 2. Acute traumatic stress symptoms (first month): early psychological interventions – children and adolescents

*Scoping question 2:* For children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in a reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> *Recommendation 2*
> **On the basis of available evidence, no specific recommendation can be made on early psychological interventions (covering problem-solving counseling, relaxation, psycho-education, eye movement desensitization and reprocessing (EMDR) and cognitive-behavioural therapy (CBT)) for children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning.**
>
> *Strength of recommendation: not applicable*
> *Quality of evidence: very low*

**Remarks**
*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.*

### 3. Acute traumatic stress symptoms (first month): pharmacological interventions – adults

*Scoping question 3:* For adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do pharmacological interventions (benzodiazepines and antidepressants), when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

---

*Recommendation 3*

**Benzodiazepines and antidepressants should not be offered to adults to reduce acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.**

*For benzodiazepines:*
*Strength of recommendation: strong*
*Quality of evidence: very low*

*For antidepressants:*
*Strength of recommendation: standard*
*Quality of evidence: very low*

---

**Remarks**
*Clinicians should rule out concurrent disorders that may warrant treatment with benzodiazepines and antidepressants.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. In addition, recommendation 1(i) (on psychological interventions for acute traumatic stress symptoms in adults) is that "cognitive-behavioural therapy (CBT) with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning". When combined, these recommendations imply that psychological first aid and (where resources exist) CBT should be considered in adults with acute traumatic stress symptoms associated with impairment in daily functioning in the first month after a potentially traumatic event.*

## 4. Acute traumatic stress symptoms (first month): pharmacological interventions – children and adolescents

*Scoping question 4:* For children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do pharmacological interventions (benzodiazepines and antidepressants), when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### *Recommendation 4*
> **Benzodiazepines and antidepressants should not be offered to reduce acute traumatic stress symptoms associated with significant impairment in daily functioning in children and adolescents.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: very low*

**Remarks**
*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.*

## Insomnia after a potentially traumatic recent event (recommendations 5–8)

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. Insomnia is a commonly reported symptom of acute stress. The GDG considered the evidence and made the following recommendations on psychological and pharmacological interventions for children and adults with insomnia after a potentially traumatic recent event.

## 5. Acute (secondary) insomnia (first month): early psychological interventions – adults

*Scoping question 5:* For adults with acute (secondary) insomnia in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> *Recommendation 5*
> **Relaxation techniques (e.g. progressive muscle relaxation or cultural equivalents) and advice about sleep hygiene (including advice about psychostimulants, such as coffee, nicotine and alcohol) should be considered for adults with acute (secondary) insomnia in the first month after exposure to a potentially traumatic event.**
>
> *Strength of recommendation: standard*
> *Quality of evidence: very low*

**Remarks**
*In many settings, relaxation may be made available through existing cultural practices.*

*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*Health-care providers should explain that insomnia is common after recent exposure to extreme stressors. If insomnia persists for more than one month, the person should be reassessed for other conditions that may need treatment, including anxiety disorders (PTSD, generalized anxiety disorder, panic disorder), depressive disorder and, in adolescents, alcohol or drug use disorder.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. When combined, these recommendations imply that psychological first aid, relaxation techniques and advice about sleep hygiene should be considered in adults with acute (secondary) insomnia in the first month after a potentially traumatic event.*

## 6. Acute (secondary) insomnia (first month): early psychological interventions – children and adolescents

*Scoping question 6:* For children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> *Recommendation 6*
> **On the basis of available evidence, no specific recommendation can be made for early psychological interventions in children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: not applicable*
> *Quality of evidence: low*

**Remarks**

*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. This includes assessment of the child's perception as to why insomnia may be present. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*Relaxation techniques and advice about sleep hygiene (see recommendation 5 on psychological interventions for insomnia in adults) may be safe, feasible and potentially effective strategies in adolescents (age 10-19 years).*

*Health-care providers should explain that insomnia is common after exposure to extreme stressors. If insomnia persists for more than one month, the person should be reassessed for other conditions that may need treatment, including anxiety disorders (PTSD, generalized anxiety disorder, panic disorder), depressive disorder and, in adolescents, alcohol or drug use disorder.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.*

## 7. Acute (secondary) insomnia (first month): pharmacological interventions – adults

*Scoping question 7:* For adults with acute (secondary) insomnia in the first month after a potentially traumatic event, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in a reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

*Recommendation 7*
**Benzodiazepines should not be offered to adults with insomnia in the first month after a potentially traumatic event.**

*Strength of recommendation: standard*
*Quality of evidence: moderate*

**Remarks**
*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*There are alternatives to pharmacological treatment (see (a) recommendation 5 on psychological interventions for insomnia in adults and (b) WHO (2010) mhGAP recommendations on psychological first aid).*

*In exceptional cases when psychologically oriented interventions are not feasible, short-term treatment (3–7 days) with benzodiazepines may be considered as a treatment option for insomnia that interferes severely with daily functioning. The following precautions should be considered: (a) there are possible interactions with other drugs; (b) necessary precautions should be taken when prescribing to elderly populations and pregnant or breastfeeding women; and (c) use of benzodiazepines can quickly lead to dependence in some people. Accordingly benzodiazepines should be prescribed for insomnia only in exceptional cases and for a very short time period. Benzodiazepines are often overprescribed.*

*Health-care providers should explain that insomnia is common after recent exposure to extreme stressors. If insomnia persists for more than one month, the person should be reassessed for other conditions that may need treatment, including anxiety disorders (PTSD, generalized anxiety disorder, panic disorder), depression and alcohol or drug use disorder.*

## 8. Acute (secondary) insomnia (first month): pharmacological interventions – children and adolescents

*Scoping question 8:* For children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### Recommendation 8
> **Benzodiazepines should not be offered to children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: very low*

**Remarks**
*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*There are alternatives to pharmacological treatment (see recommendation 6's remarks on psychological interventions for insomnia in children and adolescents).*

*Health-care providers should explain that insomnia is common after recent exposure to extreme stressors. If insomnia persists for more than one month, the person should be reassessed for other conditions that may need treatment, including anxiety disorders (PTSD, generalized anxiety disorder, panic disorder), depression and, in adolescents, alcohol or drug use disorder.*

## Enuresis after a potentially traumatic recent event (recommendation 9)

Enuresis is a common complaint in primary care for children recently exposed to potentially traumatic events and may have important harmful mental and social consequences, including decreased sense of self-worth, anxiety and harsh punitive parental reactions. The ICD-10 describes non-organic enuresis as "involuntary voiding of urine, by day and/or by night which is abnormal in relation to the individual's mental age and which is not a consequence of a lack of bladder control due to any neurological disorder, to epileptic attacks or to any structural abnormality of the urinary tract". The GDG considered the evidence on management of enuresis, and developed the following recommendation.

## 9. Secondary non-organic enuresis (first month): early psychological interventions – children

*Scoping question 9:* In children with secondary non-organic enuresis after a potentially traumatic recent event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> *Recommendation 9*
> **(i) Psycho-education about the negative effects of punitive responses should be given to caregivers of children with secondary non-organic enuresis in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: very low*
>
> **(ii) Parenting skills training and the use of simple behavioural interventions (i.e. star charts, toileting before sleep and rewarding having nights without wetting the bed) should be considered. In addition, where resources permit, alarms should be considered.**
>
> *Strength of recommendation: standard*
> *Quality of evidence: moderate for alarms, low or very low for other behavioural interventions*

**Remarks**
*Medical causes of bedwetting should be assessed and managed to ensure that the bedwetting is indeed secondary to a potentially traumatic event.*

*Health-care providers should explain that bedwetting is common after recent exposure to extreme stressors. If the bedwetting persists for more than one month, the child should be reassessed for other disorders that may need treatment.*

## Dissociative (conversion) disorders after a potentially traumatic recent event (recommendations 10–11)

Dissociative (conversion) disorders can, according to ICD-10, be "associated closely in time with traumatic events, insoluble and intolerable problems, or disturbed relationships". Dissociative symptoms have been observed in varying ways (e.g. expressed through different psychological or somatic idioms of distress) in various cultures. The evidence search covered both psychological and somatoform dissociation in adults in the first month after a potentially traumatic event. The GDG considered the evidence retrieved, and it made two recommendations.

## 10. Symptoms of dissociative (conversion) disorders (first month): early psychological interventions – adults

*Scoping question 10:* **For adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

---

*Recommendation 10*

**On the basis of available evidence, no specific recommendation can be made on psychological interventions for adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

---

**Remarks**
*Possible physical causes for dissociation should be ruled out or managed.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.*

*For somatoform dissociation (i.e. conversion disorder), existing WHO guidance on the management of somatic medically unexplained symptoms  may be considered (see Other Significant Emotional or Medically Unexplained Complaints module of the mhGAP Intervention Guide (WHO, 2010)).*

*Health-care providers should explain that these symptoms can sometimes occur after recent exposure to extreme stressors. When interacting with people with conversion disorder, clinicians should acknowledge suffering and maintain a relationship of respect with the person. At the same time they should carefully avoid reinforcing any secondary gain that the person may get from somatoform dissociation (conversion). The use of culturally appropriate interventions that are not harmful may be considered.*

## 11. Symptoms of dissociative (conversion) disorders (first month): early psychological interventions – children and adolescents

*Scoping question 11:* For children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### Recommendation 11
> **On the basis of available evidence, no specific recommendation can be made for children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: not applicable*
> *Quality of evidence: very low*

### Remarks
*Possible physical causes for dissociation should be ruled out or managed.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.*

*For somatoform dissociation (i.e. conversion disorder), existing WHO guidance on the management of somatic medically unexplained symptoms may be considered (see Other Significant Emotional or Medically Unexplained Complaints module of the mhGAP Intervention Guide (WHO, 2010)).*

*Health-care providers should explain that these symptoms can sometimes occur after recent exposure to extreme stressors. When interacting with people with conversion disorder, clinicians should acknowledge suffering and maintain a relationship of respect with the person. At the same time they should carefully avoid reinforcing any secondary gain that the person may get from somatoform dissociation (conversion). The use of culturally specific interventions that are not harmful may be considered.*

## Hyperventilation after a potentially traumatic recent event (recommendations 12–13)

Clinical experience suggests that in the immediate aftermath of potentially traumatic events, help-seeking for hyperventilation is common. Because symptoms are associated with hypocapnia, clinicians frequently encourage persons to increase their $CO_2$ levels by rebreathing into a paper bag. The evidence search focused on whether rebreathing into a paper bag, compared to treatment as usual, waiting list or no treatment, results in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects.

## 12. Hyperventilation (first month): rebreathing into a bag – adults and adolescents

*Scoping question 12:* For adolescents and adults with hyperventilation in the first month after a potentially traumatic event, does rebreathing into a paper bag, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### Recommendation 12
> **No specific recommendation can be made on the basis of available evidence on rebreathing into a paper bag for adolescents and adults with hyperventilation in the first month after exposure to a potentially traumatic event.**
>
> *Strength of recommendation: not applicable*
> *Quality of evidence: very low*

**Remarks**
*There are significant risks if this technique is used in specific populations (e.g. people with heart disease and asthma).*

*Health-care providers should always rule out physical causes before considering psychological intervention for hyperventilation. They should maintain a calm approach, where possible remove sources of anxiety and coach respiration (i.e. encourage normal breathing, not deeper and quicker than usual).*

*Health-care providers should explain that hyperventilation can sometimes occur after recent exposure to extreme stressors. Acute stress should be managed using psychological first aid as per WHO (2010) mhGAP guidelines. Moreover, as per recommendation 1 (on psychological interventions for acute traumatic stress symptoms in adults), cognitive-behavioural therapy with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning.*

## 13. Hyperventilation (first month): rebreathing into a bag – children

*Scoping question 13:* **For children with hyperventilation in the first month after a potentially traumatic event, does rebreathing into a bag, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

> *Recommendation 13*
> **Rebreathing into a paper bag should not be considered for children with hyperventilation in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: standard*
> *Quality of evidence: very low*

**Remarks**
*Health-care providers should always rule out physical causes before considering psychological intervention. They should maintain a calm approach, where possible remove sources of anxiety and coach respiration (i.e. encourage normal breathing, not deeper and quicker than usual).*

*Health-care providers should explain that hyperventilation can sometimes occur after recent exposure to extreme stressors. Acute stress in children should be managed using psychological first aid as per WHO (2010) mhGAP guidelines.*

## Posttraumatic stress disorder (recommendations 14–17)

Posttraumatic stress disorder (PTSD) is the most studied disorder occurring after exposure to potentially traumatic events. Psychological interventions for PTSD include individual and group cognitive-behavioural therapy (CBT), eye movement desensitization and reprocessing (EMDR), stress management and psycho-education for adult PTSD in non-specialized health-care settings. There is currently no consensus on the effectiveness of EMDR or pharmacological treatments between different clinical practice guidelines. For pharmacological interventions, the evidence search was limited to treatments most likely to be available now or in the next five years in non-specialized health care in low- and middle-income countries (tricyclic antidepressants (TCAs) and selective serotonin re-uptake inhibitors (SSRIs)) (cf. van Ommeren et al., 2005). The GDG considered the evidence for psychological and pharmacological interventions for PTSD and developed the following four recommendations.

## 14. Posttraumatic stress disorder (PTSD): psychological interventions – adults

*Scoping question 14:* For adults with posttraumatic stress disorder (PTSD), do psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### Recommendation 14
> **Individual or group cognitive -behavioural therapy (CBT) with a trauma focus, eye movement desensitization and reprocessing (EMDR) or stress management should be considered for adults with PTSD.**
>
> *Strength of recommendation: standard*
> *Quality of evidence: moderate for individual CBT, EMDR; low for group CBT, stress management*

### Remarks
*Individual and group CBT with a trauma focus and EMDR should be offered only in those contexts where individuals are competent (i.e. trained and supervised) to provide the therapies. Although studies show that individual CBT with a trauma focus is more effective than stress management, in resource-constrained settings stress management may be the most feasible treatment option.*

## 15. Posttraumatic stress disorder (PTSD): psychological interventions – children and adolescents

*Scoping question 15:* For children and adolescents with posttraumatic stress disorder (PTSD), do psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in a reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

---

*Recommendation 15*

**Individual or group cognitive behavioural therapy (CBT) with a trauma focus or eye movement desensitization and reprocessing (EMDR) should be considered for children and adolescents with PTSD.**

*Strength of recommendation: standard*
*Quality of evidence: moderate for individual CBT, low for EMDR, very low for group CBT*

---

**Remarks**
*Individual and group CBT with a trauma focus and EMDR should be offered only in those contexts where individuals are competent (i.e. trained and supervised) to provide the therapies. Stress management may also be beneficial for children and adolescents with PTSD.*

## 16. Posttraumatic stress disorder (PTSD): pharmacological interventions – adults

*Scoping question 16:* For adults with posttraumatic stress disorder (PTSD), do tricyclic antidepressants (TCAs) or selective serotonin re-uptake inhibitors (SSRIs), when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

---

*Recommendation 16*

**Selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) should not be offered as the first line of treatment for posttraumatic stress disorder in adults.**

**SSRIs and TCAs should be considered if:**

**(a) stress management, CBT with a trauma focus and EMDR have failed or are not available;**

or

**(b) if there is co-morbid moderate–severe depression.**

*Strength of recommendation: standard*
*Quality of evidence: low*

---

**Remarks**
*Interactions with other drugs need to be considered and necessary precautions should be taken when prescribing to elderly populations and pregnant or breastfeeding women (see WHO (2010) mhGAP Intervention Guide module on moderate–severe depression).*

# 17. Posttraumatic stress disorder (PTSD): pharmacological interventions – children and adolescents

*Scoping question 17:* For children and adolescents with posttraumatic stress disorder (PTSD), do antidepressants, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

*Recommendation 17*

**Antidepressants should not be used to manage PTSD in children and adolescents.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**Remarks**
*If there is concurrent moderate–severe depression, also use guidance for helping depressed children and adolescents as included in the WHO (2010) mhGAP Intervention Guide module on depression. There are alternatives to pharmacological treatment (see recommendation 15 on psychological interventions for PTSD in children and adolescents).*

## Bereavement in the absence of mental disorder (recommendations 18–21)

Bereavement is referred to here as the event of a loss of a loved one, a common occurrence in life, which for most people will not lead to mental disorder. For a small minority, bereavement and grief may be associated with prolonged symptomatology and impairment in functioning amounting to mental disorder. The evidence considered concerned adults, children and adolescents who do *not* meet criteria for a mental disorder.

## 18. Bereavement: universally applied structured psychological interventions – adults

*Scoping question 18:* For bereaved adults without a mental disorder, do universally applied structured psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

---

### *Recommendation 18*
**Structured psychological interventions should *not* be offered universally to (all) bereaved adults who do not meet the criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: moderate*

---

**Remarks**
*General principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being), and the principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

## 19. Bereavement: universally applied structured psychological interventions – children and adolescents

*Scoping question 19:* For bereaved children and adolescents without a mental disorder, do universally applied structured psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

---

*Recommendation 19*

**Structured psychological interventions should not be offered universally to (all) bereaved children and adolescents who do not meet the criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

---

**Remarks**

*General principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being), and principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

*In cases where the child has lost a primary caregiver, the issue of protection and continued supportive caregiving, including socio-emotional support, should be addressed.*

## 20. Bereavement: benzodiazepines – adults

*Scoping question 20:* For bereaved adults without a mental disorder, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

> ### *Recommendation 20*
> **Benzodiazepines should not be offered to bereaved adults who do not meet criteria for a mental disorder.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: very low*

**Remarks**
*As mentioned in the remarks for recommendation 18 on psychological interventions for bereaved adults, general principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being), and the principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

## 21. Bereavement: benzodiazepines – children and adolescents

*Scoping question 21:* For bereaved children and adolescents without a mental disorder, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?

*Recommendation 21*

**Benzodiazepines should not be offered to bereaved children and adolescents who do not meet criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**Remarks**

*As mentioned in the remarks for recommendation 19 on psychological interventions for bereaved children and adolescents, general principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being), and principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

*In cases where the child has lost a primary caregiver, the issue of protection and continued supportive caregiving, including socio-emotional support, should be addressed.*

# Plans for disseminating, adapting and implementing these recommendations

As described above, these recommendations will be used to develop an mhGAP clinical module on management of adults, adolescents and children for disorders and problems specifically associated with stress. This will be widely disseminated through the WHO mhGAP programme using regional and country WHO offices, collaborating centres, professional organizations and partner agencies. The module will be promoted as a WHO-UNHCR tool for humanitarian work.

The evidence profiles will be uploaded on the WHO website's mhGAP Evidence Resource Centre.

An article will be drafted and submitted to a public health journal to disseminate these guidelines and the process of developing them.

These recommendations will be adapted for the field by developing suitable training materials in consultation with regional, national and local stakeholders. Adaptation will include translation into appropriate languages and checking that the interventions are acceptable in local sociocultural contexts and are suitable for local health systems.

## Impact of the guidelines

Process measures will also be used to monitor the uptake of these guidelines (e.g. frequency of downloading of guidelines and derivative products from the Internet; frequency of citations of an article based on the guidelines).

With respect to routine monitoring and evaluation of implementation of the guidelines, WHO is developing a monitoring and evaluation tool – with input, process, output and outcome measures – to assess implementation of the mhGAP Intervention Guide. That tool will also be able to assess implementation of the mhGAP module on problems and disorders specifically related to stress. Moreover, WHO mhGAP partners (such as the International Medical Corps) are developing their own tools to evaluate mhGAP implementation.

With respect to rigorous research, the mhGAP programme has helped attract a substantial amount of funds to global mental health research partners. Major donors (e.g. Department for International Development (DFID), UK; National Institute of Mental Health (NIMH), USA; European Commission (EC); and Grand Challenges Canada) have made funds available mainly to university partners to study the impact of applying the mhGAP guidelines, including strengthening relevant implementation and dissemination science.

## Research

In several instances, the GDG decided that there was not enough evidence to make recommendations. In such instances, the quality of the evidence has been summarized as very low. New research is needed on all scoping questions with low- or very low-quality evidence.

## Review by date

The recommendations and evidence base should be reviewed within five years (before 2018).

# References

American Psychiatric Association. American Psychiatric Association Practice Guideline for the Treatment of Patients with ASD and PTSD, 2004.

Barbui, C., Dua, T., van Ommeren, M., Yasamy, M.T., Fleischmann, A., Clark, N., Thornicroft, G., Hill, S., Saxena, S. Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med. 2010;7(8). pii: e1000322.

Bisson, J., Andrew, M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2007 Jul 18;(3):CD003388.

Bryant, R.A., Friedman, M.J., Spiegel, D., Ursano, R., Strain, J. A review of acute stress disorder in DSM-5. *Depress Anxiety*. 2011 28(9):802-17.

Cohen, J.A., Mannarino, A.P., Berliner, L., Deblinger, E. Trauma-focused cognitive behavioral therapy: An empirical update. *Journal of Interpersonal Violence*. 2000;15:1203-1223.

Dua, T., Barbui, C., Clark, N., Fleischmann, A., Poznyak, V., van Ommeren, M., Yasamy, M.T., Ayuso-Mateos, J.L., Birbeck, G.L., Drummond, C., Freeman, M., Giannakopoulos, P., Levav, I., Obot, I.S., Omigbodun, O., Patel, V., Phillips, M., Prince, M., Rahimi-Movaghar, A., Rahman, A., Sander, J.W., Saunders, J.B., Servili, C., Rangaswamy, T., Unützer, J., Ventevogel, P., Vijayakumar, L., Thornicroft, G., Saxena, S. Evidence-based guidelines for mental, neurological, and substance use disorders in low- and middle-income countries: summary of WHO recommendations. PLoS Med. 2011 Nov;8(11):e1001122.

Eisenman, D., Weine, S., Green, B., de Jong, J., Rayburn, N., Ventevogel, P., Keller, A., Agani, F. The ISTSS/Rand guidelines on mental health training of primary healthcare providers for trauma-exposed populations in conflict-affected countries. *J Trauma Stress*. 2006 Feb;19(1):5-17.

Inter-Agency Standing Committee (IASC). IASC Guidelines on Mental Health and Psychosocial Support in Emergency Settings. Geneva: IASC, 2007.

National Collaborating Centre for Mental Health (NCCMH). Post-traumatic stress disorder: The management of PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline Number 26. London: National Institute for Clinical Excellence (NICE), 2005.

Patel, V. Where There is No Psychiatrist. A Mental Health Care Manual. The Royal College of Psychiatrists, 2009.

Steel, Z., Chey, T., Silove, D., Marnane, C., Bryant, R.A., van Ommeren, M. Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement: a systematic review and meta-analysis. *JAMA*. 2009 Aug 5;302(5):537-49.

Stein, D.J., Chiu, W.T., Hwang, I., Kessler, R.C., Sampson, N., Alonso, J., Borges, G., Bromet, E., Bruffaerts, R., de Girolamo, G., Florescu, S., Gureje, O., He, Y., Kovess-Masfety, V., Levinson, D., Matschinger, H., Mneimneh, Z., Nakamura, Y., Ormel, J., Posada-Villa, J., Sagar, R., Scott, K.M., Tomov, T., Viana, M.C., Williams, D.R., Nock, M.K. Cross-national analysis of the associations between traumatic events and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS One. 2010 May 13;5(5):e10574.

van Ommeren, M., Barbui, C., de Jong, K., Dua, T., Jones, L., Perez-Sales, P., Schilperoord, M., Ventevogel, P., Yasamy, M.T., Saxena, S. If you could only choose five psychotropic medicines: updating the interagency emergency health kit. PLoS Med. 2011 May;8(5):e1001030.

Wessely, S., Bryant, R.A., Greenberg, N., Earnshaw, M., Sharpley, J., Hughes, J.H. Does psychoeducation help prevent post traumatic psychological distress? *Psychiatry*. 2008 Winter;71(4):287-302.

WHO. mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized health settings. Geneva: WHO, 2010.

# Annex 1: WHO Steering Group

| Name | Position | Department/ Office |
| --- | --- | --- |
| Tarun Dua | Medical Officer | Department of Mental Health and Substance Abuse |
| Claudia Garcia-Moreno | Team Leader | Department of Reproductive Health and Research |
| Berit Kiesbelbach | Technical Officer | Department of Violence and Injury Prevention and Disability |
| Khalid Saeed | Regional Advisor | Regional Office for the Eastern Mediterranean |
| Shekhar Saxena | Director | Department of Mental Health and Substance Abuse |
| Yuta Setoya | Technical Officer | Department of Mental Health and Substance Abuse |
| Chiara Servili | Medical Officer | Department of Mental Health and Substance Abuse |
| Mark van Ommeren | Scientist | Department of Mental Health and Substance Abuse |
| Taghi Yasamy | Medical Officer | Department of Mental Health and Substance Abuse |

# Annex 2: Guideline Development Group (GDG)

## 2.1 GDG membership

1. Jonathan Bisson, Institute of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom.

2. Judith Cohen, Department of Psychiatry, Drexel University College of Medicine, Philadelphia, United States.

3. Zeinab Hijasi, International Medical Corps, Beirut, Lebanon.

4. Joop de Jong, Department of Psychiatry, Vrije Universiteit, Amsterdam, the Netherlands.

5. Olayinka Omigbodun, Department of Psychiatry, University College Hospital, Ibadan, Nigeria.

6. Soraya Seedat, Stellenbosch University, Department of Psychiatry, Tygerberg, South Africa.

7. Derrick Silove, Psychiatry Research and Teaching Unit, Liverpool Hospital's Mental Health Centre, University of New South Wales, Sydney, Australia.

8. Renato Souza, International Committee of the Red Cross, Geneva, Switzerland (until July 2012); Institute of Psychiatry, Hospital das Clínicas, University of Sao Paulo Medical School, Sao Paulo, Brazil (from July 2012).

9. Athula Sumathipala, Department of Mental Health and Population Research, Institute of Psychiatry, Kings College, London, United Kingdom and Institute for Research and Development, Colombo, Sri Lanka.

10. Lakshmi Vijayakumar, SNEHA, Voluntary Health Services, Department of Psychiatry, Chennai, India.

11. Inka Weissbecker, International Medical Corps, Washington DC, United States.

12. Doug Zatzick, Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, United States.

## 2.2 Background of Guideline Development Group members

| Name | M/F | Country of origin | WHO region | Has extensive work experience as non-specialist healthcare staff | Has extensive work experience in non-specialist health care in emergency settings | Has extensive low- and middle-income country experience | Methodologist (systematic reviews) | Expert on children | Holds an academic position |
|---|---|---|---|---|---|---|---|---|---|
| Joop de Jong (chair) | M | Netherlands | EURO | x | x | x | | | x |
| Jonathan Bisson | M | UK | EURO | | | | x | | x |
| Judith Cohen | F | USA | AMRO | | | | | x | x |
| Zeinab Hijasi | F | Lebanon | EMRO | | x | x | | | |
| Olayinka Omigbodun | F | Nigeria | AFRO | | | x | | x | x |
| Derrick Silove | M | Australia | WPRO | | x | x | | | x |
| Soraya Seedat | F | South Africa | AFRO | | | x | | | x |
| Renato Souza | M | Brazil | AMRO | | x | x | | | |
| Athula Sumathipala | M | Sri Lanka | SEARO | x | x | x | | | x |
| Laskhmi Vijaykumar | F | India | SEARO | | x | x | | | |
| Inka Weissbecker | F | Germany | EURO | | x | x | | | |
| Doug Zatzick | M | USA | AMRO | | x | x | | | x |

## 2.3 Consultants supporting the Guideline Development Group

Corrado Barbui (WHO Collaborating Centre for Research and Training in Mental Health, University of Verona, Italy).

Margaret Harris (non-affiliated consultant, Hong Kong, People's Republic of China).

Lynne Jones (FXB Center for Health and Human Rights, Harvard School of Public Health Boston, United States).

Nicola Magrini (WHO Collaborating Centre for Evidence-based Research Synthesis and Guideline Development, Bologna, Italy).

Wietse A. Tol (Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, United States).

# Annex 3: External reviewers

| Name | Affiliation | Country of residence | WHO Region |
|---|---|---|---|
| 1. Alain Brunet & Daniel Saumier | McGill University | Canada | AMRO |
| 2. Andreas Maercker | University of Zürich | Switzerland | EURO |
| 3. Andrew Rasmussen | Fordham University | United States of America | AMRO |
| 4. Alison Schafer | World Vision International | Australia | WPRO |
| 5. Boris Budosan | In non-affiliated capacity | Croatia | EURO |
| 6. Bhava Poudyal | In non-affiliated capacity | Nepal | SEARO |
| 7. Carolina Echeverri | United Nations High Commissioner of Refugees | Senegal | AFRO |
| 8. Cécile Rousseau | McGill University | France | EURO |
| 9. Laura Murray | Johns Hopkins University School of Public Health | United States of America | AMRO |
| 10. Leslie Snider | War Trauma Foundation | The Netherlands | EURO |
| 11. Miranda Olff | University of Amsterdam | The Netherlands | EURO |
| 12. Nino Makhashvili | Global Initiative on Psychiatry & Tbilisi Ilia University | Georgia | EURO |
| 13. Pam Dix | Disaster Action | United Kingdom | EURO |
| 14. Peter Hughes | National Health Service – United Kingdom | United Kingdom | EURO |
| 15. Patti Levin | In non-affiliated capacity | United States of America | AMRO |
| 16. Pau Pérez-Sales | Médicos del Mundo & Hospital La Paz, Madrid | Spain | EURO |
| 17. Robert Pynoos | University of California, Los Angeles | United States of America | AMRO |
| 18. Sarah Meyer | Johns Hopkins Bloomberg School of Public Health | United States of America | AMRO |
| 19. Sonali Sharma | In non-affiliated capacity | United States of America | AMRO |
| 20. Thomas Barrett | University of Denver | United States of America | AMRO |
| 21. William Yule | Institute of Psychiatry – King's College London | United Kingdom | EURO |
| 22. Yukiro Suzuki | National Institute of Mental Health (NIMH) Japan | Japan | WPRO |

# Annex 4: Declarations of Interest

## 4.1 Consultants

Potential perceived conflict of interest (as expressed in declaration of interest forms): none.

## 4.2 Guideline Development Group

| Name | Current affiliation | Competing interest declared? | Nature of declared competing interest (as expressed in declaration of interest form) |
|------|---------------------|------------------------------|---------------------------------------------------------------------------------------|
| 1. Joop de Jong (chair) | Vrije Universiteit | None | |
| 2. Jonathan Bisson | University of Wales | Yes: 1b (consulting) | Was paid by WHO US$ 5000 in 2009 for performing systematic review of efficacy of psychological first aid; was paid by WHO US$ 5000 in 2011 for performing systematic review of efficacy of pharmacological interventions for PTSD. |
| 3. Judith Cohen | Drexel University College of Medicine | Yes: 1b (consulting) 2a: (research support for salary) 4a: (copyright) | 1b: Consultant for training in TF-CBT treatment model in three US states: US$ 10,000 per year, ongoing; 2a: Salary paid to Allegheny Singer Research Institute by National Institute for Mental Health (US): ongoing; 4a: Copyright for book: *Treating Traumatic Grief in Children and Adolescents*: approximately US$ 5000 per year, ongoing. Judith Cohen did not participate in the recommendation development meeting in Amman, Jordan. |
| 4. Zeinab Hijasi | International Medical Corps | None | |
| 5. Olayinka Omigbodun | University of Ibadan | Yes: 5b: (held relevant office) | President of International Association for Child and Adolescent Psychiatry and Allied Professions – current |
| 6. Derrick Silove | University of New South Wales | None | |

Continues…

| Name | Current affiliation | Competing interest declared? | Nature of declared competing interest (as expressed in declaration of interest form) |
|---|---|---|---|
| 7. Soraya Seedat | Stellenbosch University | Yes: 1a (research grants) 2b (travel sponsorship) | 1a: National Research Foundation and National Institutes of Health (NIH) provided research grants of US$ 700,000 in 2002–2011 (past). 2b: Travel to congresses and educational meetings sponsored by AstraZeneca, Eli Lily, GlaxoSmithKline, Lundbeck and Servier, Dr Reddy's. Total value estimated at US$ 5000 between 2002 and 2011. 5a: Co-author of Cochrane review on pharmacological interventions for PTSD (past); involvement in making guidelines for PTSD for the South African Society for Psychiatrists (current); involvement in the International Psychopharmacological Algorithm Project's guidelines for PTSD (past). Dr Seedat did not participate in decision-making on any recommendations involving pharmacological interventions for PTSD. |
| 8. Renato Souza | International Committee of the Red Cross (until July 2012); University of Sao Paulo (from July 2012) | None | |
| 9. Athula Sumathipala | Institute for Research and Development | None | |
| 10. Laskhmi Vijaykumar | SNEHA | None | |
| 11. Inka Weissbecker | International Medical Corps | None | |
| 12. Doug Zatzick | University of Washington | 5b (holds relevant office) | Chairs a study section of the US National Institute of Mental Health (NIMH) and is on the Institute of Medicine (IOM) Committee for the study of PTSD (2011–2014). |

## 4.3. External reviewers

| Name | Potential perceived conflict of interest (as expressed in declaration of interest forms) |
|---|---|
| 1. Alain Brunet & Daniel Saumier | No No |
| 2. Andreas Maercker | Yes – consulting and positions, appointed chair to the WHO ICD-10 revision working group on disorders associated with stress (2011–2013) |
| 3. Andrew Rasmussen | No |
| 4. Alison Schafer | No |
| 5. Boris Budosan | No |
| 6. Bhava Poudyal | No |
| 7. Carolina Echeverri | No |
| 8. Cécile Rousseau | No |
| 9. Laura K. Murray | Yes – consulting, research, public speaking |
| 10. Leslie Snider | No |
| 11. Miranda Olff | No |
| 12. Nino Makhashvili | No |
| 13. Pam Dix | No |
| 14. Peter Hughes | Yes – consulting for WHO and International Medical Corps |
| 15. Patti Levin | No |
| 16. Pau Pérez-Sales | No |
| 17. Robert S. Pynoos | Yes – research, intellectual property rights (Copyright UCLA PTSD-RI for Children and Adolescents, PFA Field Operations Guide) |
| 18. Sarah Meyer | No |
| 19. Sonali Sharma | Yes – consulting, public statement and positions |
| 20. Thomas Barrett | No |
| 21. William Yule | No |
| 22. Yukiro Suzuki | No |

# Annex 5: Evidence Profiles

## 1. Acute traumatic stress symptoms (first month): early psychological interventions – adults

**Q1. For adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

### Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

*Acute traumatic stress symptoms* in the current scoping question refers to symptoms of intrusion, avoidance and hyperarousal – when these are associated with significant impairment in daily functioning in the first month after a potentially traumatic event. In terms of nosology, these symptoms can be part of:

   (a) DSM-IV Acute Stress Disorder (not included in ICD), which in DSM is limited to one month of the event; and

   (b) ICD-10 Posttraumatic Stress Disorder, which in ICD can be diagnosed within one month of the event.

Other symptoms of acute stress, including hyperventilation, conversion and dissociative symptoms, and secondary non-organic nocturnal enuresis in children, are the focus of other evidence profiles of these guidelines.

There has been no demonstrated benefit in preventing posttraumatic stress disorder (PTSD), from either psychological debriefing or multiple-session psychological interventions, when applied universally (regardless of symptom levels) in the immediate aftermath of potentially traumatic events.[3] Access to psychological first aid – which despite its name involves largely social intervention – was recommended by a WHO Guidelines Development Group in 2009 as an alternative to psychological debriefing.

An important question remains as to which other early psychological interventions may be effective in those with acute traumatic stress symptoms during the first month after the event.

In this scoping question, *early psychological interventions* may include problem-solving counselling; relaxation; psycho-education; eye movement desensitization and reprocessing (EMDR); and cognitive-behavioural-behavioural therapy (CBT) applied during the first month after

---

[3] Roberts et al. (2010b).Multiple session early psychological interventions for the prevention of posttraumatic stress disorder. Cochrane Database of Systematic Reviews, Issue 4.

the event. Psycho-education refers to "the provision of information about the nature of stress, posttraumatic and other symptoms, and what to do about them".[4]

The term *trauma-focused CBT* (TF-CBT) has been used in different manners in the literature. For example, in the widely used NICE Guidelines, this term is used for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing of thoughts related to the event), while the same term is widely used for a very specific multi-component CBT protocol for children and adolescents developed by Cohen and colleagues. To avoid confusion, these guidelines avoid the term TF-CBT and use the term *CBT with a trauma focus* for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing).

## PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:**     Adults with acute traumatic stress symptoms,[5] within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Early psychological interventions[6]
- **Comparison:**     Treatment as usual or no treatment/waitlist
- **Outcomes:**
    - Symptom severity post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

### List of the systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "acute stress" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "acute stress". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adults (>18 years). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

---

[4] Wessely et al. (2008). Does psychoeducation help prevent post traumatic psychological distress? *Psychiatry*, 71(4), 287-302.
[5] *Acute traumatic stress symptoms* in this scoping question refers to symptoms of intrusion, avoidance and hyperarousal associated with significant impairment in daily functioning in the first month after a potentially traumatic event.
[6] *Early psychological interventions* may include problem-solving counselling, relaxation, psycho-education and CBT applied during the first month after the event.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Roberts, N.P., Kitchiner, N.J., Kenardy, J., Bisson, J.I. (2010a). Early psychological interventions to treat acute traumatic stress symptoms. *Cochrane Database of Systematic Reviews*, Issue 3.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

American Psychiatric Association (2004). Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Washington, DC: APA; and Benedek, D.M., Friedman, M.J., Zatzick, D., Ursano, R.J. (2009). Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Washington, DC: American Psychiatric Association.
COMMENT: Benedek et al. (2009) describe studies that have come out since the APA (2004) publication, but this is not a formal update of the guidelines. No update of ASD-related studies is provided.
REASON FOR EXCLUSION: no formal meta-analysis reported. Only MEDLINE and PILOTS searched.

Australian Centre for Posttraumatic Mental Health (2007). Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder. Melbourne, Australia: ACPMH.
COMMENT: aimed to update both the NICE and VA/DoD guidelines; pp.103-114 focus on adults without ASD symptoms, pp.115-124 focus on people with ASD symptoms.
REASON FOR EXCLUSION: more than two years old.

Department of Veterans Affairs/Department of Defense (2010). Clinical Practice Guideline for Management of Posttraumatic Stress. Washington, DC: VA/DoD.
REASON FOR EXCLUSION: no formal meta-analysis reported.

Hofmann, S.G., Smits, J.A.J. (2008). Cognitive-Behavioral Therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. *Journal of Clinical Psychiatry*, 69, 621-632.
COMMENT: includes four studies by Bryant et al. focused on ASD.
REASON FOR EXCLUSION: more than two years old.

Kornør, H., Winje, D. Ekeberg, Ø., Weisæth, L., Kirkeheil, I., Johansen, K., Steiro, A. (2008). Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: A systematic review and meta-analysis. *BMC Psychiatry*, 8(81), doi:10.1186/1471-244X-8-81.
REASON FOR EXCLUSION: more than two years old. NOTE: findings are consistent with the selected Roberts et al. (2010a) review.

Litz, B.T., Bryant, R.A. (2009). Early cognitive behavioral interventions for adults. In E.B. Foa, T.M. Keane, M.J. Friedman, J.A. Cohen (eds). Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies 2nd Edition. New York: the Guilford Press.
REASON FOR EXCLUSION: no formal meta-analysis reported.

National Collaborating Centre for Mental Health (2005). The Management of PTSD in Adults and Children in Primary and Secondary Care. London, UK: Royal College of Psychiatrists and British Psychological Society.
REASON FOR EXCLUSION: more than two years old.

Ponniah, K., Hollon, S.D. (2009). Empirically supported psychological treatments for adult acute stress disorder and posttraumatic stress disorder: a review. *Depression and Anxiety*, 26, 1086-1109.
REASON FOR EXCLUSION: no formal meta-analysis reported.

Roberts, N.P., Kitchiner, N.J., Kenardy, J., Bisson, J.I. (2009). Systematic review and meta-analysis of multiple-session early interventions following traumatic events. *American Journal of Psychiatry*, 166, 293-301.
EASON FOR EXCLUSION: same author team published a more detailed report as a Cochrane review.

Roberts, N.P., Kitchiner, N.J., Kenardy, J., Bisson, J.I. (2010b). Multiple session early psychological interventions for the prevention of posttraumatic stress disorder. *Cochrane Database of Systematic Reviews*, Issue 4.
REASON FOR EXCLUSION: focuses on psychological interventions for people without symptoms of acute stress.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Psychological interventions vs. no treatment/control | Symptom severity Functioning Presence of disorder Adverse effects | Roberts et al. (2010a) No data Roberts et al. (2010a) (proxy follow-up effects) Roberts et al. (2010a) (proxy drop-out) | Roberts et al. (2010a) present the only recent systematic review with a formal meta-analysis. Limitation: Roberts et al. included studies up to three months after the event. |

## Narrative description of the studies that went into analysis

Roberts and colleagues performed a systematic review and meta-analysis of studies following the Cochrane Handbook, focused on people presenting with acute stress disorder and acute posttraumatic stress disorder as defined by DSM-IV (both sub-threshold and meeting diagnostic criteria) in the first three months after a traumatic event. Their search identified 15 studies, ranging in sample size from eight to 152 participants and all conducted with civilian populations exposed to single traumas in high-income countries (Australia, USA, UK, the Netherlands, Sweden and Spain). Most studies focused on cognitive-behavioural therapy (CBT) with a trauma focus, but also evaluated were general CBT, supportive counselling, stepped collaborative care, structured writing therapy, relaxation, CBT plus anxiety management and CBT plus hypnosis.

## GRADE table

**Author(s):** Corrado Barbui, Wietse Tol

**Date:** 2012-02-24

**Question:** Should early psychological interventions vs treatment as usual or no treatment/waitlist be used for adults with acute traumatic stress symptoms?

**Bibliography:** Roberts (2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Early psychological interventions | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Quality assessment | | | | No. of patients | | Effect | | | |
| Symptom severity (clinician): **after intervention** (better indicated by lower values) | | | | | | | | | | | | |
| 6[1] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | No serious imprecision | None | 243 | 226 | – | SMD 0.64 lower (1.06 to 0.23 lower) | ▢▢▢▢ MODERATE | IMPORTANT |
| Symptom severity (clinician): **3–5-month follow-up** (better indicated by lower values) | | | | | | | | | | | | |
| 2[3] | Randomized trials | Serious[4] | No serious inconsistency | No serious indirectness | Serious[5] | None | 110 | 94 | – | SMD 0.17 lower (0.45 lower to 0.11 higher) | ▢▢▢▢ LOW | IMPORTANT |
| Symptom severity (clinician): **9–11-month follow-up** (better indicated by lower values) | | | | | | | | | | | | |
| 2[6] | Randomized trials | Serious[7] | No serious inconsistency | No serious indirectness | Serious[8] | None | 37 | 36 | – | SMD 0.33 lower (0.8 lower to 0.15 higher) | ▢▢▢▢ LOW | IMPORTANT |
| Symptom severity (self-report): **after intervention** (better indicated by lower values) | | | | | | | | | | | | |
| 6[9] | Randomized trials | No serious risk of bias | Serious[10] | No serious indirectness | No serious imprecision | None | 185 | 185 | – | SMD 0.83 lower (1.43 to 0.23 lower) | ▢▢▢▢ MODERATE | IMPORTANT |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Symptom severity** (self-report): **9–11-month follow-up** (better indicated by lower values) | | | | | | | | | | | | |
| 2[11] | Randomized trials | Serious[12] | Serious[13] | No serious indirectness | Serious[5] | None | 37 | 36 | – | SMD 0.31 lower (0.79 lower to 0.17 higher) | ⊕◯◯◯ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder: PTSD diagnosis after treatment** | | | | | | | | | | | | |
| 7[14] | Randomized trials | No serious risk of bias | Serious[15] | No serious indirectness | No serious imprecision | None | 119/266 (44.7%) | 142/249 (57%) | RR 0.72 (0.5 to 1.05) | 160 fewer per 1000 (from 285 fewer to 29 more) | ⊕⊕⊕◯ MODERATE | IMPORTANT |
| **Presence of disorder: PTSD diagnosis: 3–5-month follow-up** | | | | | | | | | | | | |
| 5[16] | Randomized trials | Serious[17] | No serious inconsistency | No serious indirectness | Serious[18] | None | 22/74 (29.7%) | 31/67 (46.3%) | RR 0.64 (0.42 to 0.99) | 167 fewer per 1000 (from 5 fewer to 268 fewer) | ⊕⊕◯◯ LOW | IMPORTANT |
| **Presence of disorder: PTSD diagnosis: 9–11-month follow-up** | | | | | | | | | | | | |
| 2[19] | Randomized trials | Serious[20] | Serious[21] | No serious indirectness | Very serious[22] | None | 7/28 (25%) | 11/26 (42.3%) | RR 0.61 (0.27 to 1.36) | 165 fewer per 1000 (from 309 fewer to 152 more) | ⊕◯◯◯ VERY LOW | IMPORTANT |
| **Adverse effects: leaving the study early** | | | | | | | | | | | | |
| 6[23] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[24] | No serious imprecision | None | 48/266 (18%) | 51/249 (20.5%) | RR 0.89 (0.63 to 1.26) | 23 fewer per 1000 (from 76 fewer to 53 more) | ⊕⊕⊕◯ MODERATE | IMPORTANT |

[1] From Analysis 1.1 of Roberts (2010a).
[2] Visual inspection of forest plot highlights that confidence intervals do not overlap. I-squared = 75%.
[3] From Analysis 1.3 of Roberts (2010a).
[4] Drop-out rates exceeded 30% in one study (Foa, 2006); in the other study it was unclear whether outcome assessment was performed by masked assessors (Sijbrandij, 2007).
[5] Confidence interval does not exclude the possibility of appreciable benefit of the experimental intervention.

[6] From Analysis 1.4 of Roberts (2010a).

[7] Drop-out rates exceeded 30% in one study (Foa, 2006).

[8] Fewer than 100 patients included in this analysis. Confidence interval ranges do not exclude the possibility of appreciable benefit.

[9] From Analysis 1.5 of Roberts (2010a).

[10] Confidence intervals do not overlap. I-squared = 84%.

[11] From Analysis 1.7 of Roberts (2010a).

[12] Drop-out rates exceeded 30% in one study (Foa, 2006).

[13] I-squared = 84%.

[14] From Analysis 1.8 of Roberts (2010a).

[15] I-squared = 71%.

[16] From Analysis 1.10 of Roberts (2010a).

[17] High drop-out rates in one study (Foa, 2006); in the other study it was unclear whether outcome assessment was performed by masked assessors.

[18] Fewer than 200 patients included. Confidence interval ranges from appreciable benefit to almost no benefit.

[19] From Analysis 1.11 of Roberts (2010a).

[20] High drop-out rates in one study (Foa, 2006).

[21] I-squared = 70%.

[22] Confidence interval ranges from appreciable benefit to no difference. Fewer than 100 patients included in the analysis.

[23] From Analysis 1.18 of Roberts (2010a).

[24] Leaving the study early is only a proxy measure of the adverse effects associated with the experimental treatment.

# PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

## Evidence to recommendation table

| Benefits | **Cognitive behavioural therapy with a trauma focus**<br>There is evidence suggesting that early cognitive-behavioural interventions (CBT) with a trauma focus in adults with acute traumatic stress symptoms have a beneficial effect in decreasing symptom severity after intervention. This beneficial effect has been demonstrated using clinician-rated as well as patient-rated outcome measures. The confidence in estimate is MODERATE. The effect is less evident at follow-up assessments.<br><br>There is evidence suggesting that CBT with a trauma focus in adults with acute traumatic stress symptoms has a beneficial effect in preventing PTSD diagnosis. The confidence in estimate is MODERATE. The effect is less evident at follow-up assessments.<br><br>**Problem-solving counselling**<br>The systematic review identified one study focused on supportive counselling, which did not find an effect of counselling on PTSD symptoms, anxiety or depression.<br><br>**EMDR, relaxation, psycho-education**<br>There is no systematic review of the potential benefits of EMDR as an early intervention. Although relaxation and psycho-education are often part of or precede CBT, there is no systematic review of evidence suggesting that each of these components on their own have a beneficial effect in decreasing symptom severity after intervention, preventing PTSD or improvement of functioning. A recent systematic review of such interventions in low- and middle-income country (LMIC) humanitarian settings – all conducted more than one month after the potentially traumatic event – showed mixed evidence for psycho-education and counselling. Psycho-education was not effective in two out of three studies, and in one study adding PTSD psycho-education (i.e. discussion of PTSD symptoms) to reconciliation workshops produced worse outcomes than reconciliation workshops alone. Problem-solving counselling implemented by para-professionals was associated with minimal improvements in torture survivors in Nepal and Indonesia, and performed similarly positively to Narrative Exposure Therapy with refugees in Uganda (Tol et al., 2011, *Lancet* 378: 1581-91). No separate evidence was found for relaxation. |
|---|---|

| Harms | **CBT with a trauma focus**<br>There is evidence suggesting that CBT with a trauma focus in adults with acute traumatic stress symptoms is acceptable; intervention was not associated with more people leaving the study early, a proxy measure of treatment acceptability. The confidence in estimate is MODERATE.<br><br>**EMDR, problem-solving counselling, relaxation, psycho-education**<br>There is no systematic review of the potential negative consequences of EMDR, problem solving counselling, relaxation or psycho-education as early interventions. However, a narrative review of the evidence on psycho-education found that there may be risks associated with this intervention (Wessely et al., 2008, *Psychiatry*, 71, p.287). |
|---|---|

| Value and preferences | |
|---|---|
| In favour | The possibility of decreasing acute traumatic stress symptoms and preventing PTSD is an important value.<br><br>Help-seekers from remote areas may have travelled long distances for treatment. If treatment is known to be effective, adopting a "wait and see" approach may be impractical and unethical as symptomatic, untreated and distressed persons may not return at a later date. On the other hand, if persons have travelled far they may not have resources to stay for an extended period of time (e.g. several weeks) to participate in multiple-session psychotherapy. |
| Against | Many people with acute traumatic stress symptoms recover over time without intervention. It may be worthwhile (cf. NICE Guidelines) to wait 1–3 months to see who recovers naturally and only offer intervention to those who have disabling symptoms that have remained the same or worsened. |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in CBT would require substantial resources, including supervision.<br><br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources. Large numbers of PHC attenders suffer from acute traumatic stress symptoms (e.g. as a result of injury), especially after mass events that have numerous survivors. It would not be feasible to deliver CBT to all. Potentially those whose acute traumatic stress symptoms are associated with impairment in daily functioning should be prioritized for CBT.<br><br>All studies supporting efficacy were implemented in high-income countries and in specialized treatment settings (specialized clinics, outpatient and inpatient clinics). Implementation of CBT in non-specialized settings by non-specialized staff may pose risks of harm due to the high levels of skills required and the delicate nature of handling acute traumatic stress |
|---|---|

symptoms. Nevertheless, cognitive-behavioural interventions have been successfully implemented in low-resource settings to treat maternal depression (Rahman et al., 2008, *Lancet* 372: 902–09) and PTSD symptoms in adults and adolescents (Neuner et al., 2008, *Journal of Consulting and Clinical Psychology* 76(4): 686-94; Ertl et al., 2011, *JAMA* 306(5): 503-12). Although no or limited evidence was found for the value of relaxation and problem-solving counselling, it is noted that many CBT approaches require the person to be stable (i.e. reduced distress/symptoms) before using any form of exposure. CBT protocols often require psycho-education and relaxation and sometimes a problem-solving approach to achieve such stability.

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | **Yes X**<br>For CBT<br>**No X**<br>For other interventions |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 1*
**(i) Cognitive-behavioural therapy with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning.**

*Strength of recommendation: standard*
*Quality of evidence: moderate*

**(ii) On the basis of available evidence, no specific recommendations can be made about stand-alone problem-solving counselling, eye movement desensitization and reprocessing (EMDR), relaxation or psycho-education in the first month for adults with acute traumatic stress symptoms associated with significant impairment in daily functioning after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

**Remarks**
*CBT with a trauma focus should be offered only in those contexts where individuals are competent (trained and supervised) to provide the therapy.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. When combined, these recommendations imply that psychological first aid should be considered in all adults with acute traumatic stress symptoms; and, where competent staff are available, CBT with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event. In situations without sufficient resources to provide CBT with a trauma focus, other interventions such as stress management may be considered in addition to psychological first aid.*

## 2. Acute traumatic stress symptoms (first month): early psychological interventions – children and adolescents

**Q2. For children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

### Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

*Acute traumatic stress symptoms* in the current scoping question refers to symptoms of intrusion, avoidance and hyperarousal – when these are associated with significant impairment in daily functioning – in the first month after a potentially traumatic event. In terms of nosology, these symptoms can be part of:

       (a) DSM-IV Acute Stress Disorder (not included in ICD), which in DSM is limited to one month of the event; and
       (b) ICD-10 Posttraumatic Stress Disorder, which in ICD can be diagnosed within one month of the event.

Other symptoms of acute stress, including hyperventilation, conversion and dissociative symptoms, and secondary non-organic nocturnal enuresis in children, are the focus of other evidence profiles of these guidelines.

There has been no demonstrated benefit in preventing posttraumatic stress disorder (PTSD), from either psychological debriefing or multiple-session psychological interventions, when applied universally (regardless of symptom levels) in the immediate aftermath of potentially traumatic events.[7] Access to psychological first aid – which, despite its name, involves largely social intervention – was recommended by a WHO Guidelines Development Group in 2009 as an alternative to psychological debriefing.

An important question remains as to which other early psychological interventions may be effective in those with acute traumatic stress symptoms during the first month after the event. In this scoping question, *early psychological interventions* may include problem-solving counselling; relaxation; psycho-education; eye movement desensitization and reprocessing (EMDR); and cognitive-behavioural therapy (CBT) applied during the first month after the event. Psycho-education refers to "the provision of information about the nature of stress, posttraumatic and other symptoms, and what to do about them".[8]

---

[7] Roberts et al. (2010b).Multiple session early psychological interventions for the prevention of posttraumatic stress disorder. Cochrane Database of Systematic Reviews, Issue 4.
[8] Wessely et al (2008). Does Psychoeducation help prevent post traumatic psychological distress? *Psychiatry*, 71(4), 287-302.

The term *trauma-focused CBT* (TF-CBT) has been used in different manners in the literature. For example, in the widely used NICE Guidelines, this term is used for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing of thoughts related to the event), while the same term is widely used for a very specific multi-component CBT protocol for children and adolescents developed by Cohen and colleagues. To avoid confusion, these guidelines avoid the term TF-CBT and use the term *CBT with a trauma focus* for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing).

# PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:**    Children and adolescents with acute traumatic stress symptoms,[9] within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Early psychological interventions[10]
- **Comparison:**    Treatment as usual or no treatment/waitlist
- **Outcomes:**
    - Symptom severity post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "acute stress" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "acute stress". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents. In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

---

[9]   *Acute traumatic stress symptoms* in this scoping question refers to symptoms of intrusion, avoidance and hyperarousal associated with significant impairment in daily functioning in the first month after a potentially traumatic event.

[10] *Early psychological interventions* may include problem-solving counselling, relaxation, psycho-education and CBT.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

The most recent systematic review that was identified (Brymer et al., 2009) concluded that there are currently no sufficiently rigorous evaluation studies regarding this scoping question available and did not attempt meta-analysis because of study limitations. Therefore, no data were entered in the GRADE table. Rather, a narrative description of the most recent systematic review is provided.

NOTE: A pertinent systematic review and meta-analysis, published after the literature search was conducted, was identified during the external peer review process of this profile: Kramer, D.N. & Landolt, M.A. Characteristics and efficacy of early psychological interventions in children and adolescents after single trauma: a meta-analysis. *European Journal of Psychotraumatology* 2011, 2: 7858.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

American Psychiatric Association (2004). Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Washington, DC: APA; and Benedek, D.M., Friedman, M.J., Zatzick, D., Ursano, R.J. (2009). Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients with Acute Stress Disorder and Posttraumatic Stress Disorder. Washington, DC: American Psychiatric Association.
COMMENT: Benedek et al. (2009) describe studies that have come out since the APA (2004) publication, but this is not a formal update of the guidelines. No update of ASD-related studies is provided.
REASON FOR EXCLUSION: no formal meta-analysis reported. Only MEDLINE and PILOTS searched; research on children and adolescents not aggregated.

Australian Centre for Posttraumatic Mental Health (2007). Australian Guidelines for the Treatment of Adults with Acute Stress Disorder and Posttraumatic Stress Disorder. Melbourne, Australia: ACPMH.
COMMENT: aimed to update both the NICE and VA/DoD guidelines; pp.103-114 focus on adults without ASD symptoms, pp.115-124 focus on people with ASD symptoms.
REASON FOR EXCLUSION: more than two years old; research on children and adolescents not aggregated.

Department of Veterans Affairs/Department of Defense (2010). Clinical Practice Guideline for Management of Posttraumatic Stress. Washington, DC: VA/ DoD.
REASON FOR EXCLUSION: no formal meta-analysis reported; research on children and adolescents not aggregated.

Hofmann, S.G., Smits, J.A.J. (2008). Cognitive-Behavioral Therapy for adult anxiety disorders: A meta-analysis of randomized placebo-controlled trials. *Journal of Clinical Psychiatry*, 69, 621-632.
COMMENT: includes four studies by Bryant et al. focused on ASD.
REASON FOR EXCLUSION: more than two years old; research on children and adolescents not aggregated.

Kornør, H., Winje, D., Ekeberg, Ø., Weisæth, L., Kirkeheil, I., Johansen, K., Steiro, A. (2008). Early trauma-focused cognitive-behavioural therapy to prevent chronic post-traumatic stress disorder and related symptoms: A systematic review and meta-analysis. *BMC Psychiatry*, 8(81), doi:10.1186/1471-244X-8-81.
REASON FOR EXCLUSION: more than two years old; research on children and adolescents not aggregated.

Litz, B.T., Bryant, R.A. (2009). Early cognitive behavioral interventions for adults. In E.B. Foa, T.M. Keane, M.J. Friedman, J.A. Cohen (eds). Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies 2nd Edition. New York: the Guilford Press.
REASON FOR EXCLUSION: no formal meta-analysis reported; research on children and adolescents not aggregated.

National Collaborating Centre for Mental Health (2005). The Management of PTSD in Adults and Children in Primary and Secondary Care. London, UK: Royal College of Psychiatrists and British Psychological Society.
REASON FOR EXCLUSION: more than two years old.

Ponniah, K., Hollon, S.D. (2009). Empirically supported psychological treatments for adult acute stress disorder and posttraumatic stress disorder: a review. *Depression and Anxiety*, 26, 1086-1109.
REASON FOR EXCLUSION: no formal meta-analysis reported; research on children and adolescents not aggregated.

Roberts, N.P., Kitchiner, N.J., Kenardy, J., Bisson, J.I. (2009). Systematic review and meta-analysis of multiple-session early interventions following traumatic events. *American Journal of Psychiatry*, 166, 293-301.
REASON FOR EXCLUSION: Same author team published a more detailed report as a Cochrane review; research on children and adolescents not aggregated.

Roberts, N.P., Kitchiner, N.J., Kenardy, J., Bisson, J.I. (2010a). Early psychological interventions to treat acute traumatic stress symptoms. *Cochrane Database of Systematic Reviews*, Issue 3.
REASON FOR EXCLUSION: research on children and adolescents not aggregated.

Roberts, N.P., Kitchiner, N.J., Kenardy, J., Bisson, J.I. (2010b). Multiple session early psychological interventions for the prevention of posttraumatic stress disorder. *Cochrane Database of Systematic Reviews*, Issue 4.
REASON FOR EXCLUSION: focuses on psychological interventions for people without symptoms of acute stress; research on children and adolescents not aggregated.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Psychological interventions vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | No data |

## Narrative description of the studies that went into analysis

The most recent systematic review of relevant studies identified was Brymer et al. (2009). Acute interventions for children and adolescents. In E. Foa, T.M. Keane, M.J. Friedman, J.A. Cohen (2009). *Effective Treatments for PTSD: Practice Guidelines from the International Society for Traumatic Stress Studies*. Guilford Press: New York, NY. This systematic review identified three randomized controlled trials (RCTs) with serious study limitations, and did not perform a meta-analysis. One trial (Yule, 1992) evaluated one-day debriefing provided 10 days post a shipping disaster and followed children ($n_{treatment}$=24, $n_{control}$=15; aged 14–16 years) 5–9 months post-treatment, and found a between group effect size of 1.09 for PTSD symptoms. A second trial (Chapman et al., 2001) evaluated art therapy treatment provided to children aged 7–17 years within days after exposure at a paediatric trauma unit. No statistically significant differences were found in PTSD symptoms between the treatment group (n=31) and a control group (n=27) at one-week and one-month periods. The third study (Stallard et al., 2006) evaluated a modified debriefing intervention delivered approximately four weeks after road traffic incidents. No statistically significant differences were found in PTSD symptoms between the treatment (n=82) and control (n=76) groups at eight-month follow-up.

The systematic review and meta-analysis (Kramer & Landolt, 2011) identified by one of the peer reviewers of this profile included two studies investigating the efficacy of early psychological interventions based on the principles of CBT, and two studies investigating the efficacy of early psychological interventions based on the principles of psycho-education.

**Early psychological interventions based on the principles of CBT**
The study carried out by Berkowitz and colleagues (2011) evaluated the efficacy of a four-session, caregiver-child intervention to prevent the development of chronic PTSD provided within 30 days of exposure to a potentially traumatic event. The study carried out by Zehnder and colleagues (2010) evaluated the efficacy of a single-session early psychological manualized intervention provided to the child and at least one parent around 10 days after the child's involvement in a road traffic accident.

Berkowitz and colleagues (2011) randomized 106 children and adolescents (53 experimental and 53 control intervention consisting of four sessions of a CBT-inspired parent-child intervention, including psycho-education, assessment of symptoms, improving parent-child communication and improving coping) aged 7–17 years exposed to a potentially traumatic event, and outcomes were assessed at post-treatment and at three months. At follow-up, 23 out of 106 children and adolescents were lost. In terms of efficacy, the study found that the intervention group demonstrated significantly lower posttraumatic and anxiety scores than the comparison group, and significantly fewer full and partial PTSD diagnoses. Limitations of this study include a high attrition rate and use of the PTSD-RI instrument as both part of the intervention and as an outcome measure.

Zehnder and colleagues (2010) randomized 101 children and adolescents (51 experimental and 50 control intervention consisting of standard medical care) aged 7–16 years exposed to road traffic accidents, and outcomes were assessed at two and six months. At follow-up, only two patients were lost. In terms of efficacy, the study found no significant differences concerning PTSD symptoms at two or six months. A subgroup analysis by age suggested that the intervention may be useful in children aged 7-11 in decreasing depressive symptoms and behavioural problems.

**Early psychological interventions based on the principles of psycho-education**
The study carried out by Kenardy and colleagues (2008) evaluated the efficacy of information booklets (which normalize the common stress reaction in children following trauma and provide basic self-help advice) provided to participants within 72 hours of the initial trauma. The study carried out by Cox and colleagues (2010) evaluated the efficacy of an information provision web-based early intervention based on cognitive and resilience theories.

Kenardy and colleagues (2008) performed a cluster randomized trial with two hospitals: one provided the experimental intervention to 33 children (mean age 10 years) and the second provided standard care to 70 children (mean age 10 years) admitted to paediatric units following accidental traumatic injury. Outcomes were assessed at one and six months. Only 65 out of 103 children were evaluated at follow-up. In terms of post-trauma symptoms of intrusion and avoidance, it found no efficacy of the experimental intervention. Limitations of this study include a high attrition rate and availability of two clusters only, which may have affected the randomization process, as two clusters may be insufficient to assure random distribution of measured and unmeasured confounders.

Cox and colleagues (2010) randomized 85 children and adolescents (44 experimental and 41 control intervention consisting of standard care) aged 7–16 years exposed to unintentional injury, and outcomes were assessed at 4–6 weeks and at six months. At follow-up, outcome data were available for 29 out of 44 children randomized to the experimental intervention and for 27 out of 41 children randomized to the control intervention. In terms of efficacy, the analysis which included completers revealed that children and adolescents in the experimental group reported improved anxiety, while the analysis which employed an intention-to-treat approach failed to reveal a positive effect of the intervention group. The main limitation of this study is the high attrition rate in both the experimental and control arms.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| | |
|---|---|
| **Benefits** | A systematic review of evidence identified two studies investigating the efficacy of early psychological interventions based on the principles of CBT, and two studies investigating the efficacy of early psychological interventions based on the principles of psycho-education. While the two studies on psycho-education did not provide positive findings, one of the two studies on CBT suggested that an intervention consisting of four sessions of parent-child focused intervention may be effective in lowering posttraumatic and anxiety scores. Limitations of this study include a small sample size (106 children) and a high attrition rate. The evidence is therefore inconclusive and it is uncertain if such interventions may have a beneficial effect in preventing disorders, decreasing symptom severity or improving functioning after intervention. One randomized study on art therapy did not find an effect of intervention and two studies on debriefing found conflicting results. All studies had serious limitations. |
| **Harms** | There is no systematic review of evidence on potential negative consequences of harmful effects of early psychological interventions in children and adolescents with acute traumatic stress symptoms. |

| Value and preferences | |
|---|---|
| In favour | The possibility of lowering acute traumatic stress symptoms and preventing PTSD is an important value. |
| Against | Many people with acute traumatic stress symptoms recover over time without intervention. It may be worthwhile waiting 1–3 months to see who recovers naturally and only offer intervention to those who have disabling symptoms that have remained the same or have worsened (cf. NICE Guidelines). |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in early psychological interventions would require resources, including supervision.<br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources. Large numbers of PHC attenders suffer from acute traumatic stress symptoms (e.g. as a result of injury), especially after mass events that have numerous survivors. It would not be feasible to deliver CBT to all.<br>The limited available studies were conducted in industrialized countries. |
|---|---|

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 2*
**On the basis of available evidence, no specific recommendation can be made on early psychological interventions (covering problem-solving counselling, relaxation, psycho-education, eye movement desensitization and reprocessing (EMDR) and cognitive-behavioural therapy (CBT)) for children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

**Remarks**
*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.*

# 3. Acute traumatic stress symptoms (first month): pharmacological interventions – adults

**Q3. For adults with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do pharmacological interventions (benzodiazepines and antidepressants), when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

*Acute traumatic stress symptoms* in the current scoping question refers to symptoms of intrusion, avoidance and hyperarousal – when these are associated with significant impairment in daily functioning – in the first month after a potentially traumatic event. In terms of nosology, these symptoms can be part of:

> (a) DSM-IV Acute Stress Disorder (not included in ICD), which in DSM is limited to one month of the event; and
> (b) ICD-10 Posttraumatic Stress Disorder, which in ICD can be diagnosed within one month of the event.

Other symptoms of acute stress, including hyperventilation, conversion and dissociative symptoms, and secondary non-organic nocturnal enuresis in children, are the focus of other evidence profiles of these guidelines.

Pharmacological treatments, especially benzodiazepines, are commonly prescribed for people suffering symptoms of acute distress. However, there is currently no consensus on the effectiveness of pharmacological treatments between different clinical practice guidelines,[11] making this an important scoping question.

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Adults with acute traumatic stress symptoms,[12] within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Pharmacological interventions
- **Comparison:** Placebo/active pharmacological treatment (benzodiazepines and antidepressants)

---

[11] Forbes et al (2010). A guide to guidelines for the treatment of PTSD and related conditions. *Journal of Traumatic Stress*, 23(5), 537-52.

[12] *Acute traumatic stress symptoms* in this scoping question refers to symptoms of intrusion, avoidance and hyperarousal associated with significant impairment in daily functioning in the first month after a potentially traumatic event.

- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## Details of commissioned systematic review

*NOTE: this systematic review was commissioned for a broader set of scoping questions, including pharmacological interventions for people with bereavement, PTSD and ASD. For this scoping question, the methodology of the review is presented for all studies, but only the results of studies relevant to adults with acute traumatic stress symptoms are discussed.*

## Types of studies

All double-blind, randomized, placebo controlled and comparative trials completed between October 2005 and October 2011 were considered in our primary and additional searches, covering 13 separate databases. Trials included in the NICE, Cochrane and ANCPTMH PTSD reviews were also considered.

Published and unpublished abstracts and reports were sought out in any language. Studies were not excluded on the basis of differences between them such as sample size or duration. Trials in which there was ongoing or newly initiated trauma-focused psychotherapy or where the experimental medication served as an augmentation agent to ongoing pharmacotherapy were excluded. Trials in which there was ongoing supportive psychotherapy were allowed, provided it was not initiated during the course of the treatment. Open label trials were not considered.

## Types of participants

All studies were of subjects with PTSD, ASD or grief reactions. There was no restriction on the basis of different diagnostic criteria for PTSD, or duration or severity of PTSD symptoms. There was no restriction on the basis of co-morbid disorders, age or gender of participants.

## Types of interventions

Pharmacological treatments for children and adults with PTSD, ASD or a grief reaction, in which the comparator was a placebo (active or non-active) or other medication.

## Types of outcome measures

The primary outcomes of interest were clinician-administered PTSD symptom severity measures such as the Clinician Administered PTSD Scale (CAPS) and the Treatment Outcome PTSD Scale (TOP-8). Secondary outcomes of interest were remission rates, self-rated PTSD symptom scales such as the Impact of Event Scale (IES) and Davidson Trauma Scale (DTS) and measures of treatment response to co-morbid symptoms such as depression and anxiety (e.g. the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Hamilton Anxiety Scale (HAM-A) and the Covi Anxiety Scale (COV)). Measures of quality of life and functional disability such as the Sheehan Disability Scale (SDS) were also considered. The total number of participants who left the trial early due to any reason was used as a measure of treatment tolerability.

## Search strategy

We conducted a primary bibliographic database search of MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. This initial broad search was intended to identify not only the randomized controlled trials (RCTs) of interest but other study methodologies and journal reviews of pharmacotherapy for PTSD.

The comprehensive search term used  was created by amalgamating the previous search strategies from the NICE, Stein and Australian Guideline reviews with an updated list of medications.

Specific additional searches were carried out to identify international studies in Japanese, Chinese, Spanish and Portuguese (no additional studies identified). In addition, we searched the National PTSD Centre's PILOTS Database, the Cochrane Library, the Controlled Trials Register, Web Of Knowledge, OpenSIGLE and Google Scholar using the terms "post traumatic stress disorder" OR "PTSD" OR "posttraumatic stress disorder" OR "posttraumatic stress disorder" AND "treatment" OR "medication" OR "pharmacotherapy" AND "controlled". Reference lists of all selected studies and reviews were further scrutinized for any additional RCTs.

## Study selection

One reviewer transferred the initial search hits into EndNoteX4 software and duplicates were removed. Two reviewers then independently screened the titles and abstracts of RCTs identified from the search. Those that were clearly irrelevant were excluded and potentially relevant studies were then assessed for inclusion as full texts. Any discrepancies between reviewers' decisions were resolved by discussion and guidance from a third senior reviewer.

## Data extraction and risk of bias assessment

One reviewer extracted the details of the studies into a standardized table which was then checked by another reviewer. Details from each study were collected on:

- Study citation, year of publication, location, setting, number of centres, design, sample size, duration and length of follow-up, diagnostic criteria, inclusion and exclusion criteria;
- Characteristics of study participants including gender distribution, mean and range of age, disease severity, duration of PTSD symptoms, presence of co-morbid depression, proportion with combat-related trauma, number randomized into each group, number of drop-outs;
- Characteristics of interventions including mean and maximum doses;
- Outcome measures reported including whether the data represented an intention-to-treat (ITT) or completers-only sample. For ITT samples, the method of imputation was noted.

One reviewer input outcome data into the Cochrane Collaboration's Review Manager 5 software, which was then checked by another reviewer. Data from studies included in previous systematic reviews were extracted by one reviewer and independently cross-checked by a second reviewer for accuracy. Risk of bias was independently assessed for each trial by two reviewers using the domain-based evaluation method recommended by the Cochrane Collaboration. This method considers the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias. Discrepancies between the two raters were resolved by discussion and arbitrated by a third senior rater. Masked study assessment (hiding details of publishing journal, author, etc.) was not undertaken, since it is unclear whether this reduces bias.

## Data analysis

Review Manager 5 software was used to synthesise data using meta-analysis and to provide forest plots for dichotomous and continuous data. Confidence intervals (CI) of 95% were used for all analyses.

Categorical outcome measures such as leaving the study early were analysed using relative risk (RR) calculations. For continuous data, standardized mean differences (SMD) were used.

The degree of heterogeneity between studies was calculated using the I2 statistic. Where the statistic was less than 30%, indicating a mild degree of heterogeneity, a fixed effects model was used. A random effects model was used when the statistic was greater than 30%.

Data was analysed from the ITT sample in the "once randomized always analysed" fashion where possible to avoid effects of bias from completers-only analyses.

## Results

No RCTs of pharmacotherapy for adults with acute traumatic stress were identified.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Pharmacological interventions vs. placebo/active pharmacological treatment | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | |

# PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

## Evidence to recommendation table

| Benefits | In adults with acute traumatic stress within the first month after experiencing a potentially traumatic stressor, there is no evidence on the effect of benzodiazepines and antidepressants on symptom severity, functioning and presence of disorder.<br><br>A classic non-RCT study by Gelpin and colleagues (1996; *Journal of Clinical Psychiatry*) showed no benefits of benzodiazepines between 13 matched pairs of recent trauma survivors. |
|---|---|
| Harms | In adults with acute traumatic stress, there is no evidence on the adverse effects of benzodiazepines and antidepressants.<br><br>For benzodiazepines, in addition to the evidence from randomized trials, data from observational and epidemiological studies highlighted a risk of tolerance and dependence. According to NICE UK, one of the key concerns about the use of benzodiazepines is that many people develop tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them (10–30% of chronic benzodiazepines users are physically dependent on them) and suffer a withdrawal syndrome when they stop taking them (50% of all users suffer withdrawal symptoms).<br><br>The withdrawal syndrome includes anxiety, depression, nausea and perceptual changes.<br><br>There are also problems of abuse with benzodiazepines as they enhance and often prolong the "high" obtained from other drugs and alleviate their withdrawal effects.<br><br>The safety of psychotropic drugs in pregnancy and breastfeeding is not clearly established. In particular, exposure to benzodiazepines during the first trimester is associated with an increased risk of oral clefts, and exposure during the third trimester is associated with neonatal difficulties. For antidepressants, the risks of taking tricyclic antidepressants during |

| | |
|---|---|
| | pregnancy and when breastfeeding are better established than those of SSRIs and newer drugs. Antidepressants appeared not to be teratogenic, although SSRI exposure in late pregnancy may increase the risk of persistent pulmonary hypertension. |

| Value and preferences | |
|---|---|
| In favour | The possibility of decreasing symptoms of acute traumatic stress and improving functioning/coping in stressful environments are important values. |
| Against | Providing medication for acute traumatic stress may contribute to the medicalization of normal psychological reactions and contribute to dependence. |

| Feasibility (including economic consequences) | Training is required in the understanding and safe administration of all psychotropic medications. To avoid the risks of harm referred to above, training of primary care practitioners may be necessary on responsible use of benzodiazepines. |
|---|---|
| | In many LMIC settings, continuous availability of psychotropic drugs in non-specialized health care is a challenge. |
| | Benzodiazepines are associated with low acquisition costs. Both generic tricyclic antidepressants and many generic selective serotonin re-uptake inhibitors are associated with low acquisition costs. |
| | Diazepam (as a representative of the benzodiazepines) is included in the WHO list of essential medicines for the treatment of anxiety disorders. Amitriptyline (as a representative of the tricyclic antidepressants) and fluoxetine (*not* as a representative of SSRIs) are included in the WHO list of essential medicines for the treatment of depressive disorders. |
| | Both diazepam and amitriptyline are included in the Interagency Emergency Health Kit (IEHK), a box with medicines and medical supplies designed to meet the expected primary health-care needs of people exposed to major humanitarian emergencies. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** (benzodiazepines and antidepressants) |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X** (benzodiazepines)<br>**No X** (antidepressants) |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X** (benzodiazepines and antidepressants)<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X (benzodiazepines and antidepressants)**<br>No |

## Final recommendation by the guideline panel

*Recommendation 3*
**Benzodiazepines and antidepressants should not be offered to adults to reduce acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.**

*For benzodiazepines:*
*Strength of recommendation: strong*
*Quality of evidence: very low*

*For antidepressants:*
*Strength of recommendation: standard*
*Quality of evidence: very low*

**Remarks**
*Clinicians should rule out concurrent disorders that may warrant treatment with benzodiazepines and antidepressants.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. In addition, recommendation 1 (on psychological interventions for acute traumatic stress symptoms in adults) is that "cognitive-behavioural therapy (CBT) with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning". When combined, these recommendations imply that psychological first aid and (where resources exist) CBT should be considered in adults with acute traumatic stress symptoms associated with impairment in daily functioning in the first month after a potentially traumatic event.*

# 4. Acute traumatic stress symptoms (first month): pharmacological interventions – children and adolescents

**Q4. For children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event, do pharmacological interventions (benzodiazepines and antidepressants), when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

*Acute traumatic stress symptoms* in the current scoping question refers to symptoms of intrusion, avoidance and hyperarousal – when these are associated with significant impairment in daily functioning – in the first month after a potentially traumatic event. In terms of nosology, these symptoms can be part of:

> (a) DSM-IV Acute Stress Disorder (not included in ICD), which in DSM is limited to one month of the event; and
> (b) ICD-10 Posttraumatic Stress Disorder, which in ICD can be diagnosed within one month of the event.

Other symptoms of acute stress, including hyperventilation, conversion and dissociative symptoms, and secondary non-organic nocturnal enuresis in children, are the focus of other evidence profiles of these guidelines.

Pharmacological treatments, especially benzodiazepines, are commonly prescribed for people suffering symptoms of acute distress. There is currently no consensus on the effectiveness of pharmacological treatments between different clinical practice guidelines,[13] making this an important scoping question.

---

[13] Forbes et al (2010). A guide to guidelines for the treatment of PTSD and related conditions. *Journal of Traumatic Stress*, 23(5), 537-52.

# PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Children and adolescents with acute traumatic stress symptoms,[14] within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Pharmacological interventions (benzodiazepines and antidepressants)
- **Comparison:** Placebo/active pharmacological treatment
- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## Details of commissioned systematic review

*NOTE: this systematic review was commissioned for a broader set of scoping questions, including pharmacological interventions for people with bereavement, PTSD and ASD. For this scoping question, the methodology of the review is presented for all studies, but only the results of studies relevant to children and adolescents with acute traumatic stress are discussed.*

## Types of studies

All double-blind, randomized, placebo controlled and comparative trials completed between October 2005 and October 2011 were considered in our primary and additional searches, covering 13 separate databases. Trials included in the NICE, Cochrane and ANCPTMH PTSD reviews were also considered.

Published and unpublished abstracts and reports were sought out in any language. Studies were not excluded on the basis of differences between them such as sample size or duration. Trials in which there was ongoing or newly initiated trauma-focused psychotherapy or where the experimental medication served as an augmentation agent to ongoing pharmacotherapy were excluded. Trials in which there was ongoing supportive psychotherapy were allowed, provided it was not initiated during the course of the treatment. Open label trials were not considered.

---

[14] *Acute traumatic stress symptoms* in this scoping question refers to symptoms of intrusion, avoidance and hyperarousal associated with significant impairment in daily functioning in the first month after a potentially traumatic event.

## Types of participants
All studies were of subjects with PTSD, ASD or grief reactions. There was no restriction on the basis of different diagnostic criteria for PTSD, duration or severity of PTSD symptoms. There was no restriction on the basis of co-morbid disorders, age or gender of participants.

## Types of interventions
Pharmacological treatments for children and adults with PTSD, ASD or a grief reaction, in which the comparator was a placebo (active or non-active) or other medication.

## Types of outcome measures
The primary outcomes of interest were clinician-administered PTSD symptom severity measures such as the Clinician Administered PTSD Scale (CAPS) and the Treatment Outcome PTSD Scale (TOP-8). Secondary outcomes of interest were remission rates, self-rated PTSD symptom scales such as the Impact of Event Scale (IES) and Davidson Trauma Scale (DTS) and measures of treatment response to co-morbid symptoms such as depression and anxiety (e.g. the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Hamilton Anxiety Scale (HAM-A) and the Covi Anxiety Scale (COV)). Measures of quality of life and functional disability such as the Sheehan Disability Scale (SDS) were also considered. The total number of participants who left the trial early due to any reason was used as a measure of treatment tolerability.

## Search strategy
We conducted a primary bibliographic database search of MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. This initial broad search was intended to identify not only the randomized controlled trials (RCTs) of interest but other study methodologies and journal reviews of pharmacotherapy for PTSD.
The comprehensive search term used was created by amalgamating the previous search strategies from the NICE, Stein and Australian Guideline reviews with an updated list of medications.
Specific additional searches were carried out to identify international studies in Japanese, Chinese, Spanish and Portuguese (no additional studies identified). In addition, we searched the National PTSD Centre's PILOTS Database, the Cochrane Library, the Controlled Trials Register, Web Of Knowledge, OpenSIGLE and Google Scholar using the term "post traumatic stress disorder" OR "PTSD" OR "post-traumatic stress disorder" OR "posttraumatic stress disorder" AND "treatment" OR "medication" OR "pharmacotherapy" AND "controlled". Reference lists of all selected studies and reviews were further scrutinized for any additional RCTs.

## Study selection

One reviewer transferred the initial search hits into EndNoteX4 software and duplicates were removed. Two reviewers then independently screened the titles and abstracts of RCTs identified from the search. Those that were clearly irrelevant were excluded and potentially relevant studies were then assessed for inclusion as full texts. Any discrepancies between reviewers' decisions were resolved by discussion and guidance from a third senior reviewer.

## Data extraction and risk of bias assessment

One reviewer extracted the details of the studies into a standardized table, which was then checked by another reviewer. Details from each study were collected on:

- Study citation, year of publication, location, setting, number of centres, design, sample size, duration and length of follow-up, diagnostic criteria, inclusion and exclusion criteria;
- Characteristics of study participants including gender distribution, mean and range of age, disease severity, duration of PTSD symptoms, presence of co-morbid depression, proportion with combat-related trauma, number randomized into each group, number of drop-outs;
- Characteristics of interventions including mean and maximum doses;
- Outcome measures reported including whether the data represented an intention-to-treat (ITT) or completers-only sample. For ITT samples, the method of imputation was noted.

One reviewer input outcome data into the Cochrane Collaboration's Review Manager 5 software, which was then checked by another reviewer. Data from studies included in previous systematic reviews were extracted by one reviewer and independently cross-checked by a second reviewer for accuracy. Risk of bias was independently assessed for each trial by two reviewers using the domain-based evaluation method recommended by the Cochrane Collaboration. This method considers the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias. Discrepancies between the two raters were resolved by discussion and arbitrated by a third senior rater. Masked study assessment (hiding details of publishing journal, author, etc.) was not undertaken, since it is unclear whether this reduces bias.

## Data analysis

Review Manager 5 software was used to synthesise data using meta-analysis and to provide forest plots for dichotomous and continuous data. Confidence intervals (CI) of 95% were used for all analyses.

Categorical outcome measures such as leaving the study early were analysed using relative risk (RR) calculations. For continuous data, standardized mean differences (SMD) were used.

The degree of heterogeneity between studies was calculated using the I2 statistic. Where the statistic was less than 30%, indicating a mild degree of heterogeneity, a fixed effects model was used. A random effects model was used when the statistic was greater than 30%. Data was analysed from the ITT sample in the "once randomized always analysed" fashion where possible to avoid effects of bias from completers-only analyses.

## Results

No RCTs of pharmacotherapy for children and adolescents with acute traumatic stress were identified.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Pharmacological interventions vs. placebo/active pharmacological treatment | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | |

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

## Evidence to recommendation table

| Benefits | In children and adolescents with acute traumatic stress, there is no evidence on the effect of benzodiazepines and antidepressants on symptom severity, functioning and presence of disorder. |
|---|---|
| Harms | In children and adolescents with acute traumatic stress, there is no evidence on the adverse effects of benzodiazepines and antidepressants.<br><br>For benzodiazepines, in addition to the evidence from randomized trials, data from observational and epidemiological studies – mostly with adult populations – highlighted a risk of tolerance and dependence. According to NICE UK, one of the key concerns about the use of benzodiazepines is that many people develop tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them (10–30% of chronic benzodiazepines users are physically dependent on them) and suffer a withdrawal syndrome when they stop taking them (50% of all users suffer withdrawal symptoms). With regard to children and adolescents, very few rigorous studies have been conducted but dependency risks have been similarly reported (Witek et al., 2005, *Psychiatric Quarterly*, 76). |

| | The withdrawal syndrome includes anxiety, depression, nausea and perceptual changes. |
|---|---|
| | There are also problems of abuse with benzodiazepines as they enhance and often prolong the "high" obtained from other drugs and alleviate their withdrawal effects. |
| | For antidepressants, evidence collected in children with depression has highlighted safety and tolerability concerns, including the increased risk of suicide ideas and behaviour (see mhGAP, 2010) with some SSRIs. Tricyclics are not recommended in children and adolescents. |
| | No data on the long-term consequences of psychotropic drug exposure in children and adolescents are available. |

| Value and preferences | |
|---|---|
| In favour | |
| Against | Children and adolescents – still in development – should only be exposed to drugs if other effective treatment options have been tried, if the condition is sufficiently severe and treatment is likely to lead to a substantial improvement and if information about long-term consequences is available. |
| | Providing medication for acute stress may contribute to the medicalization of normal psychological reactions and may contribute to dependence. |

| Feasibility (including economic consequences) | Training is required in the understanding and safe administration of all psychotropic medications. Training is required to properly assess acute stress in children and adolescents with due attention to any cultural variations that may exist. |
|---|---|
| | In many LMIC settings, continuous availability of psychotropic drugs in non-specialized health care is a challenge. |
| | Benzodiazepines are associated with low acquisition costs. Both generic tricyclic antidepressants and many generic selective serotonin re-uptake inhibitors are associated with low acquisition costs. |
| | Fluoxetine is included in the WHO list of essential medicines for the treatment of depressive disorders in adolescents only (> 8 years). |
| | Amitriptyline and diazepam are included in the Interagency Emergency Health Kit (IEHK), a box with medicines and medical supplies designed to meet the expected primary health-care needs of people exposed to major humanitarian emergencies. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

> ### Recommendation 4
> **Benzodiazepines and antidepressants should not be offered to reduce acute traumatic stress symptoms associated with significant impairment in daily functioning in children and adolescents.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: very low*

**Remarks**
*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with acute traumatic stress symptoms associated with significant impairment in daily functioning in the first month after a potentially traumatic event.*

# 5. Acute (secondary) insomnia (first month): early psychological interventions – adults

**Q5. For adults with acute (secondary) insomnia in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

Insomnia is commonly associated with mood and anxiety disorders, including in the context of exposure to potentially traumatic events.[15] It is noted that insomnia may also have physical and other psychological causes, for example cardiovascular disorders, alcohol use disorder and (prescription and non-prescription) drug use disorder.

There is uncertainty how to treat adults with insomnia in the first month after a potentially traumatic event.[16] This type of insomnia is referred to as secondary insomnia (primary insomnia occurs when somatized tension and learned sleep-incompatible behaviours play a predominant role in the maintenance of poor sleep). Given the timeframe of this scoping question (within the first month of exposure to a potentially traumatic event), the focus is here on "acute (secondary) insomnia".[17] [18] This scoping question focuses on early psychological interventions, i.e. interventions delivered in the first month after exposure to a potentially traumatic event.

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Adults, after the first month of a potentially traumatic event
- **Interventions:** Early psychological interventions
- **Comparison:** Treatment as usual or no treatment/waitlist

---

[15] Lamarche & De Koninck (2007). Sleep disturbance in adults with Posttraumatic Stress Disorder. *Journal of Clinical Psychiatry*, 68, 1257-70.

[16] Harvey, Jones & Schmidt (2003). Sleep and Posttraumatic Stress Disorder: a review. *Clinical Psychology Review*, 23, 377-407.

[17] Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf

[18] Wang, Wang & Tsai (2005). Cognitive behavioural therapy for primary insomnia: a systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.

- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted on 6 March 2012 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "insomnia" AND "stress" OR "trauma". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "insomnia". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adults (>18 years), focusing on psychological and social treatments. We did not include systematic reviews of pharmacological and manual therapies (e.g. massage therapy, acupuncture, spinal manipulation). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword, and searched clinical practice guidelines related to managing acute stress reactions. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES (SEE BELOW: INCLUDED IN NARRATIVE DESCRIPTION)*

De Niet, G.J., Tiemens, B.G., Kloos, M.W., Hutschemaekers, G.J.M. (2009). Review of systematic reviews about the efficacy of non-pharmacological interventions to improve sleep quality in insomnia. *International Journal for Evidence-Based Health Care*, 7, 233-42.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Aurora, R.N., Zak, R.S., Auerbach, S.H., Casey, K.R., Chowdhuri, S., Karippot, A., Maganti, R.K., Ramar, K., Kristo, D.A., Bista, S.R., Lamm, C.I., Morgenthaler, T.I. (2010). Best practice guide for the treatment of nightmare disorder in adults. *Journal of Clinical Sleep Medicine*, 6(4), 389-401. REASON FOR EXCLUSION: focuses on nightmares specifically, only searched PubMed, and identified only studies with chronic nightmares.

Belleville, G., Cousineau, H., Levrier, K., St.-Pierre-Delorme, M. (2011). Meta-analytic review of the impact of cognitive-behavior therapy for insomnia on concomitant anxiety. *Clinical Psychology Review*, 31, 638-52. REASON FOR EXCLUSION: this study focuses on effectiveness of treatment of insomnia on associated anxiety symptoms.

Montgomery, P. & Dennis, J.A. (2009). Cognitive behavioural interventions for sleep problems in adults aged 60+. *Cochrane Database of Systematic Reviews*, 1.
REASON FOR EXCLUSION: focuses on a specific population sub-group (elderly).

Montgomery, P. & Dennis, J.A. (2009). Physical exercise for sleep problems in adults aged 60+. *Cochrane Database of Systematic Reviews*, 1.
REASON FOR EXCLUSION: focuses on a specific population sub-group (elderly).

Nappi, C.M., Drummond, S.P.A. & Hall, J.M.H. (in press). Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. *Neuropharmacology*, doi:10.1016/j.neuropharm.2011.02.029
REASON FOR EXCLUSION: no methodology of a systematic review is reported.

Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., Sateia, M. (2008). Clinical guideline for the evaluation and management of chronic insomnia in adults. *Journal of Clinical Sleep Medicine*, 15(5), 487-504.
REASON FOR EXCLUSION: focuses on chronic insomnia.

Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf
REASON FOR EXCLUSION: no methodology of a systematic review is reported.

Uchiyama, M., Inoue, Y., Uchimura, N., Kawamori, R., Kurabayashi, M., Kario, K., Watada, H. (2011). Clinical significance and management of insomnia. *Sleep and Biological Rhythms*, 9, 63-72.
REASON FOR EXCLUSION: inclusion of Japanese consensus statement, but no methodology of a systematic review is reported.

Wang, M.-Y., Wang, S.-Y. & Tsai, P.-S. (2005). Cognitive behavioural therapy for primary insomnia: a systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.
REASON FOR EXCLUSION: focuses on primary insomnia.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Early psychological intervention or acute secondary insomnia | Symptom severity (sleep quality) | No data | No data |
| | | Functioning | No data | |
| | | Presence of disorder | No data | |
| | | Adverse effects | No data | |

## Narrative description of the studies that went into analysis

De Niet and colleagues provide a broad systematic review of previous systematic reviews and meta-analyses of diverse non-pharmacological treatments for insomnia, including secondary insomnia. Databases searched included Database of Abstracts of Reviews of Effects (2002–July 2008), the Cochrane Database of Systematic Reviews (2000–July 2008) and PubMed (1955–July 2008), and identified reviews were rated using the Overview Quality Assessment Questionnaire. Of the reviews that were identified by this study that focused on insomnia (and not chronic or primary insomnia specifically), there were sufficient data to suggest the effectiveness of multi-component cognitive-behavioural therapy (CBT), paradoxical intention (which consists of persuading a person to stay awake, based on the assumption that performance anxiety prevents proper sleep), progressive muscle relaxation, relaxation training and stimulus control (see below). All these comparisons were extracted from De Niet review reference #25: Murthag (1995). Identifying effective psychological treatments for insomnia: a meta-analysis. *Journal of Consulting & Clinical Psychology*, 63, 79-89. The studies included in Murthag (1995) were described in a way that would not allow results to be entered in a GRADE table, therefore the results of Murthag (1995) are described in a narrative style. These studies were not conducted with acutely traumatized adults in low- and middle-income countries, and evidence is therefore indirect.

Intervention descriptions of studies that went into the analysis:
- Multi-component CBT: aims to improve sleep by changing disadvantageous beliefs, attitudes and behaviours. Includes cognitive therapy, one or more behavioural techniques, relaxation techniques and sleep hygiene education (a list of recommended behaviours and sleep-related factors assumed beneficial for a good night's rest);
- Paradoxical intention: persuading a person to engage in his/her most feared behaviour – staying awake, based on the assumption that performance anxiety prevents proper sleep;
- Progressive muscle relaxation: a method of tensing and relaxing different muscle groups throughout the body;
- Relaxation training: can involve diverse methods aimed at reducing tension, e.g. autogenic training (daily visualization practice), biofeedback (use of electronic sensors that make state of relaxation visible), music-assisted relaxation;
- Stimulus control: a set of instructions designed to reassociate bed and bedroom temporal stimuli with rapid sleep onset.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| | |
|---|---|
| **Benefits** | A total of 66 studies, including randomized and non-randomized trials, assessed the efficacy of multi-component CBT, paradoxical intention, progressive muscle relaxation, relaxation training and stimulus control. A total of 1,538 adults with insomnia received psychological interventions and 369 adults with insomnia received no treatment. According to the study authors, the meta-analysis indicated that psychological interventions (multi-component CBT, paradoxical intention, progressive muscle relaxation, relaxation training and stimulus control) produced considerable enhancement of sleep patterns (for definitions, see above). Average treatment effect reduced sleep onset latency from 61 to 37 minutes, increased total sleep time from 5.65 to 6.18 hours, and decreased the number of awakenings from 1.63 to 0.44. Although it was not possible to analyze this meta-analysis in a GRADE table, the confidence in estimate may be VERY LOW, as data from randomized trials are lumped together with data from non-randomized studies.<br>There is no systematic review with data for the outcomes functioning, presence of disorder or adverse effects. |
| **Harms** | There is no systematic review of evidence on potential negative consequences of psychological interventions in adults with acute secondary insomnia in the first month after a potentially traumatic event. |

| Value and preferences | |
|---|---|
| In favour | Severe insomnia undermines the capacity of persons to carry out basic tasks for day-to-day living and may result in depression or self-medication such as using excess alcohol or other substances. Self-medication and substance use may continue even when insomnia, ASD or PTSD symptoms decrease over time. After certain recent events (e.g. exposure to war or natural disaster) it is important for the survivor to sleep sufficiently to be able to carry out essential day-to-day activities. |
| Against | The overall impact on number of hours of sleep per night is limited (on average only half an hour per night). |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in multi-component CBT, paradoxical intention, progressive muscle relaxation, relaxation training and stimulus control requires resources, including supervision.<br><br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources.<br><br>Multi-component CBT (which includes relaxation training, sleep hygiene and cognitive techniques), paradoxical intention, progressive muscle relaxation, relaxation training and stimulus control differ in level of complexity. While relaxation training and sleep hygiene may be more easily learned and taught, the cognitive techniques of CBT are more resource- and time-intensive. It is noted that relaxation training is already recommended in mhGAP as an adjunct treatment for depression, and would thus not necessarily require additional investments. |
| --- | --- |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
| --- | --- |
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

*Recommendation 5*
**Relaxation techniques (e.g. progressive muscle relaxation or cultural equivalents) and advice about sleep hygiene (including advice about psychostimulants, such as coffee, nicotine and alcohol) should be considered for adults with acute (secondary) insomnia in the first month after exposure to a potentially traumatic event.**

*Strength of recommendation: standard*
*Quality of evidence: very low*

**Remarks**
*In many settings, relaxation may be made available through existing cultural practices.*

*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*Health-care providers should explain that insomnia is common after recent exposure to extreme stressors. If insomnia persists for more than one month the person should be reassessed for other conditions that may need treatment, including anxiety disorders (posttraumatic stress disorder, generalized anxiety disorder, panic disorder), depressive disorder and, in adolescents, alcohol or drug use disorder.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. When combined, these recommendations imply that psychological first aid, relaxation techniques and advice about sleep hygiene should be considered in adults with acute (secondary) insomnia in the first month after a potentially traumatic event.*

# 6. Acute (secondary) insomnia (first month): early psychological interventions – children and adolescents

**Q6. For children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

Insomnia is commonly associated with mood and anxiety disorders, including in the context of exposure to potentially traumatic events.[19] It is noted that insomnia may also have physical and other psychological causes, for example cardiovascular disorders, alcohol use disorder and (prescription and non-prescription) drug use disorder.

There is uncertainty how to treat children and adolescents with insomnia in the first month of a potentially traumatic event.[20] This type of insomnia is referred to as secondary insomnia (primary insomnia occurs when somatized tension and learned sleep-incompatible behaviours play a predominant role in the maintenance of poor sleep). Given the timeframe of this scoping question (within the first month of exposure to a potentially traumatic event), the focus is here on "acute (secondary) insomnia".[21] [22]

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Children and adolescents after the first month of a potentially traumatic event
- **Interventions:** Early psychological interventions
- **Comparison:** Treatment as usual or no treatment/waitlist
- **Outcomes:**

---

[19] Lamarche & De Koninck (2007). Sleep disturbance in adults with Posttraumatic Stress Disorder. *Journal of Clinical Psychiatry*, 68, 1257-70.
[20] Harvey, Jones & Schmidt (2003). Sleep and Posttraumatic Stress Disorder: a review. *Clinical Psychology Review*, 23, 377-407.
[21] Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf
[22] Wang, Wang & Tsai (2005). Cognitive behavioural therapy for primary insomnia: a systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.

- Symptom severity post-intervention and at follow-up
- Functioning/quality of life post-intervention and at follow-up
- Presence of mental disorder post-intervention and at follow-up
- Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted on 6 March 2012 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "insomnia" AND "stress" OR "trauma". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "insomnia". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents, focusing on psychological and social treatments. We did not include systematic reviews of pharmacological and manual therapies (e.g. massage therapy, acupuncture, spinal manipulation). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword, and searched clinical practice guidelines related to managing acute stress reactions. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Bruni, O. & Novelli, L. (2010). Sleep disorders in children. *BMJ Clinical Evidence*, 9, 2304.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Aurora, R.N., Zak, R.S., Auerbach, S.H., Casey, K.R., Chowdhuri, S., Karippot, A., Maganti, R.K., Ramar, K., Kristo, D.A., Bista, S.R., Lamm, C.I., Morgenthaler, T.I. (2010). Best practice guide for the treatment of nightmare disorder in adults. *Journal of Clinical Sleep Medicine*, 6(4), 389-401. REASON FOR EXCLUSION: focuses on nightmares specifically, only searched PubMed, and identified only studies with chronic nightmares; focused on adults only.

Belleville, G., Cousineau, H., Levrier, K., St.-Pierre-Delorme, M. (2011). Meta-analytic review of the impact of cognitive-behavior therapy for insomnia on concomitant anxiety. *Clinical Psychology Review*, 31, 638-52. REASON FOR EXCLUSION: earlier study found that CBT improves sleeping problems when treating anxiety disorders (no change in effect size for different anxiety disorders). This study focuses on effectiveness of treatment of insomnia on associated anxiety symptoms; focused on adults only.

De Niet, G.J., Tiemens, B.G., Kloos, M.W., Hutschemaekers, G.J.M. (2009). Review of systematic reviews about the efficacy of non-pharmacological interventions to improve sleep quality in insomnia. *International Journal for Evidence-Based Health Care*, 7, 233-42.
REASON FOR EXCLUSION: focused on adults only.

Montgomery, P. and Dennis, J.A. (2009). Cognitive behavioural interventions for sleep problems in adults aged 60+. *Cochrane Database of Systematic Reviews*, 1.
REASON FOR EXCLUSION: focused on adults only.

Montgomery, P. and Dennis, J.A. (2009). Physical exercise for sleep problems in adults aged 60+. *Cochrane Database of Systematic Reviews*, 1.
REASON FOR EXCLUSION: focused on adults only.

Nappi, C.M., Drummond, S.P.A. and Hall, J.M.H. (in press). Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. *Neuropharmacology*, doi:10.1016/j.neuropharm.2011.02.029.
REASON FOR EXCLUSION: no methodology of a systematic review is reported; no studies with children and adolescents discussed.

Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., Sateia, M. (2008). Clinical guideline for the evaluation and management of chronic insomnia in adults. *Journal of Clinical Sleep Medicine*, 15(5), 487-504.
REASON FOR EXCLUSION: focuses on chronic insomnia; focused on adults only.

Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf
REASON FOR EXCLUSION: no methodology of a systematic review is reported.

Uchiyama, M., Inoue, Y., Uchimura, N., Kawamori, R., Kurabayashi, M., Kario, K., Watada, H. (2011). Clinical significance and management of insomnia. *Sleep and Biological Rhythms*, 9, 63-72.
REASON FOR EXCLUSION: inclusion of Japanese consensus statement, but no methodology of a systematic review is reported.

Wang, M.-Y., Wang, S.-Y.  & Tsai, P.-S. (2005). Cognitive behavioural therapy for primary insomnia: a systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.
REASON FOR EXCLUSION: focuses on primary insomnia.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Early psychological intervention for acute secondary insomnia | Symptom severity (sleep quality) | Bruni and Novelli (2010) | Bruni and Novelli provide a systematic review of RCTs with evidence evaluated through GRADE methodology. |
| | | Functioning | No data | |
| | | Presence of disorder | No data | |
| | | Adverse effects | No data | |

## Narrative description

A systematic review conducted by Bruni and Novelli for Clinical Evidence, published by the *British Medical Journal* (Bruni and Novelli, 2010. Sleep disorders in Children. *Clinical Evidence*, 9, 2304) was identified. This systematic review searched the following databases up to September 2009: MEDLINE, Embase, the Cochrane Library, as well as harm alerts from US and UK regulatory bodies. This review found 13 randomized controlled trials (RCTs) that met inclusion criteria (a focus on dyssomnia – defined as paediatric insomnia or excessive daytime sleepiness – and parasomnia). Evidence from these studies was subsequently evaluated using GRADE methodology. The systematic review identified three RCTs relevant to this scoping question:

- Two RCTs evaluating extinction (through a standardized sleep programme) and graduated extinction vs no treatment (in otherwise healthy children) (32, 34);
- One RCT evaluating sleep hygiene vs no treatment (in otherwise healthy children) (38).

No studies concerned children with insomnia in the first month after exposure to potentially traumatic events, and the evidence must therefore be considered indirect.

In this systematic review:

- *Standardized sleep programme* (reference 32) (based on extinction) consisted of: "8 page booklet – 'Parent Guide' (that involved organized bedtime routines, procedures for settling the child, and for the handling of crying, calling out, and getting out of bed) plus a 1-hour interview. Telephone calls each day at first, then as needed. Total staff attention: 2 to 3 hours/family" and "8-page booklet 'Parent Guide' (that involved organized bedtime routines, procedures for settling the child, and for the handling of crying, calling out, and getting out of bed) plus any questions answered. Total staff attention: 5 to 10 minutes/family".
- *Graduated extinction* (reference 34) consisted of the following: "Parents put the child to bed after pre-bedtime routines, said 'good night', and left the room. If the child cried or fussed, the parents could make a brief (30 seconds) check after 5 minutes, then left the room. Brief checks could be made after another 10 minutes, then at 15-minute intervals if the child was still crying. No checks were

made after the child stopped crying. Checking intervals were lengthened by 5 minutes each night. If the child left the bedroom, he/she was given 1 warning each night. If the child left the bedroom a second time, the parent held the door closed for a short interval each time. The intervals were progressively lengthened until the child stayed in bed. Once the child stayed in bed, the door was left open. Parents explained the routine to the child before treatment, and the child's successful behaviour was rewarded with praise and small rewards."; and (reference 35) "The therapist discussed certain techniques with the parent: Extinction and graduated extinction procedures such as checking and gradual withdrawal, and stimulus-control procedures and positive reinforcement."

- *Extinction* (reference 34) consisted of the following: "Parents put the child to bed after pre-bedtime routines, said 'good night', left the room, and did not return. Parents could check the child briefly in the night if they woke, then leave and not return. If the child left the bedroom, they were given 1 warning each night. If the child left the bedroom a second time, they were kept in the room by the parents by closing the door or using a child gate. The door was kept closed until the child was asleep. Parents explained the routine to the child before treatment, and the child's successful behaviour was rewarded with praise and small rewards."
- *Sleep hygiene* (reference 38) consisted of a bedtime routine: "The bedtime routine included one week of usual routine, followed by 2 weeks of a 3-step bedtime routine of bathing, applying lotion, and quiet activities such as cuddling with the lights out within 30 minutes of the end of the bath."

## GRADE table

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-09-18
**Question:** Should sleep hygiene vs no treatment be used in children and adolescents after the first month of a potentially traumatic event?
**Bibliography:** Mindell 2009

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Sleep hygiene | No treatment | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | |
| **Symptom severity**[1,2] (better indicated by lower values) | | | | | | | | | | | | |
| 1[3] | Randomized trials | Very serious[4] | No serious inconsistency[5] | No serious indirectness | No serious imprecision | None | 0[6] | – | – | MD 0 higher (0 to 0 higher)[1,2] | ☐☐☐☐ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Prevention of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] Infant Study: Sleep latency (min) at week 3: Control 14.9 (8.69), Intervention 12.4 (9.65). Number of night wakings: Control 1.4 (0.97), Intervention 1.0 (0.76) Duration of night wakings (min): Control 18.9 (21.33), Intervention 12.6 (11.79). On the basis of these results the authors concluded that instituting a consistent nightly bedtime routine is beneficial in improving multiple aspects of infant sleep, resulting in shorter sleep onset latency, decreased wakefulness after sleep onset and increased sleep consolidation.

[2] Toddlers Study: Sleep latency (min): Control 2.6 (13.50), Intervention 16.3 (12.05). Number of night wakings: Control 1.0 (1.01), Intervention 0.6 (0.71). Duration of night wakings (min): Control 13.3 (15.65), Intervention 8.2 (9.85). On the basis of these results the authors concluded that instituting a consistent nightly bedtime routine is beneficial in improving multiple aspects of toddler sleep, resulting in shorter sleep onset latency, decreased wakefulness after sleep onset and increased sleep consolidation.

[3] Mindell (2009) as identified by BMJ Clinical Evidence (2010).

[4] Two age-specific three-week studies are described. In the first it is reported that "134 families were assigned" and the term random allocation is not mentioned. In the second it is reported that 133 families were randomly assigned. No further details are reported.

[5] Only one study included in the analysis.

[6] There were originally 209 families in the infant study who completed the study; of these, 206 (98.6%) had complete data. Similarly, there were complete data for 199 (94.8%) of the original 210 families in the toddler study.

**Author(s):** Corrado Barbui, Wietse Tol

**Date:** 2012-09-24

**Question:** Should extinction/graduated extinction vs no treatment be used in children and adolescents after the first month of a potentially traumatic event?

**Bibliography:** Reid 1999, Seymour 1989 (from BMJ Clinical Evidence 2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Extinction/graduated extinction | No treatment | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Quality assessment | | | | No. of patients | | Effect | | | |
| **Symptom severity** (better indicated by lower values) | | | | | | | | | | | | |
| 2[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Serious[4] | None | 0[5] | – | – | MD 0 higher (0 to 0 higher)[6] | ◻◻◻◻ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Prevention of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] Reid (1999), Seymour (1989) (from BMJ Clinical Evidence, 2010).
[2] Random assignment and concealment of allocation not described, no blindness.
[3] Two studies included in the analysis but no meta-analysis was carried out.
[4] Small samples in both groups.
[5] Reid (1999): 43 participants. Seymour (1989): 45 participants.
[6] Seymour (1989), experimental group (standardized sleep programme, i.e. an eight-page Parent Guide plus an hour-long interview to establish the programme, followed by telephone calls each day at first and as needed thereafter): minutes awake each night 15.2 (SD 15.2). Control group (no treatment): minutes awake each night 41.5 (SD 32.9). Reid (1999), experimental group (standard ignoring treatment/graduated ignoring treatment): average weekly number of good bedtimes: 5.36 (1.91). Control group (no treatment): average weekly number of good bedtimes: 0.62 (1.63).

## PART 2: FROM EVIDENCE TO RECOMMENDATIONS(S)

### Evidence to recommendation table

| Benefits | The evidence is very limited, so the clinical benefit of organizing bedtime routines, procedures for settling the child and for the handling of crying is unclear. |
|---|---|
| Harms | The evidence is very limited, so the harms of organizing bedtime routines, procedures for settling the child and for the handling of crying are unclear. |

| Value and preferences | |
|---|---|
| In favour | Severe insomnia undermines the capacity of persons to carry out basic tasks for day-to-day living.  After some recent potentially traumatic event (e.g. exposure to war or natural disaster) it is important for the survivor to sleep sufficiently to be able to carry out essential survival tasks. |
| Against | |

| Feasibility (including economic consequences) | |
|---|---|

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits* | Yes<br>**No X** |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

> ### Recommendation 6
> **On the basis of available evidence, no specific recommendation can be made for early psychological interventions in children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: not applicable*
> *Quality of evidence: low*

**Remarks**
*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. This includes assessment of the child's perception as to why insomnia may be present. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*Relaxation techniques and advice about sleep hygiene (see recommendation 5 on psychological interventions for insomnia in adults) may be safe, feasible and potentially effective strategies in adolescents (age 10-19 years).*

*Health-care providers should explain that insomnia is common after exposure to extreme stressors. If insomnia persists for more than one month the person should be reassessed for other conditions that may need treatment, including anxiety disorders (posttraumatic stress disorder, generalized anxiety disorder, panic disorder), depressive disorder and, in adolescents, alcohol or drug use disorder.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.*

# 7. Acute (secondary) insomnia (first month): pharmacological interventions – adults

**Q7. For adults with acute (secondary) insomnia in the first month after a potentially traumatic event, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

Insomnia is commonly associated with mood and anxiety disorders, including in the context of exposure to potentially traumatic events.[23] It is noted that insomnia may also have physical and other psychological causes, for example cardiovascular disorders, alcohol use disorder and (prescription and non-prescription) drug use disorder.

There is uncertainty how to treat adults with insomnia in the first month of a potentially traumatic event.[24] This type of insomnia is referred to as secondary insomnia (primary insomnia is diagnosed when somatized tension and learned sleep-incompatible behaviours play a predominant role in the maintenance of poor sleep). Given the timeframe of this scoping question (within the first month of exposure to a potentially traumatic event), the focus is here on "acute insomnia".[25,26]

Although benzodiazepines are commonly used, health-care providers have expressed worries about iatrogenic effects of these drugs,[27] making this an important scoping question.

---

[23] Lamarche & De Koninck (2007). Sleep disturbance in adults with Posttraumatic Stress Disorder. *Journal of Clinical Psychiatry*, 68, 1257-70.

[24] Harvey, Jones & Schmidt (2003). Sleep and Posttraumatic Stress Disorder: a review. *Clinical Psychology Review*, 23, 377-407.

[25] Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf

[26] Wang, Wang & Tsai (2005). Cognitive behavioural therapy for primary insomnia: a systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.

[27] De Niet et al. (2009). Review of systematic reviews about the efficacy of non-pharmacological interventions to improve sleep quality in insomnia. *International Journal for Evidence Based Healthcare*, 7, 233-42.

## PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:**      Adults with insomnia, within the first month of a potentially traumatic event
- **Interventions:**  Benzodiazepines
- **Comparison:**    Treatment as usual or no treatment/waitlist
- **Outcomes:**
    - Symptom severity post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

### List of the systematic reviews identified by the search process

The search was conducted on 6 March 2012 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "insomnia" AND "stress" OR "trauma". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "insomnia". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adults (>18 years), focusing on psychological and social treatments. We did not include systematic reviews of pharmacological and manual therapies (e.g. massage therapy, acupuncture, spinal manipulation). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Nappi, C.M., Drummond, S.P.A. & Hall, J.M.H. (2012). Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. *Neuropharmacology*, doi:10.1016/j.neuropharm.2011.02.029.
NOTE: This review does not provide a meta-analysis, but identifies less recent systematic reviews that included relevant meta-analyses.

Van Liempt, S., Vermetten, E., Geuze, E. & Westenberg, H.G.M. (2006). Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review. *International Clinical Psychopharmacology*, 21, 193–202.
NOTE: older than two years, but this seems to be the most up-to-date relevant review with data reported.

Acute (secondary) insomnia (first month): pharmacological interventions – adults

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Alessi, C. and Vitiello, M.V. (2011). Insomnia (primary) in older people. *Clinical Evidence*, 10, 2302.
REASON FOR EXCLUSION: focuses on primary insomnia, and on a specific population sub-group (older adults).

Aurora, R.N., Zak, R.S., Auerbach, S.H., Casey, K.R., Chowdhuri, S., Karippot, A., Maganti, R.K., Ramar, K., Kristo, D.A., Bista, S.R., Lamm, C.I., Morgenthaler, T.I. (2010). Best practice guide for the treatment of nightmare disorder in adults. *Journal of Clinical Sleep Medicine*, 6(4), 389-401.
REASON FOR EXCLUSION: focuses on nightmares specifically, only searched PubMed, and identified only studies with chronic nightmares

Buscemi, N., Vandermeer, B., Friesen, C., Bialy, C., Tubman, M., Ospina, M., Klassen, T.P., Witmans, M. (2007). The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs.
REASON FOR EXCLUSION: focuses on chronic insomnia, more than two years old.

Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., Bogg, J., Dickson, R. & Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. *Health, Technology, Assessment*, 8(24).
REASON FOR EXCLUSION: older than two years old.

Hirst, A. & Sloan, R. (2009). Benzodiazepines and related drugs for insomnia in palliative care. *Cochrane Database of Systematic Reviews*, 4.
REASON FOR EXCLUSION: focuses specifically on interventions in palliative care.

National Institute for Clinical Excellence (2004). Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia.
REASON FOR EXCLUSION: older than two years; lack of actual data in the guidelines.

Riemann, D. & Perlis, M.L. (2009). The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. *Sleep Medicine Reviews*, 13, 205-14.
REASON FOR EXCLUSION: focuses specifically on chronic insomnia.

Sateia, M.J. & Dowell, P.D. (2004). Insomnia. *Lancet*, 364, 1959-73.
REASON FOR EXCLUSION: focuses specifically on chronic insomnia, and older than two years.

Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., Sateia, M. (2008). Clinical guideline for the evaluation and management of chronic insomnia in adults. *Journal of Clinical Sleep Medicine*, 15(5), 487-504.
REASON FOR EXCLUSION: focuses on chronic insomnia, and older than two years.

Silber, M.H. (2005). Chronic insomnia. *New England Journal of Medicine*, 353, 803-10.
REASON FOR EXCLUSION: focuses on chronic insomnia, older than two years, and no systematic review methodology reported.

Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf.
REASON FOR EXCLUSION: no methodology of a systematic review is reported.

Uchiyama, M., Inoue, Y., Uchimura, N., Kawamori, R., Kurabayashi, M., Kario, K., Watada, H. (2011). Clinical significance and management of insomnia. *Sleep and Biological Rhythms*, 9, 63-72.
REASON FOR EXCLUSION: inclusion of Japanese consensus statement, but no methodology of a systematic review is reported.

Wilson, S.J., Nutt, D.J., Alford, C., Argyropoulos, S.V., Baldwin, D.S., Bateson, A.N. et al. (2009). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. *Journal of Psychopharmacology*, 24(11), 1577-1600.
REASON FOR EXCLUSION: represents a comprehensive and recent effort to make practice guidelines; consensus was reached where evidence was insufficient. However, data are not included in this paper and the Nappi et al. (2012) review is more recent.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Pharmacological intervention for acute secondary insomnia | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | Van Liempt (2006) and Nappi (2012) identified Nowell (1996) and Holbrook (2000) | Nowell (1996) provides data on the efficacy of benzodiazepines versus placebo in chronic insomnia in general patient populations. Although there is an issue with directness (the focus here is on acute insomnia in the context of exposure to trauma), it represents the most recent meta-analysis with a focus on double-blind placebo controlled trials only.<br><br>Holbrook (2000) provides data on adverse effects. |

## Narrative description of the studies that went into analysis

Van Liempt and colleagues (2006) provide a systematic review of the efficacy of PTSD-related drugs, including benzodiazepines for PTSD-related sleep complaints. A total of 48 articles were identified through searches in MEDLINE, Embase and the Cochrane Library from 1980 onwards. The authors conclude that there is little evidence to support the use of benzodiazepines for trauma-related nightmares and insomnia. Nappi, Drummond and Hall (2012) published an update of this review, which identified two further studies: one small randomized controlled trial (RCT) comparing zolpidem with hypnotherapy in persons already receiving SSRIs and supportive psychotherapy (hypnotherapy was more effective with regard to sleep quality and PTSD symptoms); and one six-month cohort study with Australian Vietnam veterans in which no pre-post differences were identified. This systematic review does not provide a meta-analysis of these data.

## GRADE table

**Author(s):** Corrado Barbui
**Date:** 2012-03-10
**Question:** Should benzodiazepines vs placebo be used in adults with insomia after the first month of a potentially traumatic event?
**Bibliography:** Nowell (1996); Holbrook (2000)

| No. of studies | Quality assessment | | | | | | No. of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Benzodiazepines | Placebo | Relative (95% CI) | Absolute | | |
| **Sleep onset latency** (better indicated by higher values) | | | | | | | | | | | | |
| 18[1] | Randomized trials | No serious risk of bias[2] | Serious[3] | Serious[4] | No serious imprecision | None | 0[5] | – | – | Cohen's d 0.56 higher (0.41 to 0.71 higher) | ⬜⬜⬜⬜ LOW | IMPORTANT |
| **Total sleep time** (better indicated by higher values) | | | | | | | | | | | | |
| 17[1] | Randomized trials | No serious risk of bias[2] | No serious inconsistency | Serious[6] | No serious imprecision | None | 0[5] | – | – | Cohen's d 0.71 higher (0.55 to 0.87 higher) | ⬜⬜⬜⬜ MODERATE | IMPORTANT |
| **Number of awakenings** (better indicated by higher values) | | | | | | | | | | | | |
| 10[1] | Randomized trials | No serious risk of bias[2] | No serious inconsistency | Serious[6] | No serious imprecision | None | 0[5] | – | – | Cohen's d 0.65 higher (0.48 to 0.82 higher) | ⬜⬜⬜⬜ MODERATE | IMPORTANT |
| **Sleep quality** (better indicated by higher values) | | | | | | | | | | | | |
| 14[1] | Randomized trials | No serious risk of bias[2] | No serious inconsistency | Serious[6] | No serious imprecision | None | 0[5] | – | – | Cohen's d 0.62 higher (0.45 to 0.79 higher) | ⬜⬜⬜⬜ MODERATE | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

| Adverse effects | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11[7] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[6] | No serious imprecision | None | 298/506 (58.9%) | 222/502 (44.2%) | OR 1.8 (1.4 to 2.4) | 146 more per 1000 (from 84 more to 213 more) | ⊡⊡⊡⊡ MODERATE | IMPORTANT |

[1] From Table 5 of Nowell (1996).

[2] Only double-blind placebo controlled studies were included.

[3] Forest plot not reported. Heterogeneity of effect size p 0.09.

[4] No explanation was provided.

[5] Unclear.

[6] The focus of this scoping question is "adults with insomnia, after the first month of a potentially traumatic event". However, Nowell (1996) is focused on primary insomnia.

[7] From Figure 2 of Holbrook (2000).

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | There is indirect evidence (based on studies with adults with chronic insomnia without exposure to a traumatic event) suggesting that benzodiazepines in adults with insomnia have a beneficial effect in terms of sleep onset latency, total sleep time, number of awakenings or sleep quality. The confidence in estimate is MODERATE (LOW for the outcome sleep onset latency).<br><br>There is no systematic review of evidence on the effect of benzodiazepines on functioning or presence of disorder. |
|---|---|
| Harms | There is evidence suggesting that benzodiazepines in adults with insomnia are associated with more persons leaving the study early, a proxy measure of treatment acceptability (58.9% versus 44.2%). The confidence in estimate is MODERATE.<br><br>In addition to the evidence from randomized trials, data from observational and epidemiological studies highlighted a risk of tolerance and dependence. According to NICE UK, one of the key concerns about the use of benzodiazepines is that many people develop tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them (10–30% of chronic benzodiazepines users are physically dependent on them) and suffer a withdrawal syndrome when they stop taking them (50% of all users suffer withdrawal symptoms). The withdrawal syndrome includes anxiety, depression, nausea and perceptual changes.<br><br>Rebound insomnia may occur and is characterized by a worsening of the original insomnia symptoms. There are also problems of abuse with benzodiazepines as they enhance and often prolong the "high" obtained from other drugs and alleviate their withdrawal effects.<br><br>The safety of psychotropic drugs in pregnancy and breastfeeding is not clearly established. In particular, exposure to benzodiazepines during the first trimester is associated with an increased risk of oral clefts, and exposure during the third trimester is associated with neonatal difficulties (Dolovich et al., 1998, *BMJ* 317: 839-43). A number of consensus-based guidelines and narrative reviews argue against the use of benzodiazepines for posttraumatic stress symptoms (see http://www.ptsd.va.gov/professional/pages/clinicians-guide-to-medications-for-ptsd.asp). |

| Value and preferences | |
|---|---|
| In favour | Severe insomnia undermines the capacity of persons to carry out basic tasks for day-to-day living and may result in depression or self-medication such as using excess alcohol or other substances. Self-medication and substance use may continue even when insomnia, ASD or PTSD symptoms decrease over time. After certain recent events (e.g. exposure to war or natural disaster) it is important for the survivor to sleep sufficiently to be able to carry out essential survival tasks. |
| Against | There is evidence that simple non-pharmacological methods – sleep hygiene and relaxation – are effective at reducing acute insomnia and have no long-term ill effects (scoping question 14). Stressor-related anxiety should be addressed before initiating benzodiazepines. |

| Feasibility (including economic consequences) | Training is required in the understanding and safe administration of all psychotropic medications. |
|---|---|
| | In many low-income countries, continuous availability of psychotropic drugs in non-specialized health care is a challenge. |
| | Benzodiazepines are associated with low acquisition costs, but shorter-acting benzodiazepines are not generally available in low-income countries. |
| | Diazepam (as a representative of the benzodiazepines) is included in the WHO list of essential medicines for the treatment of anxiety disorders. |
| | Diazepam is included in the Interagency Emergency Health Kit (IEHK), a box with medicines and medical supplies designed to meet the expected primary health care needs of people exposed to major humanitarian emergencies. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | **Yes X**<br>No |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 7*
**Benzodiazepines should not be offered to adults with insomnia in the first month after a potentially traumatic event.**

*Strength of recommendation: standard*
*Quality of evidence: moderate*

**Remarks**
*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*There are alternatives to pharmacological treatment (see (a) recommendation 5 on psychological interventions for insomnia in adults and (b) WHO (2010) mhGAP recommendations on psychological first aid).*

*In exceptional cases when psychologically oriented interventions are not feasible, short-term treatment (3–7 days) with benzodiazepines may be considered as a treatment option for insomnia that interferes severely with daily functioning. The following precautions should be considered: (a) there are possible interactions with other drugs; (b) necessary precautions should be taken when prescribing to elderly populations and pregnant or breastfeeding women; and (c) use of benzodiazepines can quickly lead to dependence in some people. Accordingly benzodiazepines should only be prescribed for insomnia in exceptional cases and for a very short time period. Benzodiazepines are often overprescribed.*

*Health-care providers should explain that insomnia is common after recent exposure to extreme stressors. If insomnia persists for more than one month, the person should be reassessed for other conditions that may need treatment, including anxiety disorders (posttraumatic stress disorder, generalized anxiety disorder, panic disorder), depression and alcohol or drug use disorder.*

# 8. Acute (secondary) insomnia (first month): pharmacological interventions – children and adolescents

**Q8. For children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

Insomnia is commonly associated with mood and anxiety disorders, including in the context of exposure to potentially traumatic events.[28] It is noted that insomnia may also have physical and other psychological causes, for example cardiovascular disorders, alcohol use disorder and (prescription and non-prescription) drug use disorder.

There is uncertainty how to treat children and adolescents with insomnia in the first month of a potentially traumatic event.[29] This type of insomnia is referred to as secondary insomnia (primary insomnia is diagnosed when somatized tension and learned sleep-incompatible behaviours play a predominant role in the maintenance of poor sleep). Given the timeframe of this scoping question (within the first month of exposure to a potentially traumatic event), the focus is here on "acute insomnia".[30,31]

Although benzodiazepines are commonly used, health-care providers have expressed worries about iatrogenic effects of these drugs,[32] making this an important scoping question.

---

[28] Lamarche & De Koninck (2007). Sleep disturbance in adults with Posttraumatic Stress Disorder. *Journal of Clinical Psychiatry*, 68, 1257-70.

[29] Harvey, Jones & Schmidt (2003). Sleep and Posttraumatic Stress Disorder: a review. *Clinical Psychology Review*, 23, 377-407.

[30] Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis. http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf.

[31] Wang, Wang & Tsai (2005). Cognitive behavioural therapy for primary insomnia: a systematic review. *Journal of Advanced Nursing*, 50(5), 553–564.

[32] De Niet et al. (2009). Review of systematic reviews about the efficacy of non-pharmacological interventions to improve sleep quality in insomnia. *International Journal for Evidence Based Healthcare*, 7, 233-42.

# PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)
- **Population:** Children and adolescents with insomnia, within the first month of a potentially traumatic event
- **Interventions:** Benzodiazepines
- **Comparison:** Treatment as usual or no treatment/waitlist
- **Outcomes:**
    - Symptom severity post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process
The search was conducted on 6 March 2012 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "insomnia" AND "stress" OR "trauma". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "insomnia". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents, focusing on pharmacological treatments. In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

We identified a systematic review conducted by Bruni and Novelli for *Clinical Evidence*, published by the *British Medical Journal* (Bruni and Novelli, 2010. Sleep disorders in Children. *Clinical Evidence*, 9, 2304). This systematic review searched the following databases up to September 2009: Medline, Embase and the Cochrane Library, as well as harm alerts from US and UK regulatory bodies. This review identified 13 randomized controlled trials (RCTs) that met inclusion criteria (a focus on dyssomnia – defined as paediatric insomnia or excessive daytime sleepiness – and parasomnia). Evidence from these studies was subsequently evaluated using GRADE methodology. However, no studies evaluating benzodiazepines were identified.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Alessi, C. & Vitiello, M.V. (2011). Insomnia (primary) in older people. *Clinical Evidence*, 10, 2302.
REASON FOR EXCLUSION: focuses on primary insomnia, and on a specific population sub-group (older adults).

Aurora, R.N., Zak, R.S., Auerbach, S.H., Casey, K.R., Chowdhuri, S., Karippot, A., Maganti, R.K., Ramar, K., Kristo, D.A., Bista, S.R., Lamm, C.I., Morgenthaler, T.I. (2010). Best practice guide for the treatment of nightmare disorder in adults. *Journal of Clinical Sleep Medicine*, 6(4), 389-401.
REASON FOR EXCLUSION: focuses on nightmares specifically, only searched PubMed, and identified only studies with chronic nightmares; no studies focused on children and adolescents.

Buscemi, N., Vandermeer, B., Friesen, C., Bialy, C., Tubman, M., Ospina, M., Klassen, T.P., Witmans, M. (2007). The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs.
REASON FOR EXCLUSION: focuses on chronic insomnia, more than two years old; no studies focused on children and adolescents.

Dündar, Y., Boland, A., Strobl, J., Dodd, S., Haycox, A., Bagust, A., Bogg, J., Dickson, R. and Walley, T. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. *Health, Technology, Assessment*, 8(24).
REASON FOR EXCLUSION: older than two years.

Hirst, A. & Sloan, R. (2009). Benzodiazepines and related drugs for insomnia in palliative care. *Cochrane Database of Systematic Reviews*, 4.
REASON FOR EXCLUSION: focuses specifically on interventions in palliative care.

Nappi, C.M., Drummond, S.P.A. & Hall, J.M.H. (2012). Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. *Neuropharmacology*, doi:10.1016/j.neuropharm.2011.02.029.
REASON FOR EXCLUSION: this review does not provide a meta-analysis; no studies focused on children and adolescents.

National Institute for Clinical Excellence (2004). Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia.
REASON FOR EXCLUSION: older than two years; lack of actual data in the guidelines.

Riemann, D. & Perlis, M.L. (2009). The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. *Sleep Medicine Reviews*, 13, 205-14.
REASON FOR EXCLUSION: focuses specifically on chronic insomnia.

Sateia, M.J. & Dowell, P.D. (2004). Insomnia. *Lancet*, 364, 1959-73.
REASON FOR EXCLUSION: focuses specifically on chronic insomnia, and older than two years.

Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., Sateia, M. (2008). Clinical guideline for the evaluation and management of chronic insomnia in adults. *Journal of Clinical Sleep Medicine*, 15(5), 487-504.
REASON FOR EXCLUSION: focuses on chronic insomnia, and older than two years.

Silber, M.H. (2005). Chronic insomnia. *New England Journal of Medicine*, 353, 803-10.
REASON FOR EXCLUSION: focuses on chronic insomnia, older than two years and no systematic review methodology reported.

Toward Optimized Practice (TOP) Program (2007). Clinical Practice Guideline Adult Insomnia: Assessment to Diagnosis.
http://www.centreforsleep.com/assets/images/pdf/insomnia_assessment_guideline07.pdf.
REASON FOR EXCLUSION: no methodology of a systematic review is reported.

Uchiyama, M., Inoue, Y., Uchimura, N., Kawamori, R., Kurabayashi, M., Kario, K., Watada, H. (2011). Clinical significance and management of insomnia. *Sleep and Biological Rhythms*, 9, 63-72.
REASON FOR EXCLUSION: inclusion of Japanese consensus statement, but no methodology of a systematic review is reported.

Van Liempt, S., Vermetten, E., Geuze, E. & Westenberg, H.G.M. (2006). Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review. *International Clinical Psychopharmacology*, 21, 193–202.
REASON FOR EXCLUSION: older than two years, but this seems to be the most up-to-date relevant review with data reported; no studies focused on children and adolescents.

Wilson, S.J., Nutt, D.J., Alford, C., Argyropoulos, S.V., Baldwin, D.S., Bateson, A.N. et al. (2009). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. *Journal of Psychopharmacology*, 24(11), 1577-1600.
REASON FOR EXCLUSION: represents a comprehensive and recent effort to make practice guidelines; consensus was reached where evidence was insufficient. However, data are not included in this paper.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Pharmacological intervention for acute secondary insomnia | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | No data |

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | A systematic review found no evidence on the benefit of benzodiazepines for children and adolescents with acute secondary insomnia with regard to symptom severity, presence of disorder or functioning. |
|---|---|
| Harms | There is no systematic review of evidence on the potential negative consequences of benzodiazepines for children and adolescents with acute secondary insomnia.<br><br>However, the NICE guidelines state the following with regard to adults:<br>"One of the key concerns about the use of benzodiazepines is that many people develop tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them (both physically and psychologically), and suffer a withdrawal syndrome when they stop taking them. The withdrawal syndrome may be prolonged and may develop at any time up to 3 weeks after cessation of a long acting benzodiazepine, or a few hours after cessation of a short-acting one. The syndrome includes anxiety, depression, nausea and perceptual changes. 'Rebound insomnia' also occurs and is characterized by a worsening of the original insomnia symptoms. There are also problems of abuse with benzodiazepines as they enhance and often prolong the 'high' obtained from other drugs and alleviate their withdrawal effects.<br><br>"It has been estimated that 10–30% of chronic benzodiazepines users are physically dependent on them and 50% of all users suffer withdrawal symptoms. Factors potentially associated with an increased risk of developing dependency include short duration of action, long-term use, high dose, high potency, alcoholism and other drug dependency, personality disorders and use without medical supervision."<br>Similarly, clinical guidelines by the British Medical Journal report "paucity of evidence about effective treatments for sleep disorders in children, especially parasomnias, but behavioural interventions may be the best first-line approach" (p.2). |

| Value and preferences | |
|---|---|
| In favour | |
| Against | Consensus statements on the use of hypnotic medications in children all recommend the use of behavioural interventions as a first-line approach. |

| Feasibility (including economic consequences) | Training is required in the understanding and safe administration of all psychotropic medications. |
|---|---|
| | Benzodiazepines may not be continuously available in LMIC settings. |
| | To avoid the risks of harm referred to above, training of primary care practitioners may be necessary on responsible use of benzodiazepines. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

*Recommendation 8*

**Benzodiazepines should not be offered to children and adolescents with acute (secondary) insomnia in the first month after a potentially traumatic event.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**Remarks**

*It is important always to assess for and manage other possible physical causes for insomnia, even when the insomnia starts within one month of a potentially traumatic event. Where possible, environmental causes for insomnia (e.g. noisy environments) should be addressed.*

*There are alternatives to pharmacological treatment (see recommendation 6's remarks on psychological interventions for insomnia in children and adolescents).*

*Health-care providers should explain that insomnia is common after recent exposure to extreme stressors. If insomnia persists for more than one month the person should be reassessed for other conditions that may need treatment, including anxiety disorders (posttraumatic stress disorder, generalized anxiety disorder, panic disorder), depression and, in adolescents, alcohol or drug use disorder.*

# 9. Secondary non-organic enuresis (first month): early psychological interventions – children

**Q9. In children with secondary non-organic enuresis after a potentially traumatic recent event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines. This scoping question covers bedwetting in the first month after a potentially traumatic event.

The ICD-10 describes non-organic enuresis as "involuntary voiding of urine, by day and/or by night which is abnormal in relation to the individual's mental age and which is not a consequence of a lack of bladder control due to any neurological disorder, to epileptic attacks or to any structural abnormality of the urinary tract" (p.285). Non-organic enuresis may be primary (in children who have never been completely continent) or secondary (in children who experience a period of acquired bladder control). Furthermore, non-organic enuresis may be mono-symptomatic (i.e. be the main complaint) or poly-symptomatic (may be one complaint among more emotional/behavioural problems). Enuresis is a common complaint in primary care for children recently exposed to potentially traumatic events[33] and may have important harmful mental and social consequences, including decreased self-esteem, anxiety and harsh punitive parental reactions.[34]

## PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:** Children with non-organic (secondary) enuresis in the first month after a potentially traumatic event
- **Interventions:** Any psychological and social intervention
- **Comparison:** Treatment as usual or no treatment/waitlist

---

[33] Al-Jawadi, A.A. & Abdul-Rhman, S. (2007). Prevalence of childhood and early adolescence mental disorders among children attending primary health care centers in Mosul, Iraq: a cross-sectional study. *BMC Public Health*, 7, 274.

[34] Sapi, M.C., Vasconcelos, J.S.P., Silva, F.G., Damião, R., da Silva, E.A. (2009). Assessment of domestic violence against children and adolescents with enuresis. *Jornal de Pediatria*, 85(5), 433-37.

- **Outcomes:**
    - Symptom severity post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "enuresis" OR "bedwetting" AND "systematic review". In addition, in the PILOTS database the keywords "dissociation" and "conversion" were used. In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keywords "bedwetting" and "enuresis". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents, focusing on psychological and social treatments. We did not include systematic reviews of pharmacological and manual therapies (e.g. massage therapy, acupuncture, spinal manipulation). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

National Clinical Guideline Centre (NICE) (2010). Nocturnal Enuresis: The Management of Bedwetting in Children and Young People. London: National Clinical Guideline Centre. Available from www.nice.org.uk.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

American Academy of Child and Adolescent Psychiatry (2004). Practice parameter for the assessment and treatment of children and adolescents with enuresis. *Journal of the American Academy of Child and Adolescent Psychiatry*, 43(12), 1540-1550.
REASON FOR EXCLUSION: more than two years old.
Butler, R.J., Gasson, S.L. (2005). Enuresis alarm treatment. *Scandinavian Journal of Urology and Nephrology*, 39, 349-357.
REASON FOR EXCLUSION: more than two years old.

Evans, J.H.C. (2001). Evidence based management of nocturnal enuresis. *British Medical Journal*, 323, 1167–1169.
REASON FOR EXCLUSION: more than two years old.

Glazener, C.M.A., Evans, J.H.C. (2009). Simple behavioural and physical interventions for nocturnal enuresis in children. *Cochrane Database of Systematic Reviews*, Issue 1.
REASON FOR EXCLUSION: the NICE (2010) review performed more recent searches.

Glazener, C.M.A., Evans, J.H.C., Cheuk, D.K.L. (2009). Complementary and miscellaneous interventions for nocturnal enuresis in children. *Cochrane Database of Systematic Reviews*, Issue 1.
REASON FOR EXCLUSION: the NICE (2010) review performed more recent searches.

Glazener, C.M.A., Evans, J.H.C., Peto, R.E. (2004). Treating nocturnal enuresis in children. *Journal of Wound Ostomy and Continence Care*, 31(4), 223-34.
REASON FOR EXCLUSION: more than two years old, and summarizes Cochrane review which was updated in the meantime.

Glazener, C.M.A., Evans, J.H.C., Peto, R.E. (2008). Complex behavioural and educational interventions for nocturnal enuresis in children. *Cochrane Database of Systematic Reviews*, Issue 3.
REASON FOR EXCLUSION: the NICE (2010) review performed more recent searches.

Glazener, C.M.A., Evans, J.H.C., Peto, R.E. (2009). Alarm interventions for enuresis in children. *Cochrane Database of Systematic Reviews*, Issue 1.
REASON FOR EXCLUSION: the NICE (2010) review performed more recent searches.

Glazener, C.M.A., Peto, R.E., Evans, J.H.C. (2003). Effects of interventions for the treatment of nocturnal enuresis in children. *Quality and Safety in Health Care*, 12, 390-394.
REASON FOR EXCLUSION: more than two years old, and summarizes Cochrane review which was updated in the meantime.

Hjalmas, K., Arnold, T., Bower, W., Caione, P., Chiozza, L.M., von Gontard, A., Han, S.W., Husman, D.A., Kawauchi, A., Läckgren, G., Lottmann, H., Mark, S., Rittig, S., Robson, L., Vande Walle, J., Yeung, C.K. on behalf of the International Children's Continence Society (2004). Nocturnal enuresis: An international evidence based management strategy. *The Journal of Urology*, 171, 2545-2561.
REASON FOR EXCLUSION: more than two years old.

Hodgkinson, B., Josephs, K., Hegney, D. (2010). Best practice in the management of primary nocturnal enuresis in children: a systematic review. *JBI Library of Systematic Reviews*; 8(5): 173-254.
REASON FOR EXCLUSION: no formal meta-analysis reported.

Jindal, V., Ge, A., Mansky, P.J. (2008). Safety and efficacy of acupuncture in children: A review of the evidence. *Journal of Pediatric Hematology & Oncology*, 30, 431-442.
REASON FOR EXCLUSION: more than two years old.

Kiddoo, D. (2007). Nocturnal enuresis. *Clinical Evidence*, 10, 305.
REASON FOR EXCLUSION: more than two years old.

Mathew, J.L. (2010). Evidence-based management of nocturnal enuresis: An overview of systematic reviews. *Indian Pediatrics*, 777-780.
REASON FOR EXCLUSION: reports on existing systematic reviews and meta-analyses. Searched Cochrane Database and MEDLINE, no new meta-analysis conducted.

Kristensen, G. and Jensen, I.N. (2003). Meta-analyses of alarm treatment for nocturnal enuresis – reporting practice, criteria, and frequency of bedwetting. *Scandinavian Journal of Urology and Nephrology*, 37(3), 232-238.
REASON FOR EXCLUSION: more than two years old.

Neveus, T. Eggert, P., Evans, J., Macedo, A., Rittig, S., Tekgül, S., Vande Walle, J., Yeung, C.K., Robson, L. (2010). Evaluation of and treatment for monosymptomatic enuresis: A standardization document from the International Children's Continence Society. *The Journal of Urology*, 83, 441-447.
REASON FOR EXCLUSION: no methods for systematic review reported.

Nunes, V.N., O'Flynn, N., Evans, J., Sawyer, L., on behalf of the Guideline Development Group (2010). Management of bedwetting in children and young people: summary of NICE guidance. *British Medical Journal*, 341, c5399.
REASON FOR EXCLUSION: summarizes NICE guidelines which were included.

Paediatric Society New Zealand (PSNZ) (2005). Best Practice Evidence Based Guideline: Nocturnal Enuresis 'Bedwetting'. Wellington: PSNZ.
REASON FOR EXCLUSION: more than two years old.

Tekgül, S., Riedmiller, H., Gerharz, E., Hoebeke, P., Kocvara, R., Nijman, R. Radmayr, C., Stein, R. (2011). Guidelines on Paediatric Urology. Arnhem, the Netherlands: European Society for Paediatric Urology.
REASON FOR EXCLUSION: no systematic review methodology described, except for a reference to searching MEDLINE.

van Dyk, J.C., Duvenhage, F., Coetzee, L.J.E., Segone, A.M., Fockema, M., Smart, D., Haffejee, M., Lefakane, S.B.I., Roos, J., Stellmacher, G., McGillevray, D., Bereczky, Z. (2003). South African guidelines for the management of nocturnal enuresis. *South African Medical Journal*, 93(5), 338-340.
REASON FOR EXCLUSION: more than two years old.

Wespes, E. (2010). Enurésie: les traitements soumis à l'épreuve EBM. *Revue Medicale de Bruxelles*, 31, 351-355.
REASON FOR EXCLUSION: based on guidelines by the European Urological Association and the International Children's Continence Society (Neveus et al., 2010). No systematic review methodology reported.

COMMENT: Glazener, Evans & Peto (2008), Glazener, Evans & Cheuk (2009), Glazener, Evans & Peto (2009) and NICE (2010) are all rigorous systematic reviews and meta-analyses of strong quality, focusing on specific psychological and social interventions for enuresis. However, NICE (2010) performed searches more recently (in April 2009, vs. 22 November 2005, 20 March 2008, 16 November 2006 and 28 February 2007 for Glazener and team reviews respectively). NICE (2010) additionally provides GRADEd evidence.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Fluid and diet restriction vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | NICE (2010), Glazener (2009) included Bhatia (1990)<br>No data<br>No data<br>No data | NICE (2010) provides the most recent high-quality systematic review and meta-analysis of psychological and social treatments for enuresis.<br>Note: NICE (2010) does not focus specifically on treatments in the first month of a potentially traumatic event(s).<br>Bhatia (1990): Our calculation of the comparison between: imipramine and simple behavioural intervention |

Continues…

| | | | | |
|---|---|---|---|---|
| | | | | (waking, fluid restriction, avoiding parental punishment) vs. imipramine alone. |
| 2 | Lifting and waking vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | NICE (2010), Glazener (2009) included Fournier (1987) and Turner (1970)<br>No data<br>No data<br>No data | |
| 3 | Bladder training and retention control vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | NICE (2010), Glazener (2009) included Harris (1977)<br>No data<br>No data<br>No data | Harris (1977) is the only RCT that compared retention training vs. waiting list. |
| 4 | Star charts vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | NICE (2010), Glazener (2009) included Fava (1981)<br><br>No data<br>No data | |
| 5 | Dry bed training[35] vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | NICE (2010)<br>No data<br>No data<br>No data | NICE (2010): dry bed training without an alarm compared to no treatment; dry bed training with an alarm compared to no treatment. |
| 6 | Alarms vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | NICE (2010)<br>No data<br>No data<br>No data | |

---

[35] Dry bed training is a training programme which may include combinations of a number of different behavioural interventions, and which may include rewards, punishment, training routines and waking routines, and may be undertaken with or without an alarm (NICE, 2010).

| 7 | Other psychological treatments vs. no treatment/control | Symptom severity Functioning Presence of disorder Adverse effects | NICE (2010) No data No data No data | Only one study compared psychological interventions with no treatment: CBT compared to no treatment (other studies are head-to-head comparisons). |
|---|---|---|---|---|
| 8 | Information and educational interventions vs. no treatment/control | Symptom severity Functioning Presence of disorder Adverse effects | NICE (2010) No data No data NICE (2010) | No studies available comparing information and educational interventions vs. no treatment/control (only head-to-head). |
| 9 | Alternative treatments (hypnosis) vs. no treatment/control | Symptom severity Functioning Presence of disorder Adverse effects | NICE (2010) No data No data NICE (2010) | No studies comparing hypnosis with no treatment/control (only head-to-head). |

## Narrative description of the studies that went into analysis

NICE provides clinical guidelines based on a thorough systematic review of evidence for both pharmacological and psychological interventions. NICE included randomized controlled trials (RCTs) comparing active treatments with treatment as usual or control conditions, as well as RCTs comparing active treatment conditions. Here, RCTs with a treatment as usual or control condition are included in GRADE tables. These studies were not conducted with acutely traumatized children in low- and middle-income countries. The following studies were included in NICE:

- Fluid and diet restriction (i.e. restriction of fluids, particularly before bed) will have been tried by many families before they seek professional help. Children with bedwetting may also have daytime urinary symptoms, and fluid restriction during the day may be used by children and young people themselves to manage symptoms of frequency and urgency when out of the home. The hypothesis that dietary restrictions may be beneficial to children with bedwetting is based on the idea that food allergies may provoke bladder instability): one RCT.
- Lifting and waking (i.e. lifting is described as lifting the child from their bed while they sleep or walking the child to the bathroom to pass urine, without necessarily waking the child. Waking is described as waking the child from their sleep and taking them to the bathroom to pass urine. Children can be woken at either set times or randomly during the night.): six RCTs.

- Bladder training (also described as bladder retraining, bladder drill, bladder re-education, bladder discipline) (i.e. involves the individual in attempting to increase the interval between the desire to void and actual void): five RCTs.
- Star charts (i.e. star charts and rewards systems are the giving of some reward either for a dry night or for the correct toileting behaviour, regardless of the child actually being dry overnight. The rewards can range from stars on charts in the child's room or in a family room to pocket money or time earned for a preferred activity, such as playing): six RCTs.
- Dry bed training (the dry bed training procedure was described as a first night of intensive training which included positive practice one hour before bedtime, being given fluid at bedtime, an alarm, hourly waking and cleanliness training when the child was wet. After the initial night's treatment, post-training supervision was given which continued to include an alarm, positive practice if the child was wet the night before, waking the child when the parent went to bed, cleanliness training if the child wet the bed, and praise if the child was dry in the morning. If the child was dry for seven consecutive nights the alarm was removed, and the parent would continue to check the bed in the morning. If the child was wet, cleanliness training would be used and positive practice was given the following evening. If the child was wet twice in a week, then post-training supervision was started again): five RCTs.
- Enuresis alarm (i.e. a battery-powered alarm that is triggered by urine coming into contact with the alarm sensor. Alarms come in two main groups: bed alarms where the sensor pad is placed under a draw sheet and body-worn alarms where the sensor is placed e.g. between two pairs of snugly fitting underpants. The alarms can generate various noises or sometimes pre-recorded sounds. Some body-worn alarms can be set to vibration with or without sound): 10 RCTs.

137

# GRADE tables

**Author(s):** Corrado Barbui

**Date:** 2012-02-27

**Question:** Should fluid and diet restriction vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?

**Bibliography:** Bhatia (1990) as described in NICE (2010) and in Glazener (2009)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Fluid and diet restriction | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity: number not achieving 14 dry nights** | | | | | | | | | | | | |
| 1[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | Serious[4] | Serious[5] | None | 2/20 (10%) | 8/20 (40%) | RR 0.25 (0.06 to 1.03)[6] | 300 fewer per 1000 (from 376 fewer to 12 more) | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] Bhatia (2009) as described in NICE (2010) and in Glazener (2009), p.14.

[2] High drop-out rate due to inadequate follow-up.

[3] Only one study included in this analysis.

[4] It is unclear if children were included in the first month after a potentially traumatic event.

[5] Only 40 patients included in this analysis.

[6] Our calculation with Cochrane RevMan Software.

138

**Author(s):** Corrado Barbui
**Date:** 2012-02-27
**Question:** Should lifting and waking vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?
**Bibliography:** Fournier (1987) and Turner (1970) as described in NICE (2010) and in Glazener (2009)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Lifting and waking | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Symptom severity: number not achieving 14 consecutive dry nights** | | | | | | | | | | | | |
| 1[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Very serious[4] | None | 14/15 (93.3%) | 13/17 (76.5%) | RR 1.22 (0.91 to 1.64) | 168 more per 1000 (from 69 fewer to 489 more) | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Symptom severity: mean wet nights on treatment** (better indicated by lower values) | | | | | | | | | | | | |
| 1[5] | Randomized trials | Serious[6] | No serious inconsistency[3] | No serious indirectness | Very serious[7] | None | 8 | 8 | – | MD 0 higher (0 to 0 higher)[8] | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Analysis 3.2 of Glazener (2009).

[2] Allocation was by means of stratification based on age and sex, but children who dropped out were replaced by the next child referred to the clinic.

[3] Only one study included in the analysis.

[4] Only 32 patients included in this analysis. Confidence interval ranges from no benefit to appreciable harm.

[5] From Analysis 3.5 of Glazener (2009).

[6] This study failed to provide standard deviations for continuous data.

[7] Only 16 patients included in is analysis.

[8] Not reported as standard deviations were not available.

**Author(s):** Corrado Barbui

**Date:** 2012-02-27

**Question:** Should bladder training and retention control vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?

**Bibliography:** Harris (1977) and Turner (1970) as described in NICE (2010) and in Glazener (2009)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Bladder training and retention control | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity: mean wet nights on treatment** (better indicated by lower values) | | | | | | | | | | | | |
| 1[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Very serious[4] | None | 9 | 9 | – | MD 0 higher (0 to 0 higher)[5] | ⬜⬜⬜⬜ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Analysis 1.5 of Glazener (2009).
[2] Groups were not comparable at baseline.
[3] Only one study included in the analysis.
[4] Only 18 patients included in the analysis.
[5] No data.

**Author(s):** Corrado Barbui
**Date:** 2012-02-27
**Question:** Should star charts vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?
**Bibliography:** Fava (1981) and Turner (1970) as described in NICE (2010) and in Glazener (2009)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Star charts | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Quality assessment | | | | | No. of patients | | Effect | | |
| **Symptom severity: number not achieving 14 consecutive dry nights** | | | | | | | | | | | | |
| 1[1] | Randomized trials | Serious[2] | No serious inconsistency | No serious indirectness | Very serious[3] | None | 2/10 (20%) | 9/10 (90%) | RR 0.22 (0.06 to 0.78) | 702 fewer per 1000 (from 198 fewer to 846 fewer) | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Analysis 1.2 of Glazener (2009).
[2] Baseline comparison of measurements of wetting were not reported. Children with physical causes for their enuresis were not explicitly excluded (the criterion was not mentioned).
[3] Only 20 patients included in this analysis.

**Author(s):** Corrado Barbui
**Date:** 2012-02-27
**Question:** Should dry bed training vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?
**Bibliography:** NICE (2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Dry bed training | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity: number of children who achieved 14 consecutive dry nights** | | | | | | | | | | | | |
| 2[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Very serious[4] | None | 7/30 (23.3%) | 2/30 (6.7%) | RR 2.9 (0.75 to 11.14)[5] | 127 more per 1000 (from 17 fewer to 676 more) | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From NICE (2010) Appendix H, p.18.
[2] Unclear allocation concealment in Bollard (1981) and Bollard (1982). Bollard (1981) did not report method of blinding.
[3] From NICE (2010) Appendix H, p.18.
[4] Only 60 patients included in the analysis (see NICE 2010, Full Guidance, p.186). Confidence interval ranges from no benefit to appreciable benefit.
[5] From NICE (2010) p.186.

**Author(s):** Corrado Barbui
**Date:** 2012-02-27
**Question:** Should dry bed training with an alarm vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?
**Bibliography:** NICE (2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Dry bed training with an alarm | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Symptom severity: number of children who achieved 14 consecutive dry nights** | | | | | | | | | | | | |
| 2[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Serious[4] | None | 29/30 (96.7%) | 2/30 (6.7%) | RR 9.34 (3.2 to 27.27)[5] | 556 more per 1000 (from 147 more to 1000 more) | ◻◻◻◻ LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From NICE (2010) Appendix H, p.20.
[2] Unclear allocation concealment in Bollard (1981) and Bollard (1982). Bollard (1981) did not report method of blinding
[3] From NICE (2010) Appendix H, p.21.
[4] Only 60 patients included in the analysis. Very wide confidence interval, but suggesting a clinical benefit.
[5] From NICE (2010) Full Guidance, p.189.

**Author(s):** Corrado Barbui
**Date:** 2012-02-27
**Question:** Should enuresis alarms vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?
**Bibliography:** NICE (2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Enuresis alarms | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Quality assessment | | | | | | No. of patients | | Effect | | | |
| **Symptom severity: number of children who achieved 14 consecutive dry nights** | | | | | | | | | | | | |
| 6[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | No serious imprecision | None | 108/141 (76.6%) | 3/135 (2.2%) | RR 16.9 (7.17 to 39.85)[4] | 353 more per 1000 (from 137 more to 863 more) | ⊕⊕⊕◯ MODERATE | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From NICE (2010) Appendix H, p.30.
[2] Unclear allocation concealment and blinding.
[3] From NICE (2010) Appendix H, p.30.
[4] From NICE (2010) Full Guidance, p.214.

**Author(s):** Corrado Barbui
**Date:** 2012-02-27
**Question:** Should other psychological treatments (CBT) vs treatment as usual or no treatment/waitlist be used in children and adolescents with non-organic (secondary) enuresis?
**Bibliography:** Ronen (1992) as described in NICE (2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Other psychological treatments (CBT) | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quality assessment | | | | | | | No. of patients | | Effect | | | |
| **Symptom severity: number of children who became dry for 3 weeks** | | | | | | | | | | | | |
| 1[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Serious[4] | None | 15/20 (75%) | 0/18 (0%) | RR 28.05 (1.8 to 437.4) | – | ☐☐☐☐ LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From NICE (2010) Appendix H, p.95.
[2] Unclear allocation concealment and blinding.
[3] Only one study included in the analysis.
[4] Only 38 patients included in the analysis. Confidence interval ranges from minimal benefit to clinically appreciable benefit.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | **Fluid and diet restriction**<br>There is one study only suggesting a beneficial effect, although the confidence in estimate is VERY LOW (the 95% confidence interval ranges from substantial benefit of the intervention to no benefit at all). No evidence is available for the outcomes functioning and presence of disorder.<br><br>**Lifting and waking**<br>There is one study only suggesting lack of benefit. The confidence in estimate is VERY LOW. No evidence is available for the outcomes functioning and presence of disorder.<br><br>**Bladder training and retention**<br>There is one study only suggesting lack of benefit. The confidence in estimate is VERY LOW. No evidence is available for the outcomes functioning and presence of disorder.<br><br>**Star charts**<br>There is one study only suggesting a statistically significant beneficial effect, although the confidence in estimate is VERY LOW. No systematic review of evidence is available for the outcomes functioning and presence of disorder.<br><br>**Dry bed training**<br>There are two small studies only suggesting a beneficial effect, although the confidence in estimate is VERY LOW (the 95% confidence interval ranges from substantial benefit of the intervention to no benefit at all). No systematic review of evidence is available for the outcomes functioning and presence of disorder.<br><br>**Dry bed training with an alarm**<br>There are two small studies only suggesting a statistically significant beneficial effect, although the confidence in estimate is VERY LOW. No systematic review of evidence is available for the outcomes functioning and presence of disorder.<br><br>**Enuresis alarm**<br>There is evidence (six studies) suggesting that enuresis alarm is effective in terms of number of children who achieved 14 consecutive dry nights (76.6% versus 2.2%). The confidence in estimate is MODERATE. No systematic review of evidence is |
|---|---|

| | |
|---|---|
| | available for the outcomes functioning and presence of disorder.<br><br>**Other psychological treatments (CBT)**<br>There is one study only suggesting a statistically significant beneficial effect, although the confidence in estimate is LOW. No systematic review of evidence is available for the outcomes functioning and presence of disorder. |
| **Harms** | No systematic review of evidence is available for adverse effects in any of the studied psychological treatments. |

| **Value and preferences** | |
|---|---|
| In favour | Effective psychological interventions are preferable over potentially harsh and counterproductive punitive measures by caregivers and others that may be elicited by non-organic secondary enuresis. Difficult living conditions and lack of access to water for washing make alleviation of symptoms preferable to waiting for natural recovery. |
| Against | Some regression in development – potentially involving bedwetting but also separation anxiety – is common after recent exposure to traumatic events and natural recovery may be expected in most cases. |

| **Feasibility (including economic consequences)** | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in specific psychological interventions would require some resources, including supervision.<br><br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources.<br><br>Provision of alarms may not be feasible in all resource-constrained settings.<br><br>Behavioural interventions (e.g. reward systems) may be simpler and quicker to train and easily understood by parents and staff (NICE, 2010). |
|---|---|

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | **Yes X**<br>(for alarm)<br>**No X**<br>(for other interventions) |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>(for psycho-education)<br>**No X**<br>(for other interventions) |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>(for psycho-education)<br>**No X**<br>(for other interventions) |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>(for psycho-education)<br>**No X**<br>(for other interventions) |

## Final recommendation by the guideline panel

*Recommendation 9*

**(i) Psycho-education about the negative effects of punitive responses should be given to caregivers of children with secondary non-organic enuresis in the first month after a potentially traumatic event.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**(ii) Parenting skills training and the use of simple behavioural interventions (i.e. star charts, toileting before sleep and rewarding having nights without wetting the bed) should be considered. In addition, where resources permit, alarms should be considered.**

*Strength of recommendation: standard*
*Quality of evidence: moderate for alarms, low or very low for other behavioural interventions*

**Remarks**
*Medical causes of bedwetting should be assessed and managed to ensure that the bedwetting is indeed secondary to a potentially traumatic event.*

*Health-care providers should explain that bedwetting is common after recent exposure to extreme stressors. If the bedwetting persists for more than one month, the child should be reasssesed for other disorders that may need treatment.*

# 10. Symptoms of dissociative (conversion) disorders (first month): early psychological interventions – adults

**Q10. For adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

This scoping question covers both psychological and somatoform dissociation in adults in the first month after a potentially traumatic event. Dissociative (conversion) disorders[36] are described by ICD-10 as "being associated closely in time with traumatic events, insoluble and intolerable problems, or disturbed relationships". Dissociative symptoms have been observed in varying ways (e.g. expressed through different idioms of distress) in various cultures.[37]

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Adults with symptoms of dissociative (conversion) disorders, within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Any psychological interventions
- **Comparison:** Treatment as usual or no treatment/waitlist

---

[36] *Dissociative (conversion) disorders* in ICD-10 include dissociative amnesia (F44.0), dissociative fugue (F44.1), dissociative stupor (F44.2), trance and possession disorders (F44.3), dissociative disorders of movement and sensation (F44.4–F44.7), mixed and other dissociative (conversion) disorders (Ganser's syndrome, multiple personality disorder, transient dissociative disorders occurring in childhood and adolescence). The DSM-IV lists conversion disorder (cf. ICD-10 F44.4–F44.7) within the category of somatoform disorders.

[37] Van Duijl, M., Nijenhuis, E., Komproe, I.H., Gernaat, H.B.P.E., de Jong, J.T.V.M. (2010). Dissociative symptoms and reported trauma among patients with spirit possession and matched healthy controls in Uganda, *Culture Medicine & Psychiatry*, 34, 380–400.

- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "dissociative disorder" OR "conversion disorder" AND "systematic review". In addition, in the PILOTS database the keywords "dissociation" and "conversion" were used. In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keywords "dissociative disorder" and "conversion disorder". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adults (>18 years). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keywords. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Ruddy, R., House, A. (2009). Psychosocial interventions for conversion disorder. *Cochrane Database of Systematic Reviews*, Issue 1.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

During, E.H., Elahi, F.M., Taieb, O., Moro, M., Baubet, T. (2011). A critical review of dissociative trance and possession disorders: etiological, diagnostic, therapeutic and nosological issues. *Canadian Journal of Psychiatry*, 56(4), 235-242
REASON FOR EXCLUSION: systematic review of all study types, not only evaluation studies. Does not list inclusion/exclusion criteria, quality appraisal or formal meta-analysis for evaluation studies.

International Society for Study of Dissociation [Chu, J.A., Loewenstein, R., Dell, P.F., Barach, P.M., Somer, E., Kluft, R.P., Gelinas, D.J., Van der Hart, O., Dalenberg, C.J., Nijenhuis, E.R.S., Bowman, E.S., Boon, S., Goodwin, J., Jacobson, M., Ross, C.A., Sar, V., Fine, C.G., Frankel, A.S., Coons, P.M., Courtois, C.A., Gold, S.N. & Howell, E.] (2005). Guidelines for Treating Dissociative Identity Disorder in Adults. *Journal of Trauma and Dissociation*, 6(4), 69-149.
REASON FOR EXCLUSION: methods of systematic review not reported. The guidelines state that no research with comparison groups exists.

Kroenke, K. (2007). Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. *Psychosomatic Medicine*, 69, 881-888.
REASON FOR EXCLUSION: systematic review of all somatoform disorders according to DSM-IV, including conversion disorder. Identified same studies as Ruddy & House (2009), which is more recent.

Poole, N.A., Wuerz, A., Agrawal, N. (2010). Abreaction for conversion disorder: systematic review with meta-analysis. *British Journal of Psychiatry*, 197, 91-95.
REASON FOR EXCLUSION: focuses specifically on drug interviews as intervention.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Psychological interventions vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | Ruddy & House (2009) (physical signs and mental state)<br>No data<br>No data<br>Ruddy & House (2009) (drop-out as proxy) | Ruddy & House (2009) is the most recent systematic review meeting inclusion criteria, but does not apply a one-month-after-event limit and identified three studies of poor methodological quality. No meta-analysis was attempted. |

## Narrative description of the studies that went into analysis

Ruddy & House (2009) systematically searched for randomized controlled trials (RCTs) evaluating psychological and social treatments for dissociative (conversion disorders) as defined by ICD-10 and DSM-IV, without age, nationality or gender limitations. Three studies met the inclusion criteria of the review, with altogether 119 participants:

- One study (Ataoglu, 2003) compared paradoxical intention therapy (two sessions a day for three weeks) for inpatients with diazepam for outpatient adults (mean age 27 years) with non-epileptic seizures in Turkey. Outcomes were: no statistically significant differences for physical signs and drop-out, and better outcome for the psychological treatment for anxiety.
- One study (Moene, 2002) compared an inpatient treatment programme (including group psychotherapy, social skills training, a planning group, creative therapy, sports, as well as physiotherapy) for adults (mean age 37 years) with conversion disorder (motor type) with and

without hypnosis (eight one-hour weekly sessions) in the Netherlands. Outcomes were: no statistically significant difference on drop-out (physical and mental variables not reported).

- One study (Moene, 2003) compared outpatient hypnosis (eight one-hour weekly sessions) for adults (mean age 37 years) with conversion disorder (motor type) with a waitlist control group in the Netherlands. Outcomes were: no statistically significant differences on mental state and drop-out, and treatment benefits for physical signs (no numerical data for physical disability).

The studies were judged to be of poor methodological quality, and they were not combined in a statistical meta-analysis because of differences in intervention and control groups across studies. The authors conclude that psychological and social interventions for people with dissociative (conversion) disorders "should be viewed as experimental, with slight evidence in favor of help rather than harm in terms of engagement, mental state and physical functioning".

## GRADE table

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-02-27
**Question:** Should psychological interventions vs treatment as usual or no treatment/waitlist be used in adults with symptoms of dissociative (conversion) disorders?
**Bibliography:** Ruddy (2009)

| Quality assessment | | | | | | | No. of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Psychological interventions | Treatment as usual or no treatment/ waitlist | Relative (95% CI) | Absolute | | |
| **Symptom severity** (inpatient paradoxical intention therapy) (better indicated by lower values) | | | | | | | | | | | | |
| 1[1,2] | Randomized trials | Serious[3] | No serious inconsistency[4] | Serious[5] | Serious[6] | None | 15 | 15 | – | MD 3.73 lower (6.96 to 0.5 lower) | ⬜⬜⬜⬜ VERY LOW | IMPORTANT |
| **Functioning** (inpatient paradoxical intention therapy) (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (inpatient paradoxical intention therapy) (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

| **Adverse effects: leaving the study early** (inpatient paradoxical intention therapy) | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1[2,7] | Randomized trials | Serious[3] | No serious inconsistency[4] | Serious[5] | Serious[6] | None | 0/15 (0%) | 0/15 (0%) | – | – | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Symptom severity** (outpatient hypnosis versus waiting list) (better indicated by lower values) | | | | | | | | | | | | |
| 1[8] | Randomized trials | Serious[9] | No serious inconsistency[4] | Serious[5] | Very serious[10] | None | 20 | 23 | – | MD 12.30 lower (44.28 lower to 19.68 higher) | ☐☐☐☐ VERY LOW | IMPORTANT |
| **Functioning** (outpatient hypnosis versus waiting list) (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (outpatient hypnosis versus waiting list) (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effect: leaving the study early** (outpatient hypnosis versus waiting list) | | | | | | | | | | | | |
| 1[11] | Randomized trials | Serious[9] | No serious inconsistency[4] | Serious[5] | Very serious[12] | None | 4/24 (16.7%) | 2/25 (8%) | RR 2.08 (0.42 to 10.34) | 86 more per 1000 (from 46 fewer to 747 more) | ☐☐☐☐ VERY LOW | IMPORTANT |

[1] From Analysis 1.2 of Ruddy (2009).

[2] The included study compared paradoxical intention therapy as an inpatient with outpatient follow-up and diazepam for pseudo-seizures.

[3] In the included study the two groups had a different length of treatment (three weeks for the inpatients and 45 days for the outpatients) but they were all followed up at six weeks.

[4] Only one study included in this analysis.

[5] Included patients were adults with symptoms of dissociative (conversion) disorders, but the occurrence of symptoms within one month of exposure to a potentially traumatic event was not an inclusion criterion.

[6] Only 30 patients included in this analysis (all but one female, all suffering pseudo-seizures).

[7] From Analysis 1.3 of Ruddy (2009).

[8] From Analysis 3.2 of Ruddy (2009).

[9] In the included study there is information about the number of people who were lost to follow-up but there is no specific information about why they were lost.

[10] Only 43 patients included. Confidence interval ranges from appreciable benefit to appreciable harm.

[11] From Analysis 3.4 of Ruddy (2009).

[12] Only 49 patients included. Confidence interval ranges from appreciable benefit to appreciable harm.

# PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

## Evidence to recommendation table

| Benefits | The evidence is indirect (people with conversion disorder but not after exposure to a traumatic event), limited and inconclusive and so it is uncertain if psychological interventions may be beneficial in people with dissociative (conversion) disorders within one month of exposure to a traumatic event. The confidence in estimate from the two studies that were GRADEd is VERY LOW. |
|---|---|
| Harms | The two studies that were GRADEd provided inconclusive findings on leaving the study early, a proxy measure of treatment acceptability. The confidence in estimates is VERY LOW. |

| Value and preferences | |
|---|---|
| In favour | |
| Against | It has been argued that dissociative symptoms (e.g. medically unexplained paralysis and other forms of somatoform dissociation) often take the form of culturally sanctioned idioms of distress. People suffering dissociative symptoms often seek care in the non-formal health sector (e.g. religious and traditional healing settings) (see Van Duijl et al., *Culture, Medicine and Psychiatry* 2010, 34(2):380-400). As such, making interventions (for which there is inconclusive evidence of effectiveness) available through formal health-care settings may not provide additional value to these existing community resources.<br><br>International consensus-based guidelines on mental health practices in emergency settings advocate learning about and, where appropriate, collaborating with local, indigenous and traditional health systems, but also warn against the risk that such services may do harm (IASC, 2007). |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in paradoxical intention therapy and hypnosis would require resources, including supervision. The tested psychological interventions were evaluated in specialized settings (inpatient and outpatient clinics) and it is not known to what extent they can be applied in PHC.<br><br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources. |

155

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes<br>**No X** |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 10*
**On the basis of available evidence, no specific recommendation can be made on psychological interventions for adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

*Remarks*
*Possible physical causes for dissociation should be ruled out or managed.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in adults with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.*

*For somatoform dissociation (i.e. conversion disorder), existing WHO guidance on the management of somatic medically unexplained symptoms may be considered (see Other Significant Emotional or Medically Unexplained Complaints module of the mhGAP Intervention Guide (WHO, 2010)).*

*Health-care providers should explain that these symptoms can sometimes occur after recent exposure to extreme stressors. When interacting with people with conversion disorder, clinicians should acknowledge suffering and maintain a relationship of respect with the person. At the same time they should carefully avoid reinforcing any secondary gain that the person may get from somatoform dissociation (conversion). The use of culturally appropriate interventions that are not harmful may be considered.*

# 11. Symptoms of dissociative (conversion) disorders (first month): early psychological interventions – children and adolescents

**Q11. For children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event, do early psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

This scoping question covers both psychological and somatoform dissociation in children and adolescents in the first month after a potentially traumatic event. Dissociative (conversion) disorders[38] are described by ICD-10 as "being associated closely in time with traumatic events, insoluble and intolerable problems, or disturbed relationships". Dissociative symptoms have been observed in varying ways (e.g. expressed through different idioms of distress) in various cultures.[39]

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Children and adolescents with symptoms of dissociative (conversion) disorders, within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Any psychological interventions
- **Comparison:** Treatment as usual or no treatment/waitlist

---

[38] *Dissociative (conversion) disorders* in ICD-10 include dissociative amnesia (F44.0), dissociative fugue (F44.1), dissociative stupor (F44.2), trance and possession disorders (F44.3), dissociative disorders of movement and sensation (F44.4–F44.7), mixed and other dissociative (conversion) disorders (Ganser's syndrome, multiple personality disorder, transient dissociative disorders occurring in childhood and adolescence). The DSM-IV lists conversion disorder (cf. ICD-10 F44.4–F44.7) within the category of somatoform disorders.

[39] Van Duijl, M., Nijenhuis, E., Komproe, I.H., Gernaat, H.B.P.E., de Jong, J.T.V.M. (2010). Dissociative symptoms and reported trauma among patients with spirit possession and matched healthy controls in Uganda, *Culture, Medicine and Psychiatry*, 34, 380–400.

- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "dissociative disorder" OR "conversion disorder" AND "systematic review". In addition, in the PILOTS database the keywords "dissociation" and "conversion" were used. In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keywords "dissociative disorder" and "conversion disorder". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents. In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keywords. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

The most rigorous and recent systematic review that was identified (Ruddy & House, 2009) looked for but did not find any studies with children and adolescents pertaining to this scoping question.
Ruddy, R. & House, A. (2009). Psychosocial interventions for conversion disorder. *Cochrane Database of Systematic Reviews*, Issue 1.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

During, E.H., Elahi, F.M., Taieb, O., Moro, M., Baubet, T. (2011). A critical review of dissociative trance and possession disorders: etiological, diagnostic, therapeutic and nosological issues. *Canadian Journal of Psychiatry*, 56(4), 235-242.
REASON FOR EXCLUSION: systematic review of all study types, not only evaluation studies. Does not list inclusion/exclusion criteria, quality appraisal or formal meta-analysis for evaluation studies.

International Society for Study of Dissociation [Chu, J.A., Loewenstein, R., Dell, P.F., Barach, P.M., Somer, E., Kluft, R.P., Gelinas, D.J., Van der Hart, O., Dalenberg, C.J., Nijenhuis, E.R.S., Bowman, E.S., Boon, S., Goodwin, J., Jacobson, M., Ross, C.A., Sar, V., Fine, C.G., Frankel, A.S., Coons, P.M., Courtois, C.A., Gold, S.N. & Howell, E.] (2005). Guidelines for treating dissociative identity disorder in adults. *Journal of Trauma and Dissociation*, 6(4), 69-149.
REASON FOR EXCLUSION: methods of systematic review not reported. The guidelines state that no research with comparison groups exists.

Kroenke, K. (2007). Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. *Psychosomatic Medicine*, 69, 881-888.
REASON FOR EXCLUSION: systematic review of all somatoform disorders according to DSM-IV, including conversion disorder. Identified same studies as Ruddy & House (2009), which is more recent.

Poole, N.A., Wuerz, A., Agrawal, N. (2010). Abreaction for conversion disorder: systematic review with meta-analysis. *British Journal of Psychiatry*, 197, 91-95.
REASON FOR EXCLUSION: focuses specifically on drug interviews as intervention.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Psychological interventions vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | No data |

## Narrative description of the studies that went into analysis
N/A.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | A recent systematic review found no evidence on the benefit of psychological interventions in children and adolescents with dissociative (conversion) disorders in the first month of a potentially traumatic event with regard to symptom severity, presence of disorder or functioning. |
|---|---|
| Harms | There is no systematic review on the potential harms of psychological interventions for children and adolescents with dissociative (conversion) disorders in the first month of a potentially traumatic event. |

| Value and preferences | |
|---|---|
| In favour | |
| Against | It has been argued that dissociative symptoms (e.g. medically unexplained paralysis and other forms of somatoform dissociation) often take the form of culturally sanctioned idioms of distress. People suffering dissociative symptoms often seek care in the non-formal health sector (e.g. religious and traditional healing settings) (see Van Duijl et al., *Culture, Medicine and Psychiatry* 2010, 34(2):380-400), which may or may not provide effective services.<br><br>International consensus-based guidelines on mental health practices in emergency settings advocate learning about and, where appropriate, collaborating with local, indigenous and traditional health systems, but also warn against the risk that such services may do harm (IASC, 2007). |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in paradoxical intention therapy and hypnosis would require resources, including supervision. The tested psychological interventions were evaluated in specialized settings (inpatient and outpatient clinics) and it is not known to what extent they can be applied in PHC.<br><br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes<br>**No X** |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 11*
**On the basis of available evidence, no specific recommendation can be made for children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

**Remarks**
*Possible physical causes for dissociation should be ruled out or managed.*

*There is already a WHO (2010) mhGAP recommendation to offer access to psychological first aid to people who have been recently exposed to potentially traumatic events. Therefore, as no further specific recommendation can be made, psychological first aid should be considered in children and adolescents with symptoms of dissociative (conversion) disorders in the first month after a potentially traumatic event.*

*For somatoform dissociation (i.e. conversion disorder), existing WHO guidance on the management of somatic medically unexplained symptoms may be considered (see Other Significant Emotional or Medically Unexplained Complaints module of the mhGAP Intervention Guide (WHO, 2010)).*

*Health-care providers should explain that these symptoms can sometimes occur after recent exposure to extreme stressors. When interacting with people with conversion disorder, clinicians should acknowledge suffering and maintain a relationship of respect with the person. At the same time they should carefully avoid reinforcing any secondary gain that the person may get from somatoform dissociation (conversion). The use of culturally specific interventions that are not harmful may be considered.*

# 12. Hyperventilation (first month): rebreathing into a bag – adults and adolescents

**Q12. For adolescents and adults with hyperventilation in the first month after a potentially traumatic event, does rebreathing into a paper bag, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

This scoping question covers hyperventilation in adolescents and adults in the first month after a potentially traumatic event.   Around half of populations exposed to potentially traumatic events have been reported to experience panic symptoms during the first month after the event.[40] Indeed, clinical experience suggests that in the immediate aftermath of potentially traumatic events, help-seeking for hyperventilation is common. Because symptoms are associated with hypocapnia, clinicians frequently encourage persons to increase their CO2 levels by rebreathing into a paper bag.

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Adolescents and adults with hyperventilation, within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Rebreathing into a paper bag
- **Comparison:** Treatment as usual or no treatment/waitlist
- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

---

[40] Nixon & Bryant (2003). Peritraumatic and persistent panic attacks in acute stress disorder. *Behavior Research & Therapy*, 41(10), 1237-42; Bryant & Panasetis (2001). Panic symptoms during trauma and acute stress disorder. *Behavior Research & Therapy*, 39(8), 961-6.

## List of the systematic reviews identified by the search process

The search was conducted in week 29 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "hyperventilation" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "hyperventilation". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adolescents (10-19 years) and adults (>18 years). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

Given that no systematic reviews were identified, a systematic review was conducted in week 24 of 2012. This systematic review searched the Cochrane Library, MEDLINE, Embase, CINAHL and PsycINFO for studies with the following keywords: "traumatic event" OR "acute stress" OR PTSD AND "hyperventilation". This review returned 81 records: three in Cochrane; 31 in MEDLINE; 43 in Embase; three in CINAHL; and one in PsycINFO (where the randomized controlled trial function was selected). These results were hand-searched for relevant studies, but none were identified.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

The systematic review did not identify any studies that could be entered in GRADE tables.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Australian Resuscitation Council (2008). Guideline 9.2.8. The first aid management of hyperventilation syndrome.
REASON FOR EXCLUSION: older than two years; no systematic review methodology described; no meta-analysis reported.

Warwick University (2006). Hyperventilation syndrome: specific treatment options. Available at http://www2.warwick.ac.uk/fac/med/research/hsri/emergencycare/prehospitalcare/jrcalcstakeholderwebsite/guidelines/hyperventilation_syndrome_2006.pdf. Last accessed 24 April 2012.
REASON FOR EXCLUSION: older than two years; no systematic review methodology described; no meta-analysis reported.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Rebreathing into a paper bag vs. no treatment/control | Symptom severity | No data | No data |
| | | Functioning | No data | |
| | | Presence of disorder | No data | |
| | | Adverse effects | No data | |

## Narrative description of the studies that went into analysis
N/A.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | No studies were available to suggest benefits of rebreathing into a paper bag for adolescents and adults with hyperventilation in the first month after exposure to traumatic stress, with regard to symptom severity, presence of disorder and quality of life. |
|---|---|
| Harms | No studies were available to evaluate whether rebreathing into a paper bag for adolescents and adults with hyperventilation in the first month after exposure to traumatic stress may do harm. |

| Value and preferences | |
|---|---|
| In favour | A common approach to dealing with hyperventilation caused by stress may be rebreathing into a paper bag. Anecdotal clinical experience has suggested some effectiveness. |
| Against | Clinical guidelines recommend *not* rebreathing into a paper bag in pre-hospital settings. Rebreathing CO2 rather than providing oxygen may be dangerous for adolescents and adults with medical conditions that resemble hyperventilation (e.g. heart attacks and asthma). |

| Feasibility (including economic consequences) | Making a recommendation *not* to carry out a specific intervention is feasible. |
|---|---|

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 12*
**No specific recommendation can be made on the basis of available evidence on rebreathing into a paper bag for adolescents and adults with hyperventilation in the first month after exposure to a potentially traumatic event.**

*Strength of recommendation: not applicable*
*Quality of evidence: very low*

***Remarks***
*There are significant risks if this technique is used in specific populations (e.g. people with heart disease and asthma).*

*Health-care providers should always rule out physical causes before considering psychological intervention for hyperventilation. They should maintain a calm approach, where possible remove sources of anxiety and coach respirations (i.e. encourage normal breathing, not deeper and quicker than usual).*

*Health-care providers should explain that hyperventilation can sometimes occur after recent exposure to extreme stressors. Acute stress should be managed using psychological first aid as per WHO (2010) mhGAP guidelines. Moreover, as per recommendation 1 (on psychological interventions for acute traumatic stress symptoms in adults), cognitive-behavioural therapy (CBT) with a trauma focus should be considered in adults with acute traumatic stress symptoms associated with significant impairment in daily functioning.*

## 13. Hyperventilation (first month): rebreathing into a bag – children

**Q13. For children with hyperventilation in the first month after a potentially traumatic event, does rebreathing into a bag, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

### Background on the scoping question

Exposure to potentially traumatic events is common, and symptoms of acute stress in the aftermath of such events are frequently reported. A range of symptoms of acute stress exist, such as intrusion, avoidance, hyperarousal, hyperventilation, dissociation, insomnia and – in children – bedwetting. These symptoms are covered in different evidence profiles of these guidelines.

This scoping question covers hyperventilation in children in the first month after a potentially traumatic event. Around half of populations exposed to potentially traumatic events have been reported to experience panic symptoms during the first month after the event.[41] Indeed, clinical experience suggests that in the immediate aftermath of potentially traumatic events, help-seeking for hyperventilation is common. Because symptoms are associated with hypocapnia, clinicians frequently encourage persons to increase their $CO_2$ levels by rebreathing into a paper bag.

### PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:** Children with hyperventilation, within one month of exposure to a potentially traumatic event(s)
- **Interventions:** Rebreathing into a paper bag
- **Comparison:** Treatment as usual or no treatment/waitlist
- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

---

[41] Nixon & Bryant (2003). Peritraumatic and persistent panic attacks in acute stress disorder. *Behavior Research & Therapy*, 41(10), 1237-42; Bryant & Panasetis (2001). Panic symptoms during trauma and acute stress disorder. *Behavior Research & Therapy*, 39(8), 961-6.

## List of the systematic reviews identified by the search process

The search was conducted in week 29 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "hyperventilation" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "hyperventilation". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children (<10 years). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

Given that no systematic reviews were identified, a systematic review was conducted in week 24 of 2012. This systematic review searched the Cochrane Library, MEDLINE, Embase, CINAHL and PsycINFO for studies with the following keywords: "traumatic event" OR "acute stress" OR PTSD AND "hyperventilation". This review returned 81 records: three in Cochrane; 31 in MEDLINE; 43 in Embase; three in CINAHL; and one in PsycINFO (where the randomized controlled trial function was selected). These results were hand-searched for relevant studies, but none were identified.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

The systematic review did not identify any studies that could be entered in GRADE tables.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Australian Resuscitation Council (2008). Guideline 9.2.8. The first aid management of hyperventilation syndrome.
REASON FOR EXCLUSION: older than two years; no systematic review methodology described; no meta-analysis reported.

Warwick University (2006). Hyperventilation syndrome: specific treatment options. Available at
http://www2.warwick.ac.uk/fac/med/research/hsri/emergencycare/prehospitalcare/jrcalcstakeholderwebsite/guidelines/hyperventilation_syndrome_2006.pdf. Last accessed 24 April 2012.
REASON FOR EXCLUSION: older than two years; no systematic review methodology described; no meta-analysis reported.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Rebreathing into a bag vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | No data |

## Narrative description of the studies that went into analysis
N/A.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| | |
|---|---|
| **Benefits** | No studies were available and therefore it is not possible to ascertain whether rebreathing into a bag has a beneficial effect in children with hyperventilation in the first month after exposure to traumatic stress, with regard to symptom severity, presence of disorder and quality of life. |
| **Harms** | No studies were available to evaluate whether rebreathing into a bag for children with hyperventilation in the first month after exposure to traumatic stress may do harm. |

| Value and preferences | |
|---|---|
| In favour | A common approach to dealing with hyperventilation caused by stress may be rebreathing into a paper bag. Anecdotal clinical experience has demonstrated some effectiveness. |
| Against | Clinical guidelines recommend *not* rebreathing into a paper bag in pre-hospital settings. Rebreathing $CO_2$ rather than providing oxygen may be dangerous for children with medical conditions that resemble hyperventilation (e.g. asthma). |

| Feasibility (including economic consequences) | Making a recommendation *not* to carry out a specific intervention is feasible. |
|---|---|

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | Yes<br>**No X** |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

> *Recommendation 13*
> **Rebreathing into a paper bag should not be considered for children with hyperventilation in the first month after a potentially traumatic event.**
>
> *Strength of recommendation: standard*
> *Quality of evidence: very low*

**Remarks**
*Health-care providers should always rule out physical causes before considering psychological intervention. They should maintain a calm approach, where possible remove sources of anxiety and coach respirations (i.e. encourage normal breathing, not deeper and quicker than usual).*

*Health-care providers should explain that hyperventilation can sometimes occur after recent exposure to extreme stressors. Acute stress in children should be managed using psychological first aid as per WHO (2010) mhGAP guidelines.*

# 14. Posttraumatic stress disorder (PTSD): psychological interventions – adults

**Q14. For adults with posttraumatic stress disorder (PTSD), do psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Posttraumatic stress disorder (PTSD) is the most studied disorder after exposure to potentially traumatic events, with prevalence rates ranging from 0.3% to 6.1% in general populations globally and 15.4% in conflict-affected populations,[42] and can be associated with significant impairment in functioning. Much has been written about best practices in treatment of PTSD.

This scoping question focuses on psychological interventions (individual and group cognitive-behavioural therapy (CBT), eye movement desensitization and reprocessing (EMDR) and stress management) for adult PTSD.

A large number of research trials have been conducted on (a) cognitive behaviour therapy (CBT) with a trauma focus (with most research on prolonged exposure therapy and cognitive processing therapy) and (b) eye movement desensitization and reprocessing (EMDR).

With respect to CBT, this guideline does not use the term *trauma-focused CBT* (TF CBT), because this term has been used in different manners in the international literature. For example, in NICE/Cochrane, it is used for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing of thoughts related to the event), while the same term is also widely used for a very specific multi-component CBT protocol for children and adolescents developed by Cohen and colleagues. To avoid confusion, this guideline avoids the term TF CBT and uses the term *CBT with a trauma focus* for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing). The term *CBT with a trauma focus* is thus synonymous with the term TF CBT as used in NICE/Cochrane.

EMDR is a new treatment, developed in the late 1980s. Proponents of EMDR usually do not consider it as a type of CBT. This is in contrast to many proponents of CBT, who consider EMDR to be a form of CBT.

Traditional CBT PTSD treatments involve teaching an individual skills to change unhelpful thoughts and behaviours to more helpful or productive thoughts and behaviours, leading the person to feel better. These treatments utilize procedures that directly target the person's beliefs and behaviours (e.g. prolonged exposure, challenging of beliefs). EMDR procedures focus on spontaneous associative processing of memories with a component of bilateral stimulation (e.g. eye movements). Unlike traditional CBT PTSD treatments, EMDR therapy (a) does not involve the direct procedural targeting of beliefs or behaviours; (b) does not use daily homework (although the person may be encouraged to test themselves in previously feared situations near the end of the treatment when symptoms have already reduced); and (c) involves treatment that is conducted

---

[42] Kessler, R.C. & Üstün, T. B. (eds). (2008). *The WHO World Mental Health Surveys: global perspectives on the epidemiology of mental disorders*. New York: Cambridge University Press, 1-580; Steel, Z., Chey, T., Silove, D., Marnane, C., Bryant, R.A., van Ommeren, M. (2009) Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement. *Journal of the American Medical Association*, 302(5), 537-549.

without detailed descriptions of the event and without direct challenging of beliefs and without extended exposure. Relative to CBT, the underlying theoretical treatment mechanisms of EMDR are still largely speculative and this has been a source of controversy.

It should be noted that exposure treatment (which is often part of CBT with a trauma focus) is very different from psychological debriefing (i.e. promotion of ventilation by requesting a person to briefly but systematically recount perceptions, thoughts and emotional reactions experienced during the event). The latter does not involve enough exposure to the traumatic memory to reduce symptoms (see mhGAP Guidelines, 2009). Consistent with the NICE Guidelines for adults, in these guidelines the term *stress management* refers to psychological treatments that use cognitive or behavioural techniques that do not focus on trauma (e.g. relaxation, stress inoculation training).

# PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)
- **Population:**     Adults with PTSD, after the first month of a potentially traumatic event
- **Interventions:**  Individual and group CBT with a trauma focus, EMDR, stress management
- **Comparison:**    Treatment as usual or no treatment/waitlist
- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process
The search was conducted in week 30 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "PTSD" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "PTSD". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adults (>18 years), focusing on psychological treatments. We did not include systematic reviews of pharmacological and manual therapies (e.g. massage therapy, acupuncture, spinal manipulation). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

COMMENT: The above search identified 28 relevant systematic reviews. Given the large number of reviews, and in accordance with the WHO Handbook on Guideline Development, only reviews published in the last two years (>2009) are discussed here (other reviews are available upon request).

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Bisson, J., Andrew, M., Cooper, R., Lewis, C. Psychological treatment of chronic post-traumatic stress disorder (PTSD). *Cochrane Database of Systematic Reviews*, in preparation.
COMMENT: this is an update of the 2007 Cochrane review on the same topic. This update has the same conclusions as the previous review.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Amstadter, A.B., Broman-Fulks, J., Zinzow, H., Ruggiero, K.J., Cercone, J. (2009). Internet-based interventions for traumatic stress-related mental health problems: A review and suggestion for future research. *Clinical Psychology Review*, 29, 410-420.
REASON FOR EXCLUSION: focuses on interventions delivered in a specific modality.

Crumlish, N., O'Rourke, G. (2010). A systematic review of treatments for post-traumatic stress disorder among refugees and asylum seekers. *Journal of Nervous and Mental Disease*, 198, 237-251.
REASON FOR EXCLUSION: focuses on specific population sub-group of refugees and asylum-seekers, and does not report a formal meta-analysis.

Cuijpers, P., Marks, I.M., van Straten, A., Cavanagh, K., Gega, L., Anderson, G. (2009). Computer-aided psychotherapy for anxiety disorders: A meta-analytic review. *Cognitive Behaviour Therapy*, 38(2), 66-82.

REASON FOR EXCLUSION: focuses on interventions delivered in a specific modality.

Department of Veterans Affairs Health Services Research and Development Service (2009). The assessment and treatment of individuals with history of traumatic brain injury and post-traumatic stress disorder: A systematic review of the evidence.
REASON FOR EXCLUSION: focuses on specific population sub-group.

Lawrence, S., De Silva, M., Henley, R. (2010). Sports and games for posttraumatic stress disorder (PTSD). *Cochrane Database of Systematic Reviews*, Issue 1.
REASON FOR EXCLUSION: did not identify any studies that met inclusion criteria.

Mulligan, K., Fear, N.T., Jones, N., Wessely, S., Greenberg, N. (2011). Psycho-educational interventions designed to prevent deployment-related psychological ill health in Armed Forces personnel: A review. *Psychological Medicine*, 41, 673-686.
REASON FOR EXCLUSION: focuses on specific population sub-group and does not report formal meta-analysis.

Palic, S., Elklit, A. (2011). Psychosocial treatment of posttraumatic stress disorder in adult refugees: A systematic review of prospective treatment outcome studies and a critique. *Journal of Affective Disorders*, 131, 8-23.
REASON FOR EXCLUSION: focuses on specific population sub-group.

Ponniah, K., Hollon, S.D. (2009). Empirically supported psychological treatments for adult acute stress disorder and posttraumatic stress disorder: a review. *Depression and Anxiety*, 26, 1086-1109.
REASON FOR EXCLUSION: no formal meta-analysis reported.

Possemato, K. (2011). The current state of intervention research for posttraumatic stress disorder within the primary care setting. *Journal of Clinical Psychology in Medical Settings*, DOI 10.1007/s10880-011-9237-4.
REASON FOR EXCLUSION: no systematic review methodology reported.

Powers, M.B., Halpern, J.M., Ferenschak, M.P., Gillihan, S.J., Foa, E. (2010). A meta-analytic review of prolonged exposure for posttraumatic stress disorder. *Clinical Psychology Review*, 30, 635-641.
REASON FOR EXCLUSION: focuses on one specific form of CBT. i.e. prolonged exposure therapy.

Sloan, D.M., Gallagher, M.W., Feinstein, B.A., Lee, D.J., Pruneau, G.M. (2011). Efficacy of telehealth treatments for posttraumatic stress-related symptoms: a meta-analysis. *Cognitive Behaviour Therapy*, 40(2), 111-125.
REASON FOR EXCLUSION: focuses on interventions delivered in a specific modality.

Stewart, C.L., Wrobel, T.A. (2009). Evaluation of the efficacy of pharmacotherapy and psychotherapy in the treatment of combat-related post-traumatic stress disorder: A meta-analytic review of outcome studies.
REASON FOR EXCLUSION: focuses on specific population sub-group.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Individual CBT with a trauma focus vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br><br>Adverse effects | Bisson et al. (in preparation) (severity of PTSD symptoms)<br>No data<br>Bisson et al. (in preparation) (PTSD diagnosis)<br>Bisson et al. (in preparation) (proxy drop-out) | Bisson et al. (in preparation) is the most recent review of high quality. Limitations:  this Cochrane review focuses on PTSD from the third month after a potentially traumatic event, and does not specifically address treatments in non-specialized health-care settings. |
| 2 | Group CBT with a trauma focus vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br><br>Adverse effects | Bisson et al. (in preparation) (severity of PTSD symptoms)<br>No data<br>Bisson et al. (in preparation) (PTSD diagnosis)<br>Bisson et al. (in preparation) (proxy drop-out) | See above. |
| 3 | EMDR vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br><br>Adverse effects | Bisson et al. (in preparation) (severity of PTSD symptoms)<br>No data<br>Bisson et al. (in preparation) (PTSD diagnosis)<br>Bisson et al. (in preparation) (proxy drop-out) | See above. |

| 4 | Stress management vs. no treatment/control | Symptom severity | Bisson et al. (in preparation) (severity of PTSD symptoms) | See above. |
| | | Functioning | No data | |
| | | Presence of disorder | Bisson et al. (in preparation) (PTSD diagnosis) | |
| | | Adverse effects | Bisson et al. (in preparation) (proxy drop-out) | |

## Narrative description of the studies that went into analysis

Bisson et al. (in preparation) is a recent update (searches up to 31 December 2010) of the Bisson and Andrew (2007) Cochrane review. This study identified 61 randomized controlled trials (RCTs), of which 39 studies included individual CBT with a trauma focus, nine studies included group CBT with a trauma focus and 16 studies included EMDR. The review identified seven studies including stress management (two including stress inoculation training, two including unspecified forms of relaxation, one including biofeedback-assisted relaxation and one including progressive relaxation training) and seven studies considering other therapies. The latter included non-directive counselling, psychodynamic therapy, hypnotherapy and person-centred therapy. There was no significant statistical heterogeneity ($I^2 < 50\%$) on outcomes for stress management and other therapies, so fixed effects models were applied in meta-analysis. The quality of the studies addressing CBT with a trauma focus was variable: eight studies were evaluated to have low risk of bias, seven studies were judged to have high risk of bias and for 24 studies this was unclear. Of the nine studies that focused on group CBT with a trauma focus, two studies were evaluated to have low risk of bias, one study was judged to have high risk of bias and for the remaining six there was insufficient information. None of the 16 studies focused on EMDR were rated as having low risk of bias, two had high risk of bias and for 14 this was uncertain.

Altogether, the systematic review identified only a few large RCTs with sample sizes over 100. There was significant statistical heterogeneity ($I^2 > 50\%$) on most outcomes across comparisons, so random effects models were applied in meta-analysis. There was insufficient information to judge the risk of bias in a majority of the included studies. In addition, a funnel plot showed some evidence of publication bias.

The authors conclude that individual CBT with a trauma focus, EMDR, stress management and group CBT with a trauma focus are effective in the treatment of PTSD. In addition: "There was some evidence that individual CBT with a trauma focus and EMDR are superior to stress management in the treatment of PTSD at between 1 and 4 months following treatment, and also that CBT, EMDR and stress management are more effective than other therapies."

NOTE: systematic reviews conducted by Crumlish & Rourke (2010) and Palic & Elklit (2011) were excluded, because they focused on refugees and asylum seekers. It is noted that these studies came to similar conclusions as the Cochrane review that was GRADEd. Crumlish & Rourke found 10 RCTs (generally small and with inadequate allocation concealment and blinding), and concluded that: "No treatment was firmly

179

supported, but there was evidence for narrative exposure therapy and cognitive-behavioral therapy." Palic & Elklit (2011) identified 12 RCTs and concluded: "…indicating a broad suitability of CBT in the treatment of core symptoms of PTSD in adult refugees", adding "There are few studies of treatments alternative to CBT and they are less methodologically rigorous than the CBT studies."

## GRADE table

**Author(s):** Corrado Barbui
**Date:** 2012-03-09
**Question:** Should individual CBT with a trauma focus vs treatment as usual or no treatment/waitlist be used in adults with PTSD?
**Bibliography:** Bisson Cochrane review (in preparation)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Individual CBT | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Quality assessment | | | | | No. of patients | | Effect | | | |
| **Symptom severity – clinician** (better indicated by lower values) | | | | | | | | | | | | |
| 15[1] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | No serious imprecision | None | 284 | 269 | – | SMD 1.27 lower (1.82 to 0.73 lower) | ▢▢▢▢ MODERATE | CRITICAL |
| **Symptom severity – clinician** (1–4-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 3[3] | Randomized trials | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None | 146 | 131 | – | MD 17.68 lower (19.68 to 15.68 lower) | ▢▢▢▢ HIGH | CRITICAL |
| **Symptom severity – clinician** (5–8-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 2[4] | Randomized trials | No serious risk of bias | Serious[5] | No serious indirectness | Serious[6] | None | 65 | 85 | – | MD 8.52 lower (15.37 to 1.67 lower) | ▢▢▢▢ LOW | CRITICAL |
| **Symptom severity – clinician** (9–12-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 1[7] | Randomized trials | Serious[8] | No serious inconsistency[9] | No serious indirectness | Serious[6] | None | 62 | 47 | – | MD 22.28 lower (32.2 to 12.36 lower) | ▢▢▢▢ LOW | CRITICAL |
| **Symptom severity – self-report** (better indicated by lower values) | | | | | | | | | | | | |
| 11[10] | Randomized trials | No serious risk of bias | Serious[11] | No serious indirectness | No serious imprecision | None | 258 | 215 | – | SMD 1.56 lower (1.98 to 1.14 lower) | ▢▢▢▢ MODERATE | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Symptom severity – self-report** (1–4-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 2[12] | Randomized trials | Serious[13] | No serious inconsistency | No serious indirectness | Serious[6] | None | 91 | 90 | – | MD 11.03 lower (12.1 to 9.96 lower) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Symptom severity – self-report** (9–12-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 1[14] | Randomized trials | Serious[15] | No serious inconsistency[9] | No serious indirectness | Serious[6] | None | 61 | 60 | – | MD 12.64 lower (16.29 to 8.99 lower) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Presence of disorder – PTSD diagnosis after treatment** | | | | | | | | | | | | |
| 18[16] | Randomized trials | No serious risk of bias | Serious[17] | No serious indirectness | No serious imprecision | None | 242/522 (46.4%) | 322/362 (89%) | RR 0.52 (0.41 to 0.65) | 427 fewer per 1000 (from 311 fewer to 525 fewer) | ⬜⬜⬜⬜ MODERATE | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 22[18] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[19] | No serious imprecision | None | 211/853 (24.7%) | 76/564 (13.5%) | RR 1.72 (1.33 to 2.22) | 97 more per 1000 (from 44 more to 164 more) | ⬜⬜⬜⬜ MODERATE | IMPORTANT |

[1] From Analysis 1.1.1 of Bisson Cochrane review (in preparation).
[2] Visual inspection of forest plot suggests heterogeneity. I-squared = 87%.
[3] From Analysis 1.2.1 of Bisson Cochrane review (in preparation).
[4] From Analysis 1.8 of Bisson Cochrane review (in preparation).
[5] I-squared = 56%.
[6] Fewer than 200 patients contributed to this analysis.
[7] From Analysis 1.10 of Bisson Cochrane review (in preparation).
[8] Quote: "Independent raters who were not otherwise involved in the project conducted assessments of treatment adherence and therapist competence."
[9] Only one study contributed to the analysis.
[10] From Analysis 1.1.2 of Bisson Cochrane review (in preparation).
[11] Visual inspection of forest plot suggests heterogeneity. I-squared = 71%.
[12] From Analysis 1.12 of Bisson Cochrane review (in preparation).
[13] Unclear risk of bias in one study. In the second one, quote: "Independent raters who were not otherwise involved in the project conducted assessments of treatment adherence and therapist competence."
[14] From Analysis 1.16 of Bisson Cochrane review (in preparation).
[15] Unclear random allocation.

[16] From Analysis 1.6 of Bisson Cochrane review (in preparation).
[17] Visual inspection of forest plot suggests heterogeneity. I-squared = 83%.
[18] From Analysis 1.5 of Bisson Cochrane review (in preparation).
[19] Total drop-outs are only a proxy measure of adverse effects.

**Author(s):** Corrado Barbui
**Date:** 2012-03-09
**Question:** Should group CBT with a trauma focus vs treatment as usual or no treatment/waitlist be used in adults with PTSD?
**Bibliography:** Bisson Cochrane review (in preparation)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Group CBT | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity – clinician** (better indicated by lower values) | | | | | | | | | | | | |
| 3[1] | Randomized trials | Serious[2] | Serious[3] | Serious[4] | Serious[5] | None | 0[6] | – | – | MD 0 higher (0 to 0 higher)[6] | ⬜⬜⬜⬜ VERY LOW | CRITICAL |
| **Symptom severity – clinician** (1–4-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 0[7] | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Symptom severity – clinician** (5–8-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 1[8] | Randomized trials | Serious[9] | No serious inconsistency[10] | No serious indirectness | Serious[11] | None | 45 | 52 | – | MD 18.79 lower (28.98 to 8.6 lower) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Symptom severity – clinician** (9–12-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 0[12] | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Symptom severity – self-report** (better indicated by lower values) | | | | | | | | | | | | |
| 5[13] | Randomized trials | No serious risk of bias | Serious[3] | No serious indirectness | No serious imprecision | None | 125 | 125 | – | SMD 1.15 lower (1.72 to 0.58 lower) | ⬜⬜⬜⬜ MODERATE | CRITICAL |
| **Symptom severity – self-report** (1–4-month follow-up) (better indicated by lower values) | | | | | | | | | | | | |
| 1[14] | Randomized trials | Serious[15] | No serious inconsistency[10] | No serious indirectness | Serious[11] | None | 53 | 24 | – | MD 11.24 lower (18.11 to 4.37 lower) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |

| Presence of disorder – PTSD diagnosis after treatment | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1[16] | Randomized trials | No serious risk of bias | No serious inconsistency[10] | No serious indirectness | Very serious[17] | None | 9/24 (37.5%) | 16/24 (66.7%) | RR 0.56 (0.31 to 1.01) | 293 fewer per 1000 (from 460 fewer to 7 more) | ▢▢▢▢ LOW | IMPORTANT |
| Adverse effects | | | | | | | | | | |
| 5[18] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[19] | No serious imprecision | None | 50/199 (25.1%) | 38/181 (21%) | RR 1.19 (0.82 to 1.74) | 40 more per 1000 (from 38 fewer to 155 more) | ▢▢▢▢ MODERATE | IMPORTANT |

[1] From Analysis 4.2 of Bisson Cochrane review (in preparation).
[2] Studies did not provide full details of the method of allocation.
[3] Visual inspection of forest plot suggests significant heterogeneity.
[4] The study populations were varied and not directly comparable. All studies included individuals at least three months following the trauma.
[5] Fewer than 200 patients included in the analysis.
[6] No overall treatment estimate was calculated.
[7] No data according to Analysis 4.7 of Bisson Cochrane review (in preparation).
[8] From Analysis 4.11 of Bisson Cochrane review (in preparation).
[9] Unclear allocation concealment.
[10] Only one study included in the analysis.
[11] Fewer than 100 patients included in the analysis.
[12] No data according to Analysis 4.12 of Bisson Cochrane review (in preparation).
[13] From Analysis 4.1 of Bisson Cochrane review (in preparation).
[14] From Analysis 4.8 of Bisson Cochrane review (in preparation).
[15] Outcomes rated by patients only.
[16] From Analysis 4.6 of Bisson Cochrane review (in preparation).
[17] Fewer than 100 patients included. Confidence interval ranges from appreciable benefit to no benefit.
[18] From Analysis 4.5 of Bisson Cochrane review (in preparation).
[19] Total drop-outs are a proxy measure of adverse effects.

**Author(s):** Corrado Barbui
**Date:** 2012-03-09
**Question:** Should EMDR vs treatment as usual or no treatment/waitlist be used in adults with PTSD?
**Bibliography:** Bisson Cochrane review (in preparation)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | EMDR | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quality assessment | | | | | | | No. of patients | | Effect | | | |
| **Symptom severity – clinician** (better indicated by lower values) | | | | | | | | | | | | |
| 6[1] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | Serious[3] | None | 93 | 90 | – | MD 13.24 lower (16.39 to 10.1 lower) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Symptom severity – self-report** (better indicated by lower values) | | | | | | | | | | | | |
| 6[4] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | Serious[3] | None | 84 | 75 | – | MD 15.97 lower (19.86 to 12.08 lower) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Presence of disorder** | | | | | | | | | | | | |
| 6[5] | Randomized trials | No serious risk of bias | No serious inconsistency | No serious indirectness | No serious imprecision | None | 52/107 (48.6%) | 97/102 (95.1%) | OR 0.05 (0.02 to 0.14) | 459 fewer per 1000 (from 220 fewer to 671 fewer) | ⬜⬜⬜⬜ HIGH | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 7[1,6] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[7] | No serious imprecision | None | 24/120 (20%) | 19/107 (17.8%) | OR 1.07 (0.54 to 2.11) | 10 more per 1000 (from 73 fewer to 135 more) | ⬜⬜⬜⬜ MODERATE | IMPORTANT |

[1] From Analysis 9.1 of Bisson Cochrane review (in preparation).
[2] Visual inspection of forest plot suggested significant heterogeneity.
[3] Fewer than 200 patients included in the analysis.
[4] From Analysis 9.2 of Bisson Cochrane review (in preparation).
[5] From Analysis 9.6 of Bisson Cochrane review (in preparation).
[6] From Analysis 9.5 of Bisson Cochrane review (in preparation).
[7] Total drop-outs are only a proxy measure of adverse effects.

**Author(s):** Corrado Barbui
**Date:** 2012-03-10
**Question:** Should stress management vs treatment as usual or no treatment/waitlist be used in adults with PTSD?
**Bibliography:** Bisson Cochrane review (in preparation)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Stress management | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | **Quality assessment** | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity – clinician** (better indicated by lower values) | | | | | | | | | | | | |
| 3[1] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | Serious[3] | None | 44 | 42 | – | SMD 1.14 lower (1.62 to 0.67 lower) | ☐☐☐☐ LOW | CRITICAL |
| **Symptom severity – self-report** (better indicated by lower values) | | | | | | | | | | | | |
| 1[4] | Randomized trials | No serious risk of bias | No serious inconsistency[5] | No serious indirectness | Very serious[6] | None | 12 | 12 | – | SMD 0.33 higher (0.47 lower to 1.14 higher) | ☐☐☐☐ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** | | | | | | | | | | | | |
| 4[7] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | Serious[3,8] | None | 41/67 (61.2%) | 54/54 (100%) | RR 0.65 (0.5 to 0.86) | 350 fewer per 1000 (from 140 fewer to 500 fewer) | ☐☐☐☐ LOW | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 4[9] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[10] | Very serious[8] | None | 12/67 (17.9%) | 4/54 (7.4%) | RR 2.19 (0.71 to 6.73) | 88 more per 1000 (from 21 fewer to 424 more) | ☐☐☐☐ VERY LOW | IMPORTANT |

[1] From Analysis 2.1.1 of Bisson Cochrane review (in preparation).
[2] Visual inspection of forest plots suggests some heterogeneity.
[3] Fewer than 100 patients included in the analysis.
[4] From Analysis 2.2.2 of Bisson Cochrane review (in preparation).

[5] Only one study contributed to the analysis.

[6] Only 24 patients contributed to the analysis. Confidence interval ranges from appreciable benefit to appreciable harm.

[7] From Analysis 2.6 of Bisson Cochrane review (in preparation).

[8] Fewer than 200 patients included in the analysis. Confidence interval ranges from appreciable benefit to appreciable harm.

[9] From Analysis 2.5 of Bisson Cochrane review (in preparation).

[10] Total drop-outs are only a proxy measure of adverse effects.

# PART 2: FROM EVIDENCE TO RECOMMENDATIONS(S)

## Evidence to recommendation table

| Benefits | **Individual CBT with a trauma focus**<br><br>There is evidence suggesting that individual CBT with a trauma focus in adults with PTSD has a beneficial effect in decreasing symptom severity after intervention. This beneficial effect has been demonstrated using clinician-rated as well as service user-rated outcome measures. The confidence in estimate is MODERATE. The effect persists at follow-up assessments, although the confidence in estimates at follow-up is LOW.<br><br>There is evidence suggesting that individual CBT with a trauma focus in adults with PTSD has a beneficial effect in reducing PTSD diagnosis after treatment (individuals with PTSD diagnosis at follow-up: 46.4% (CBT) versus 89% (control group)). The confidence in estimate is MODERATE.<br><br>There is no systematic review of the evidence on the effect of CBT with a trauma focus on functioning.<br><br>**Group CBT with a trauma focus**<br><br>There is evidence suggesting that group CBT with a trauma focus in adults with PTSD has a beneficial effect in decreasing symptom severity after intervention. This beneficial effect has been demonstrated using patient-rated outcome measures only. The confidence in estimate is MODERATE. The effect may persist at follow-up assessments, although the confidence in estimates at follow-up is LOW.<br><br>There is some evidence, from one trial only, suggesting that group CBT with a trauma focus in adults with PTSD has a beneficial effect in reducing PTSD diagnosis after treatment (individuals with PTSD diagnosis at follow-up: 37.5% (group CBT with a trauma focus) versus 66.7% (control group)). The confidence in this estimate is LOW.<br><br>There is no systematic review of evidence on the effect of group CBT on functioning.<br><br>**EMDR**<br><br>There is evidence suggesting that EMDR in adults with PTSD has a beneficial effect in decreasing symptom severity after intervention. This beneficial effect has been demonstrated using clinician-rated as well as patient-rated outcome measures. The confidence in estimate is LOW. It is uncertain if the effect persists at follow-up assessments, as no systematic review of evidence is available. |
|---|---|

| | |
|---|---|
| | There is evidence suggesting that EMDR in adults with PTSD has a beneficial effect in reducing PTSD diagnosis after treatment (individuals with PTSD diagnosis at follow-up: 48.6% (EMDR) versus 95.1% (control group)). The confidence in estimate is HIGH.<br><br>There is no systematic review of evidence on the effect of EMDR on functioning.<br><br>**Stress management**<br>There is evidence suggesting that stress management in adults with PTSD has a beneficial effect in decreasing symptom severity after intervention. This beneficial effect has been demonstrated using clinician-rated outcome measures only. The confidence in estimate is LOW. It is unclear if the effect persists at follow-up assessments, as no evidence is available.<br><br>There is evidence suggesting that stress management in adults with PTSD has a beneficial effect in decreasing PTSD diagnosis after treatment (individuals with PTSD diagnosis at follow-up: 61.2% (stress management) versus 100% (control group)). The confidence in estimate is LOW.<br><br>There is no systematic review of evidence on the effect of stress management on functioning. |
| **Harms** | **Individual CBT with a trauma focus**<br>There is evidence suggesting that CBT with a trauma focus in adults with PTSD *is* associated with more persons leaving the study early, a proxy measure of treatment acceptability (24.7% versus 13.5%). The confidence in estimate is MODERATE.<br>**Group CBT with a trauma focus**<br>There is evidence suggesting that group CBT with a trauma focus in adults with PTSD is *not* associated with more people leaving the study early, a proxy measure of treatment acceptability (25.1% versus 21%). The confidence in estimate is MODERATE.<br><br>**EMDR**<br>There is evidence suggesting that EMDR in adults with PTSD is *not* associated with more people leaving the study early, a proxy measure of treatment acceptability (20% versus 17.8%). The confidence in estimate is MODERATE.<br><br>**Stress management**<br>There is evidence suggesting that stress management in adults with PTSD is associated with more people leaving the study early, a proxy measure of treatment acceptability (17.9% versus 7.4%), although this difference does not reach statistical significance. The confidence in estimate is VERY LOW. |

| Value and preferences | |
|---|---|
| In favour | The possibility of decreasing PTSD symptoms and enhancing recovery from PTSD is an important value.<br><br>Psychological treatment based on CBT principles, including stress management and exposure-based CBT with a trauma focus, has value in that it may possibly build life skills in the person to address stressors in the long term. Skills applied in these treatments may be applied for treatment of other disorders.<br><br>Psychological treatment based on EMDR does not require the person to verbalize details of the traumatic event. Compared with CBT, this makes treatment easier when the traumatic event (e.g. sexual violence) carries social stigma, and when therapists are at risk of burn-out.<br><br>Psychological treatment based on stress management has value in it that can be learned relatively easily by para-professionals. |
| Against | Prolonged exposure therapy involves being extensively exposed to frightening or horrific memories that one is trying to avoid, and as such can be counter-intuitive to the person. Some clinicians and many help-seekers prefer treatments that are easier to endure. (A counter-argument is that, despite such preferences, research using exposure for all types of anxiety disorders shows large effect sizes for reduction in symptoms. Discomfort remembering traumatic memories may be likened to medical procedures where an individual has to undergo discomfort to heal an injury.)<br>EMDR can involve the person suddenly thinking about other traumatic memories, which they may not welcome.<br><br>Relative to CBT, EMDR's underlying treatment mechanisms are largely unknown.<br><br>Although a number of studies have reported positive results with EMDR in diverse situations (e.g. evidence exists from Iran and Mexico),[43] EMDR used in certain cultural situations has been interpreted as witchcraft and has increased stress and anxiety in some of the recipients (Melville, A., Psychosocial Interventions: Psychosocial evaluation of UNICEF supported projects (1999–2001), UNICEF Indonesia, 2003 (www.ecdgroup.com/docs/lib_005421517.pdf)). (A counter-argument is that public health experience with other interventions (e.g. vaccinations) suggests that such cultural interpretations can become a significant barrier to implementation, but do not necessarily constitute sufficient reason for deciding to not make the intervention available.) |

---

[43] Abbasnejad, M., Mahani, K.N. & Zamyad, A. (2007). Efficacy of "eye movement desensitization and reprocessing" in reducing anxiety and unpleasant feelings due to earthquake experience. *Psychological Research*, 9, 104-117; Jarero, I., Artigas, L. & Luber, M. (2011). The EMDR protocol for recent critical incidents: Application in a disaster mental health continuum of care context. *Journal of EMDR Practice and Research*, 5, 82-94.

| Feasibility (including economic consequences) | Most studies supporting efficacy were implemented in high-income countries (except two published CBT with a trauma focus studies in Turkey and one unpublished EMDR study in Pakistan) and by trained clinicians. All three non-western studies had positive findings. |
|---|---|
| | Most staff in PHC in LMIC have not been extensively trained in communication skills and basic emotional support. Any additional training in delivery of CBT with a trauma focus and EMDR would require substantial resources, including supervision. CBT with a trauma focus and EMDR are both specialized techniques. The clinician using these techniques should also have additional capacities to help the person, including (a) the ability to make differential diagnosis, (b) problem-solving techniques and (c) relaxation/stabilizing techniques. The likelihood that full-time PHC clinicians have the time to learn and practice all these techniques is limited. |
| | Given the delicate and technical nature of CBT with a trauma focus and EMDR, implementation by para-professionals may carry risks. Nevertheless, cognitive-behavioural interventions have been successfully implemented in low-resource settings by para-professionals (e.g. community health workers) to treat maternal depression (Rahman et al., 2008 *Lancet* 372: 902–09) and PTSD symptoms in adults and adolescents (Neuner et al., 2008 *Journal of Consulting and Clinical Psychology*, 76(4): 686-94; Ertl et al., 2011 *JAMA* 306(5): 503-12). |
| | There is no randomized evidence that EMDR can feasibly implemented by non-specialized health staff. The EMDR Institute requires prospective trainees to "have a masters degree or higher in the mental health field and are licensed or certified through a state or national board which authorizes independent practice". |
| | Stress management training can be carried out relatively simply and practised on a regular group basis by para-professionals. It has value across a range of disorders. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | **Yes X** (CBT/EMDR)<br>**No X**<br>(Group CBT/Stress management) |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 14*
**Individual or group cognitive-behavioural therapy (CBT) with a trauma focus, eye movement desensitization and reprocessing (EMDR) or stress management should be considered for adults with PTSD.**

*Strength of recommendation: standard*
*Quality of evidence: moderate for individual CBT, EMDR; low for group CBT, stress management*

**Remarks**
*Individual and group CBT with a trauma focus and EMDR should be offered only in those contexts where individuals are competent (i.e. trained and supervised) to provide the therapies. Although studies show that individual CBT with a trauma focus is more effective than stress management, in resource-constrained settings stress management may be the most feasible treatment option.*

# 15. Posttraumatic stress disorder (PTSD): psychological interventions – children and adolescents

**Q15. For children and adolescents with posttraumatic stress disorder (PTSD), do psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

This scoping question focuses on psychological interventions (individual and group cognitive-behavioural therapy (CBT), eye movement desensitization and reprocessing (EMDR), stress management and psycho-education) for child and adolescent PTSD.

With respect to CBT, this guideline does not use the *term trauma-focused CBT* (TF CBT), because this term has been used in different manners in the international literature. For example, in the widely used NICE Guidelines, it is used for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing of thoughts related to the event), while the same term is also widely used for a very specific multi-component CBT protocol for children and adolescents developed by Cohen and colleagues. To avoid confusion, this guideline avoids the term TF CBT and uses the term *CBT with a trauma focus* for all CBT interventions that involve a trauma focus (e.g. through exposure or cognitive processing). The term *CBT with a trauma focus* is thus synonymous with the term TF CBT as used in the NICE Guidelines.

EMDR is a new treatment, developed in the late 1980s. Proponents of EMDR usually do not consider EMDR as a type of CBT. This is in contrast to many proponents of CBT, who consider EMDR to be a form of CBT.

Traditional CBT PTSD treatments involve teaching an individual skills to change unhelpful thoughts and behaviours to more helpful or productive thoughts and behaviours, leading the person to feel better. These treatments utilize procedures that directly target the person's beliefs and behaviours (e.g. exposure, challenging of beliefs). EMDR procedures focus on spontaneous associative processing of memories with a component of bilateral stimulation (e.g. eye movements). Unlike traditional CBT PTSD treatments, EMDR therapy (a) does not involve the direct procedural targeting of beliefs or behaviours; (b) does not use daily homework (although the person may be encouraged to test themselves in previously feared situations near the end of the treatment when symptoms have already reduced); and (c) involves treatment that is conducted without detailed descriptions of the event and without direct challenging of beliefs and without extended exposure. Relative to CBT, the underlying theoretical treatment mechanisms of EMDR are still largely speculative, and this has been a source of controversy.

It should be noted that exposure treatment (which often is part of CBT with a trauma focus) is very different from psychological debriefing (i.e. promotion of ventilation by requesting a person to briefly but systematically recount perceptions, thoughts and emotional reactions experienced during the event). The latter does not involve sufficient exposure to the traumatic memory to reduce symptoms (see mhGAP Guidelines 2009). Consistent with the NICE Guidelines for adults, the term *stress management* refers in these guidelines to psychological treatments that use cognitive or behavioural techniques that do not focus on trauma (e.g. relaxation, stress inoculation training).

Psycho-education refers in these guidelines to "the provision of information about the nature of stress, posttraumatic and other symptoms, and what to do about them".

# PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)
- **Population:**      Children and adolescents with PTSD, after the first month of a potentially traumatic event
- **Interventions:**  Individual and group CBT with a trauma focus, EMDR, stress management
- **Comparison:**     Treatment as usual or no treatment/waitlist
- **Outcomes:**
  - Symptom severity post-intervention
  - Functioning/quality of life post-intervention
  - Presence of mental disorder at 6- to 12-month follow-up
  - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process
The search was conducted in week 30 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "PTSD" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option, and used only the keyword "PTSD". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents, focusing on psychological and social treatments. We did not include systematic reviews of pharmacological and manual therapies (e.g. massage therapy, acupuncture, spinal manipulation). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE using the same keyword. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Kowalik, J., Weller, J., Venter, J., Drachman, D. (2011). Cognitive behavioral therapy for the treatment of pediatric posttraumatic stress disorder: A review and meta-analysis. *Journal of Behavior Therapy & Experimental Psychiatry*, 42, 405-413.

Rodenburg, R., Benjamin, A., de Roos, C., Meijer, A., Stams, G. (2009). Efficacy of EMDR in children: A meta-analysis. *Clinical Psychology Review*, 29, 599-606.

Rolfsnes, E.S., Idsoe, T.E. (2011). School-based intervention programs for PTSD symptoms: A review and meta-analysis. *Journal of Traumatic Stress*, 24(2), 155-165.

Silverman, W.K., Ortiz, C.D., Viswesvaran, C., Burns, B, Kolko, D.J., Putnam, F., Amaya-Jackson, L. (2008). Evidence-based psychosocial treatments for children and adolescents exposed to traumatic events. *Journal of Clinical Child & Adolescent Psychology*, 37(1), 156-183.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

American Academy of Child & Adolescent Psychiatry (AACAP) (2010). Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, 49(4), 414-430.
REASON FOR EXCLUSION: minimal description of systematic review methodology, e.g. no description of quality appraisal of studies, and no formal meta-analysis reported.

Cartwright-Hatton, S., Roberts, C., Chitsabesan, P., Fothergill, C., Harrington, R. (2004). Systematic review of the efficacy of cognitive behaviour therapies for childhood and adolescent anxiety disorders. *British Journal of Clinical Psychology*, 43, 421-436.
REASON FOR EXCLUSION: more than two years old, excluded trials solely focusing on PTSD.

Cohen, J.A., Mannarino, A.P. (2010). Psychotherapeutic options for traumatized children. *Current Opinion in Pediatrics*, 22, 605-609.
REASON FOR EXCLUSION: no systematic review methodology is described.

Ehntholt, K., Yule, W. (2006). Practitioner Review: Assessment and treatment of refugee children and adolescents who have experienced war-related trauma. *Journal of Child Psychology & Psychiatry*, 47(12), 1197-1210.
REASON FOR EXCLUSION: more than two years old, no systematic review methodology is described.

Macdonald, G., Higgins, J., Ramchandi, P. (2006). Cognitive-behavioral interventions for children who have been sexually abused. *Campbell Systematic Reviews*, DOI 10.4073/csr.2006.10.
REASON FOR EXCLUSION: more than two years old, focused on specific population sub-group.

Peltonen, K., Punamäki, R. (2010). Preventive interventions among children exposed to trauma of armed conflict: A literature review. *Aggressive Behavior*, 36, 95-116.
REASON FOR EXCLUSION: focused on specific population sub-group; missed studies published in recent years.

Taylor, T.L., Chemtob, C.M. (2004). Efficacy of treatment for child and adolescent traumatic stress. *Archives of Pediatrics and Adolescent Medicine*, 158, 786-791.
REASON FOR EXCLUSION: more than two years old, no formal meta-analysis reported.

Trask, E.V., Walsh, K., DiLillo, D. (2011). Treatment effects for common outcomes of child sexual abuse: A current meta-analysis. *Aggression and Violent Behavior*, 16, 6-19.
REASON FOR EXCLUSION: focused on specific population sub-group.

Wethington, H.R., Hahn, R.A., Fuqua-Whitley, D.S., Sipe, T.A., Crosby, A.E., Johnson, R.L., Liberman, A.M., Mos'cicki, E., Price, L.N., Tuma, F.K. Kalra, G., Chattopadhyay, S.K., Task Force on Community Preventive Services (2008). The effectiveness of interventions to reduce psychological harm from traumatic events among children and adolescents: A systematic review. *American Journal of Preventive Medicine*, 35(3), 287-313 and Task Force on Community Preventive Services (2008). Recommendations to reduce psychological harm from traumatic events among children and adolescents. *American Journal of Preventive Medicine*, 35(3), 314-316.
REASON FOR EXCLUSION: excluded studies in middle-income and low-income countries (no further details on reports excluded for this reason), and merged EMDR within the CBT category.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Individual CBT vs. no treatment/control | Symptom severity<br><br>Functioning<br>Presence of disorder<br>Adverse effects | Silverman et al. (2008) for PTSD symptoms; Kowalik et al. (2011) for internalizing/externalizing problems<br>No data<br>No data<br>No data | Silverman and colleagues is more than two years old, but reviews interventions that are not reviewed elsewhere. This review is supplemented by the more recent Kowalik et al. (2011) study for other than PTSD outcomes. |
| 2 | Group CBT vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Rolfsnes & Idsoe (2011)<br>No data<br>No data<br>No data | Rolfsnes & Idsoe (2011) is the most recent review of group CBT interventions, but also included non-randomized controlled studies. |

| 3 | EMDR vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Rodenburg et al. (2009)<br>No data<br>No data<br>No data | Rodenburg et al. (2009) is the most recent high-quality systematic review and meta-analysis including EMDR as a separate intervention. |
| 4 | Stress management vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | |

## Narrative description of the studies that went into analysis

Silverman and colleagues' (2008) review is older than two years, but is the most recent systematic review and meta-analysis that reviewed a variety of psychosocial/psychological interventions of interest to this scoping question (e.g. the Task Force on Community Preventive Services (2008) merged EMDR within a CBT category). Altogether, the review identified 21 randomized controlled trials (RCTs). Most studies evaluated individual or group CBT with a trauma focus. Included studies focused on children exposed to a variety of traumatic stressors, with a large group of studies focused on sexual abuse and maltreatment. Two separate studies (total n=324) were found that focused on group CBT, both implemented in school settings in the United States. Meta-analysis focused on the variables treatment (CBT vs non-CBT), parent involvement and type of trauma. The authors concluded that significant effect sizes were found favouring CBT treatment and treatment of sexually abused children.

Kowalik and colleagues (2011) identified a similar group of studies as Silverman and colleagues (2008) (n=21, no studies dated past 2007). Subsequent to observing that the Child Behaviour Checklist (CBCL) was a measure consistently used, authors focused on meta-analyses of the three subscales of this measure (total problems, internalizing and externalizing problems).

For a more up-to-date review of group CBT, Rolfsnes & Idsoe's (2011) review of school-based interventions was selected. This review included 19 studies, of which 16 applied a form of CBT. However, this review also included non-randomized controlled studies.

Rodenburg and colleagues' (2009) systematic review and meta-analysis of EMDR for the treatment of PTSD in children and adolescents identified seven RCTs. These studies included children experiencing a range of traumas (dominantly one-off events), who were offered between three and eight sessions of EMDR. Meta-analysis focused on PTSD symptoms post-treatment as few studies assessed longitudinal changes.

Altogether, EMDR was effective with a medium effect size (Cohen's *d* =.56), and found to be more effective than CBT treatments when comparing effect sizes. The variation in effect sizes between studies was partly explained by both treatment and study methodology factors, including year of publication (more recent studies associated with lower effect sizes), type of informant (parent-child reports associated with higher effect sizes than studies using only child reports), drop-out (more drop-out associated with lower effect sizes), type of comparison (comparison with established treatments associated with lower effect sizes) and number of sessions (fewer sessions associated with higher effect sizes).

## GRADE tables

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-02-27
**Question:** Should individual CBT vs treatment as usual or no treatment/waitlist be used in children and adolescents with PTSD?
**Bibliography:** Silverman (2008), Kowalik (2011)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Individual CBT | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **PTSD symptoms** (better indicated by higher values) | | | | | | | | | | | | |
| 16[1] | Randomized trials | No serious risk of bias[2] | Serious[3] | No serious indirectness | No serious imprecision | None | 0[2] | – | – | Sample size weighted average effect size 0.50 higher (0.03 to 0.98 higher) | ⬜⬜⬜ MODERATE | CRITICAL |
| **Co-morbid internalizing symptoms** (better indicated by lower values) | | | | | | | | | | | | |
| 7[4] | Randomized trials | Serious[5] | No serious inconsistency[6] | No serious indirectness | No serious imprecision[7] | None | 0[2] | – | – | Average effect size 0.314 lower (0.505 to 0.122 lower) | ⬜⬜⬜ MODERATE | CRITICAL |
| **Co-morbid externalizing symptoms** (better indicated by lower values) | | | | | | | | | | | | |
| 8[4] | Randomized trials | Serious[5] | No serious inconsistency | No serious indirectness | No serious imprecision[7] | None | 0[2] | – | – | Average effect size 0.192 lower (0.376 to 0.008 lower) | ⬜⬜⬜ MODERATE | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | No evidence available | | | | | None | 0 | _ | _ | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | _ | _ | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Silverman (2008) Table 5.
[2] Not clearly reported.
[3] Funnel plot not available, but significant variability among effect sizes is reported.
[4] From Kowalik (2011).
[5] From Table 1 of Kowalik (2011).
[6] I-squared = 20.3%.
[7] Overall number of patients included in this analysis not reported.

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-02-27
**Question:** Should group CBT vs treatment as usual or no treatment/waitlist be used in children and adolescents with PTSD?
**Bibliography:** Rolfsnes (2011)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Group CBT | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity** (better indicated by higher values) | | | | | | | | | | | | |
| 19[1] | Observational studies | Very serious[2] | No serious inconsistency[3] | No serious indirectness | No serious imprecision[4] | None | 0[5] | – | – | Cohen's d 0.68 higher (0 to 0 higher)[5] | ⬜⬜⬜⬜ VERY LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Rolfsnes (2011) p.163.
[2] Randomized trials were pooled together with non-randomized trials.
[3] Not reported.
[4] Overall number of included patients not reported.
[5] CI not reported. SD = 0.41

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-02-27
**Question:** Should EMDR vs treatment as usual or no treatment/waitlist be used in children and adolescents with PTSD?
**Bibliography:** Rodenburg (2009)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | EMDR | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity (better indicated by higher values)** | | | | | | | | | | | | |
| 7[1] | Randomized trials | Serious[2] | Serious[3] | No serious indirectness | No serious imprecision | None | 0[4] | – | – | Cohen's d 0.56 higher (0.42 to 0.7 higher) | ⬜⬜⬜⬜ LOW | CRITICAL |
| **Functioning (better indicated by lower values)** | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder (better indicated by lower values)** | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects (better indicated by lower values)** | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Rodenburg (2009) Table 3.
[2] Unclear random allocation and concealment of allocation.
[3] Funnel plot not available but inconsistency reported by the authors.
[4] Overall sample size is 209.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | **Individual CBT with trauma focus** |
|---|---|
| | There is evidence suggesting that individual CBT with trauma focus in children with PTSD has a beneficial effect in decreasing symptom severity after intervention. The confidence in estimate is MODERATE. It is unclear if the effect persists at follow-up assessments, as no systematic review of evidence is available. |
| | There is no systematic review of evidence on the effect of individual trauma-focused CBT on presence of disorder and functioning. |
| | **Group CBT with trauma focus** |
| | There is evidence suggesting that group CBT with trauma focus in children with PTSD may have a beneficial effect in decreasing symptom severity after intervention. However, the confidence in estimate is VERY LOW (randomized controlled trials were meta-analysed together with non-randomized controlled trials). It is unclear if the effect persists at follow-up assessments, as no systematic review of evidence is available. |
| | There is no systematic review of evidence on the effect of group CBT with trauma focus on presence of disorder and functioning. |
| | **EMDR** |
| | There is evidence suggesting that EMDR in children with PTSD may have a beneficial effect in decreasing symptom severity after intervention. However, the confidence in estimate is LOW. It is unclear if the effect persists at follow-up assessments, as no systematic review of evidence is available. |
| | There is no systematic review of evidence on the effect of EMDR on functioning, presence of disorder and adverse effects. |
| | **Stress management** |
| | There is no systematic review of evidence on the effect of stress management on decreasing PTSD symptoms, reducing PTSD or functioning. |
| Harms | There is no systematic review of evidence available to evaluate if CBT with trauma focus, EMDR or stress management may do harm for children and adolescents with PTSD. |

| Value and preferences | |
|---|---|
| In favour | The possibility of decreasing PTSD symptoms and decreasing presence of PTSD is an important value.<br><br>Psychological treatment based on CBT principles has value in that it may possibly build life skills in the person to address stressors in the long term. Skills applied in these treatments may be applied for treatment of other disorders.<br><br>Psychological treatment based on EMDR does not require the child or adolescent to verbalize details of the traumatic event. Compared with CBT, this makes treatment easier when the traumatic event (e.g. sexual violence) carries social stigma; when the child has for any other reason (e.g. developmental stage) difficulties verbalizing what has happened; and when therapists are at risk of burn-out. |
| Against | CBT with a trauma focus includes imaginal or in vivo exposure. Exposure therapy involves being exposed to frightening or horrific memories that one is trying to avoid (e.g. through drawing, stories), and as such can be counter-intuitive to the child or adolescent. Some clinicians and many help-seekers prefer treatments that are easier to endure. (A counter-argument is that, despite such preferences, research using exposure for all types of anxiety disorders shows large effect sizes for reduction in symptoms. Discomfort remembering traumatic memories may be likened to medical procedures where an individual has to undergo discomfort to heal an injury.)<br><br>EMDR can involve the person suddenly thinking about other traumatic memories, which they may not welcome. Relative to CBT, the underlying treatment mechanisms of EMDR are largely unknown.<br><br>Although a number of studies (with adults) have reported positive results with EMDR in diverse situations (e.g. from Iran[44]), EMDR used in certain cultural situations has been interpreted as witchcraft and has increased stress and anxiety in some of the recipients (Melville, A., Psychosocial Interventions: Psychosocial evaluation of UNICEF supported projects (1999–2001), UNICEF Indonesia, 2003 (www.ecdgroup.com/docs/lib_005421517.pdf). Public health experience with other interventions (e.g. vaccinations) suggests that such cultural interpretations can become a significant barrier to implementation, but do not necessarily constitute sufficient reason for deciding to not make the intervention available. |

---

[44] Jaberghaderi, N., Greenwald, R., Rubin, A., Dolatabadim S. & Zand, S.O. (2004). A comparison of CBT and EMDR for sexually abused Iranian girls. *Clinical Psychology and Psychotherapy*, 11, 358-368.

| Feasibility (including economic consequences) | Most studies supporting efficacy were implemented in high-income countries and by trained clinicians.<br><br>Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in CBT and EMDR would require substantial resources, including supervision. CBT and EMDR are both specialized techniques. The clinician using these techniques should also have additional capacities to help the person, including (a) the ability to make differential diagnosis, (b) problem-solving techniques, (c) relaxation/stabilizing techniques and (d) working with children. The likelihood that full-time PHC clinicians have the time to learn and practice all these techniques is limited.<br><br>CBT and EMDR involve thinking about trauma-related reminders. Given the delicate nature of this process, implementation by para-professionals may carry risks. Nevertheless, cognitive-behavioural interventions have been successfully implemented in low-resource settings by para-professionals (e.g. community health workers) to treat maternal depression (Rahman et al., 2008 *Lancet* 372: 902–09) and PTSD symptoms in adults and adolescents (Neuner et al., 2008 *Journal of Consulting and Clinical Psychology* 76(4): 686-94; Ertl et al., 2011 *JAMA* 306(5): 503-12).<br><br>There is no randomized evidence that EMDR can feasibly be implemented by non-specialized health staff. The EMDR Institute requires prospective trainees to "have a masters degree or higher in the mental health field and are licensed or certified through a state or national board which authorizes independent practice". |
|---|---|

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | **Yes X** (Individual CBT)<br>**No X**<br>(Group CBT/EMDR) |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X** (Individual CBT)<br>**No X**<br>(Group CBT/EMDR) |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

*Recommendation 15*

**Individual or group cognitive-behavioural therapy (CBT) with a trauma focus or eye movement desensitization and reprocessing (EMDR) should be considered for children and adolescents with PTSD.**

*Strength of recommendation: standard*
*Quality of evidence: moderate for individual CBT, low for EMDR, very low for group CBT*

***Remarks***
*Individual and group CBT with a trauma focus and EMDR should be offered only in those contexts where individuals are competent (i.e. trained and supervised) to provide the therapies. Stress management may also be beneficial for children and adolescents with PTSD.*

# 16. Posttraumatic stress disorder (PTSD): pharmacological interventions – adults

**Q16. For adults with posttraumatic stress disorder (PTSD), do tricyclic antidepressants (TCAs) or selective serotonin re-uptake inhibitors (SSRIs), when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic stressors is common. Posttraumatic stress disorder (PTSD) is the most studied disorder after exposure to potentially traumatic events, with prevalence rates ranging from 0.3% to 6.1% in general populations globally and 15.4% in conflict-affected populations,[45][46] and can be associated with significant impairment in functioning.

Pharmacological treatments, especially antidepressants, are commonly prescribed for people suffering PTSD. However, there is currently no consensus on the effectiveness of pharmacological treatments between different clinical practice guidelines,[47] making this an important scoping question.

The question is limited to those pharmacological treatments that are most likely available now or in the next five years in non-specialized health care in low- and middle-income countries. Amitriptyline (as a representative of the tricyclic antidepressants) and fluoxetine (*not* as a representative of SSRIs) are included in the WHO model list of essential medicines for the treatment of depressive disorders. The scoping question addresses (a) tricyclic antidepressants (TCAs, as a category of antidepressants), (b) selective serotonin re-uptake inhibitors (SSRIs, as a category of antidepressants) and (c) fluoxetine (*not* as a representative of SSRIs).

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Adults with PTSD, after the first month of a potentially traumatic event
- **Interventions:** Antidepressants
- **Comparison:** Treatment as usual or no treatment/waitlist

---

[45] Kessler, R.C. & Üstün, T.B. (eds.) (2008). *The WHO World Mental Health Surveys: Global perspectives on the epidemiology of mental disorders*. New York: Cambridge University Press, 1-580.

[46] Steel, Z., Chey, T., Silove, D., Marnane, C., Bryant, R.A., van Ommeren, M. (2009). Association of torture and other potentially traumatic events with mental health outcomes among populations exposed to mass conflict and displacement. *Journal of the American Medical Association*, 302(5), 537-549.

[47] Forbes, D., Creamer, M., Bisson, J., Cohen, J.A., Crow, B.E., Foa, E., Friedman, M.J., Keane, T.M., Kudler, H.S., Ursano, R.J. (2010). A guide to guidelines for the treatment of PTSD and related conditions. *Journal of Traumatic Stress*, 23(5), 537-552.

- **Outcomes:**
  - Symptom severity post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## Details of commissioned systematic review

*NOTE: this systematic review was commissioned for a broader set of scoping questions, including pharmacological interventions for people with bereavement and ASD. For this scoping question, the methodology of the review is presented for all studies, but only the results of studies relevant to adults with PTSD symptoms are discussed.*

## Types of studies

All double-blind, randomized, placebo controlled and comparative trials completed between October 2005 and October 2011 were considered in our primary and additional searches, covering 13 separate databases. Trials included in the NICE, Cochrane and ANCPTSD reviews were also considered.

Published and unpublished abstracts and reports were sought out in any language. Studies were not excluded on the basis of differences between them such as sample size or duration. Trials in which there was ongoing or newly initiated trauma-focused psychotherapy or where the experimental medication served as an augmentation agent to ongoing pharmacotherapy were excluded. Trials in which there was ongoing supportive psychotherapy were allowed, provided it was not initiated during the course of the treatment. Open label trials were not considered.

## Types of participants

All studies of subjects with PTSD, ASD or grief reactions. There was no restriction on the basis of different diagnostic criteria for PTSD, duration or severity of PTSD symptoms. There was no restriction on the basis of co-morbid disorders, age or gender of participants.

## Types of interventions

Pharmacological treatments for children and adults with PTSD, ASD or a grief reaction, in which the comparator was a placebo (active or non-active) or other medication.

## Types of outcome measures

The primary outcomes of interest were clinician-administered PTSD symptom severity measures such as the Clinician Administered PTSD Scale (CAPS) and the Treatment Outcome PTSD Scale (TOP-8). Secondary outcomes of interest were remission rates, self-rated PTSD symptom scales such as the Impact of Event Scale (IES) and Davidson Trauma Scale (DTS) and measures of treatment response to co-morbid symptoms such as

depression and anxiety (e.g. the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Hamilton Anxiety Scale (HAM-A) and the Covi Anxiety Scale (COV)). Measures of quality of life and functional disability such as the Sheehan Disability Scale (SDS) were also considered. The total number of participants who left the trial early due to any reason was used as a measure of treatment tolerability.

## Search strategy

We conducted a primary bibliographic database search of MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. This initial broad search was intended to identify not only the RCTs of interest but other study methodologies and journal reviews of pharmacotherapy for PTSD.

The comprehensive search term used was created by amalgamating the previous search strategies from the NICE, Stein and Australian Guideline reviews with an updated list of medications.

Specific additional searches were carried out to identify international studies in Japanese, Chinese, Spanish and Portuguese (no additional studies identified). In addition, we searched the National PTSD Centre's PILOTS Database, the Cochrane Library, the Controlled Trials Register, Web Of Knowledge, OpenSIGLE and Google Scholar using the term "post traumatic stress disorder" OR "PTSD" OR "post-traumatic stress disorder" OR "posttraumatic stress disorder" AND "treatment" OR "medication" OR "pharmacotherapy" AND "controlled". Reference lists of all selected studies and reviews were further scrutinized for any additional RCTs.

## Study selection

One reviewer transferred the initial search hits into EndNoteX4 software and duplicates were removed. Two reviewers then independently screened the titles and abstracts of RCTs identified from the search. Those that were clearly irrelevant were excluded and potentially relevant studies were then assessed for inclusion as full texts. Any discrepancies between reviewers' decisions were resolved by discussion and guidance from a third senior reviewer.

## Data extraction and risk of bias assessment

One reviewer extracted the details of the studies into a standardized table which was then checked by another reviewer. Details from each study were collected on:

- Study citation, year of publication, location, setting, number of centres, design, sample size, duration and length of follow-up, diagnostic criteria, inclusion and exclusion criteria;
- Characteristics of study participants including gender distribution, mean and range of age, disease severity, duration of PTSD symptoms, presence of co-morbid depression, proportion with combat-related trauma, number randomized into each group, number of drop-outs;
- Characteristics of interventions including mean and maximum doses;

- Outcome measures reported including whether the data represented an intention-to-treat (ITT) or completers only sample. For ITT samples, the method of imputation was noted.

One reviewer input outcome data into the Cochrane Collaboration's Review Manager 5 software, which was then checked by another reviewer. Data from studies included in previous systematic reviews were extracted by one reviewer and independently cross-checked by a second reviewer for accuracy. Risk of bias was independently assessed for each trial by two reviewers using the domain-based evaluation method recommended by the Cochrane Collaboration. This method considers the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias. Discrepancies between the two raters were resolved by discussion and arbitrated by a third senior rater. Masked study assessment (hiding details of publishing journal, author, etc.) was not undertaken, since it is unclear whether this reduces bias.

## Data analysis

Review Manager 5 software was used to synthesise data using meta-analysis and to provide forest plots for dichotomous and continuous data. Confidence intervals (CI) of 95% were used for all analyses.
Categorical outcome measures such as leaving the study early were analysed using relative risk (RR) calculations. For continuous data, standardized mean differences (SMD) were used.
The degree of heterogeneity between studies was calculated using the I2 statistic. Where the statistic was less than 30%, indicating a mild degree of heterogeneity, a fixed effects model was used. A random effects model was used when the statistic was greater than 30%.
Data were analysed from the ITT sample in the "once randomized always analysed" fashion where possible to avoid effects of bias from completers-only analyses.

## Narrative description of the studies that went into analysis

All but one of the studies employed a placebo comparator arm, Spivak (2006) being the exception (reboxetine versus fluvoxamine). There were 22 comparisons in seven SSRI trials, two of which included sertraline (Friedman, 2007, Panahi, 2011), two fluoxetine (Martenyi, 2007, van der Kolk, 2007), one escitalopram (Shalev, 2011) and one fluvoxamine (Spivak, 2006). One trial compared the SNRI venlafaxine against placebo (Davidson, 2006). One trial assessed the atypical antipsychotic risperidone (Padala, 2006). One trial included the mood stabilizer divalproex (Davis, 2008). Two trials assessed the anticonvulsant topiramate (Tucker, 2007, Yeh, 2010) and one trial considered tiagabine (Davidson, 2007). Matthew (2011) assessed a novel new selective neurokinin-1 receptor antagonist called GR205171.
All but two of the trials were between 8–12 weeks of treatment duration. Davidson (2006) compared venlafaxine to placebo over six months and Shalev (2011) compared escitalopram to placebo over five months. No RCTs of pharmacotherapy for ASD or grief reactions were found.

## Risk of bias assessments

Eight of the studies included enough information on adequate random sequence generation to be judged as having a low risk of bias; the remainder were unclear. Only two studies included an adequate description of allocation concealment. All 14 studies described themselves as double-blind but a total of eight provided sufficient information to judge the blinding of participants, personnel and outcome assessors as low risk. Incomplete outcome data was addressed adequately in five studies. Ten of the studies were deemed to be free of selective reporting.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | TCA versus placebo | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Bisson review (submitted)<br>No data<br>No data<br>Bisson review (submitted) | |
| 2 | SSRI versus placebo | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Bisson review (submitted)<br>No data<br>No data<br>Bisson review (submitted) | |
| 3 | Fluoxetine versus placebo | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Bisson review (submitted)<br>No data<br>No data<br>Bisson review (submitted) | |

## TCA versus placebo

Efficacy: self-rated IES (Impact of Events Scale, total score)

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|---|
| Davidson 1990 | 25 | 11.5 | 17 | 33.7 | 6.6 | 16 | 69.6% | -8.70 [-15.05, -2.35] | |
| Kosten 1991 | 27.4 | 16.3 | 23 | 31.3 | 15 | 18 | 30.4% | -3.90 [-13.51, 5.71] | |
| | | | | | | | | | |
| Total (95% CI) | | | 40 | | | 34 | 100.0% | -7.24 [-12.54, -1.94] | |

Heterogeneity: Chi² = 0.67, df = 1 (P = 0.41); I² = 0%

Test for overall effect: Z = 2.68 (P = 0.007)

-10  -5  0  5  10
Favours experimental    Favours control

Davidson (1990) = amitriptyline; Kosten (1991) = imipramine

## Leaving the study early

| Study or Subgroup | Experimental Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|
| Davidson 1990 | 8 | 25 | 5 | 21 | 28.0% | 1.34 [0.52, 3.49] | |
| Kosten 1991 | 12 | 23 | 12 | 18 | 69.4% | 0.78 [0.47, 1.30] | |
| Reist 1989 | 2 | 27 | 0 | 27 | 2.6% | 5.00 [0.25, 99.51] | |
| | | | | | | | |
| Total (95% CI) | | 75 | | 66 | 100.0% | 1.05 [0.66, 1.66] | |
| Total events | 22 | | 17 | | | | |

Heterogeneity: Chi² = 2.57, df = 2 (P = 0.28); I² = 22%

Test for overall effect: Z = 0.20 (P = 0.84)

0.2  0.5  1  2  5
Favours experimental    Favours control

Davidson (1990) = amitriptyline; Kosten (1991) = imipramine; Reist (1989) = desipramine

## SSRI versus placebo

Efficacy: PTSD symptom severity (any continuous outcome).

| Study or Subgroup | Experimental Mean | SD | Total | Control Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Brady 2000 | 43.4 | 28.1 | 93 | 51.9 | 28.7 | 90 | 5.6% | -0.30 [-0.59, -0.01] |
| Brady 2004 | 32.56 | 15.69 | 49 | 32.7 | 28.75 | 45 | 4.2% | -0.01 [-0.41, 0.40] |
| Connor 1999 | 10.1 | 9.8 | 25 | 20.5 | 12.6 | 22 | 2.5% | -0.91 [-1.52, -0.31] |
| Davidson | -39.4 | 27.12 | 173 | -34.5 | 28.42 | 179 | 6.9% | -0.18 [-0.39, 0.03] |
| Davidson 2001c | -33 | 23.8 | 98 | -26.2 | 23.46 | 104 | 5.8% | -0.29 [-0.56, -0.01] |
| Ely lily | -10.42 | 7.5 | 323 | -10.59 | 10.21 | 88 | 6.5% | 0.02 [-0.21, 0.26] |
| Friedman 2007 | -13.1 | 27.5 | 84 | -15.4 | 28.07 | 82 | 5.5% | 0.08 [-0.22, 0.39] |
| Hertzberg 2000 | 47 | 8 | 6 | 42 | 11 | 6 | 0.9% | 0.48 [-0.68, 1.64] |
| Marshall 2001 | -38.75 | 27.24 | 365 | -25.3 | 25.8 | 186 | 7.3% | -0.50 [-0.68, -0.32] |
| Marshall 2004 | 55.6 | 33.4 | 25 | 62.8 | 40.8 | 27 | 2.9% | -0.19 [-0.73, 0.36] |
| Martenyi 2002A | -34.6 | 28.1 | 226 | -26.8 | 26.1 | 75 | 6.1% | -0.28 [-0.54, -0.02] |
| Martenyi 2007 | -42.9 | 23.1 | 114 | -36.6 | 25.7 | 64 | 5.4% | -0.26 [-0.57, 0.05] |
| Panahi 2011 | -22.7 | 7.3 | 35 | -17.5 | 7.5 | 35 | 3.4% | -0.69 [-1.18, -0.21] |
| Pfizer588 | -27.4 | 27.12 | 94 | -27.9 | 28.42 | 94 | 5.7% | 0.02 [-0.27, 0.30] |
| Pfizer589 | -13.1 | 21.12 | 84 | -15.4 | 28.42 | 82 | 5.5% | 0.09 [-0.21, 0.40] |
| Robb 2010 | -17.7 | 1.9 | 67 | -20.8 | 2.1 | 61 | 0.0% | 1.54 [1.15, 1.94] |
| Shalev 2011 | -31.12 | 29.63 | 23 | -27.8 | 20.13 | 23 | 2.7% | -0.13 [-0.71, 0.45] |
| SKB627 | -36.5 | 26.1 | 109 | -30.8 | 25.37 | 103 | 5.9% | -0.22 [-0.49, 0.05] |
| Tucker 2001 | -35.5 | 24.58 | 151 | -24.7 | 24.98 | 156 | 6.6% | -0.43 [-0.66, -0.21] |
| Tucker 2003 | 60.28 | 26.15 | 25 | 29.07 | 55.5 | 10 | 1.8% | 0.83 [0.07, 1.60] |
| van der Kolk 2004 | 42.7 | 22.1 | 30 | 43.6 | 22.6 | 29 | 3.2% | -0.04 [-0.55, 0.47] |
| van der Kolk 2007 | -33.23 | 22.11 | 30 | -30.95 | 22.6 | 29 | 3.2% | -0.10 [-0.61, 0.41] |
| Zohar 2002 | -18.7 | 6.7 | 23 | -13.5 | 6.6 | 19 | 2.4% | -0.77 [-1.40, -0.14] |
| **Total (95% CI)** | | | **2185** | | | **1548** | **100.0%** | **-0.20 [-0.32, -0.09]** |

Heterogeneity: Tau² = 0.04; Chi² = 50.64, df = 21 (P = 0.0003); I² = 59%

Test for overall effect: Z = 3.51 (P = 0.0005)



Favours experimental    Favours control

## Leaving the study early

| Study or Subgroup | Experimental Events | Total | Control Events | Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|---|
| Brady 2000 | 29 | 94 | 25 | 93 | 8.5% | 1.15 [0.73, 1.80] | |
| Connor 1999 | 6 | 27 | 12 | 27 | 3.6% | 0.50 [0.22, 1.14] | |
| Davidson | 62 | 173 | 65 | 179 | 13.4% | 0.99 [0.75, 1.30] | |
| Davidson 2001 | 0 | 0 | 0 | 0 | | Not estimable | |
| Davidson 2001c | 2 | 100 | 4 | 108 | 1.0% | 0.54 [0.10, 2.88] | |
| Davidson 2003 | 0 | 0 | 0 | 0 | | Not estimable | |
| Friedman 2007 | 26 | 86 | 14 | 83 | 6.2% | 1.79 [1.01, 3.19] | |
| Hertzberg 2000 | 1 | 6 | 0 | 6 | 0.3% | 3.00 [0.15, 61.74] | |
| Marshall 2001 | 127 | 369 | 69 | 182 | 15.1% | 0.91 [0.72, 1.15] | |
| Marshall 2004 | 8 | 25 | 14 | 27 | 4.9% | 0.62 [0.31, 1.21] | |
| Martenyi 2007 | 50 | 163 | 24 | 88 | 9.4% | 1.12 [0.75, 1.70] | |
| Panahi 2011 | 3 | 35 | 5 | 35 | 1.5% | 0.60 [0.16, 2.32] | |
| Pfizer588 | 24 | 95 | 25 | 95 | 7.8% | 0.96 [0.59, 1.56] | |
| Pfizer589 | 28 | 86 | 15 | 83 | 6.6% | 1.80 [1.04, 3.12] | |
| SKB627 | 49 | 160 | 56 | 162 | 12.2% | 0.89 [0.65, 1.21] | |
| Tucker 2001 | 12 | 163 | 4 | 160 | 2.1% | 2.94 [0.97, 8.94] | |
| van der Kolk 1994 | 12 | 33 | 4 | 31 | 2.5% | 2.82 [1.02, 7.81] | |
| van der Kolk 2004 | 4 | 30 | 3 | 29 | 1.4% | 1.29 [0.32, 5.26] | |
| van der Kolk 2007 | 6 | 30 | 3 | 29 | 1.6% | 1.93 [0.53, 7.01] | |
| Zohar 2002 | 6 | 23 | 4 | 19 | 2.1% | 1.24 [0.41, 3.76] | |
| | | | | | | | |
| **Total (95% CI)** | | 1698 | | 1436 | 100.0% | **1.07 [0.91, 1.27]** | |
| Total events | 455 | | 346 | | | | |

Heterogeneity: Tau² = 0.04; Chi² = 25.44, df = 17 (P = 0.09); I² = 33%
Test for overall effect: Z = 0.83 (P = 0.41)

0.5  0.7  1  1.5  2
Favours experimental    Favours control

## Fluoxetine versus placebo

Efficacy: PTSD symptom severity

| Study or Subgroup | Fluoxetine Mean | SD | Total | Placebo Mean | SD | Total | Weight | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|---|---|---|---|---|---|---|---|---|---|
| **4.1.1 CAPS** | | | | | | | | | |
| Martenyi 2002A | -34.6 | 28.1 | 226 | -26.8 | 26.1 | 75 | 44.4% | -0.28 [-0.54, -0.02] | |
| Martenyi 2007 | -42.9 | 23.1 | 114 | -36.6 | 25.7 | 64 | 32.3% | -0.26 [-0.57, 0.05] | |
| van der Kolk 2004 | 42.7 | 22.1 | 30 | 43.6 | 22.6 | 29 | 11.7% | -0.04 [-0.55, 0.47] | |
| van der Kolk 2007 | -33.23 | 22.11 | 30 | -30.95 | 22.6 | 29 | 11.7% | -0.10 [-0.61, 0.41] | |
| **Subtotal (95% CI)** | | | **400** | | | **197** | **100.0%** | **-0.23 [-0.40, -0.05]** | |

Heterogeneity: Tau² = 0.00; Chi² = 0.97, df = 3 (P = 0.81); I² = 0%

Test for overall effect: Z = 2.53 (P = 0.01)

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| **4.1.2 TOP-8** | | | | | | | | | |
| Ely lily | -10.42 | 7.5 | 323 | -10.59 | 10.21 | 88 | | Not estimable | |
| Martenyi 2007 | -10.59 | 0.58 | 140 | -10.59 | 0.81 | 77 | | Not estimable | |
| **Subtotal (95% CI)** | | | **0** | | | **0** | | **Not estimable** | |

Heterogeneity: Not applicable

Test for overall effect: Not applicable

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| **4.1.3 Other measures** | | | | | | | | | |
| Connor 1999 | 10.1 | 9.8 | 25 | 20.5 | 12.6 | 22 | | Not estimable | |
| Hertzberg 2000 | 47 | 8 | 6 | 42 | 11 | 6 | | Not estimable | |
| **Subtotal (95% CI)** | | | **0** | | | **0** | | **Not estimable** | |

Heterogeneity: Not applicable

Test for overall effect: Not applicable

| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| **4.1.4 Continuous outcome, best available scale** | | | | | | | | | |
| Connor 1999 | 10.1 | 9.8 | 25 | 20.5 | 12.6 | 22 | 8.7% | -0.91 [-1.52, -0.31] | |
| Ely lily | -10.42 | 7.5 | 323 | -10.59 | 10.21 | 88 | 24.2% | 0.02 [-0.21, 0.26] | |
| Hertzberg 2000 | 47 | 8 | 6 | 42 | 11 | 6 | 2.9% | 0.48 [-0.68, 1.64] | |
| Martenyi 2002A | -34.6 | 28.1 | 226 | -26.8 | 26.1 | 75 | 22.5% | -0.28 [-0.54, -0.02] | |
| Martenyi 2007 | -42.9 | 23.1 | 114 | -36.6 | 25.7 | 64 | 19.7% | -0.26 [-0.57, 0.05] | |
| van der Kolk 2004 | 42.7 | 22.1 | 30 | 43.6 | 22.6 | 29 | 11.1% | -0.04 [-0.55, 0.47] | |
| van der Kolk 2007 | -33.23 | 22.11 | 30 | -30.95 | 22.6 | 29 | 11.1% | -0.10 [-0.61, 0.41] | |
| **Subtotal (95% CI)** | | | **754** | | | **313** | **100.0%** | **-0.19 [-0.39, 0.01]** | |

Heterogeneity: Tau² = 0.03; Chi² = 10.90, df = 6 (P = 0.09); I² = 45%

Test for overall effect: Z = 1.83 (P = 0.07)

-1    -0.5    0    0.5    1

Favours experimental    Favours control

Test for subgroup differences: Chi² = 0.07, df = 1 (P = 0.80), I² = 0%

## Leaving the study early

| Study or Subgroup | Fluoxetine Events | Fluoxetine Total | Placebo Events | Placebo Total | Weight | Risk Ratio M-H, Random, 95% CI | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|---|
| Connor 1999 | 6 | 27 | 12 | 27 | 21.5% | 0.50 [0.22, 1.14] | |
| Hertzberg 2000 | 1 | 6 | 0 | 6 | 2.7% | 3.00 [0.15, 61.74] | |
| Martenyi 2007 | 50 | 163 | 24 | 88 | 36.8% | 1.12 [0.75, 1.70] | |
| van der Kolk 1994 | 12 | 33 | 4 | 31 | 16.6% | 2.82 [1.02, 7.81] | |
| van der Kolk 2004 | 4 | 30 | 3 | 29 | 10.4% | 1.29 [0.32, 5.26] | |
| van der Kolk 2007 | 6 | 30 | 3 | 29 | 11.9% | 1.93 [0.53, 7.01] | |
| **Total (95% CI)** | | 289 | | 210 | 100.0% | 1.22 [0.73, 2.04] | |
| Total events | 79 | | 46 | | | | |

Heterogeneity: Tau² = 0.14; Chi² = 8.00, df = 5 (P = 0.16); I² = 38%

Test for overall effect: Z = 0.77 (P = 0.44)



0.01   0.1   1   10   100
Favours experimental   Favours control

# GRADE table

**Author(s):** Corrado Barbui, Wietse Tol, Jonathan Bisson
**Date:** 2012-04-19
**Question:** Should TCAs vs placebo be used in adults with PTSD?
**Bibliography:** Bisson review (submitted)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TCAs | Placebo | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quality assessment | | | | | | | No. of patients | | Effect | | | |
| **Symptom severity** (better indicated by lower values) | | | | | | | | | | | | |
| 2[1] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[2] | Serious[3] | None | 40 | 34 | – | MD 7.24 lower (12.54 to 1.94 lower) | ☐☐☐☐ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 3[1] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[4] | Serious[5] | None | 22/75 (29.3%) | 17/66 (25.8%) | RR 1.05 (0.66 to 1.66) | 13 more per 1000 (from 88 fewer to 170 more) | ☐☐☐☐ LOW | IMPORTANT |

[1] Bisson review (submitted).
[2] Self-rated outcome measure.
[3] Fewer than 100 patients in the analysis.
[4] Total drop-outs are only a proxy measure of adverse effects.
[5] Fewer than 200 patients in the analysis, and the CI ranges from substantial advantage for TCAs to substantial advantage for placebo.

**Author(s):** Corrado Barbui, Wietse Tol, Jonathan Bisson
**Date:** 2012-04-19
**Question:** Should SSRIs vs placebo be used in adults with PTSD?
**Bibliography:** Bisson review (submitted)

| Quality assessment | | | | | | | No. of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | SSRIs | Placebo | Relative (95% CI) | Absolute | | |
| **Symptom severity** (better indicated by lower values) | | | | | | | | | | | | |
| 22[1] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | No serious imprecision | None | 2185 | 1548 | – | SMD 0.20 lower (0.32 to 0.09 lower) | ⊕⊕⊕◯ MODERATE | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 18[1] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[3] | No serious imprecision | None | 455/1698 (26.8%) | 346/1436 (24.1%) | RR 1.07 (0.91 to 1.27) | 17 more per 1000 (from 22 fewer to 65 more) | ⊕⊕⊕◯ MODERATE | IMPORTANT |

[1] Bisson review (submitted).
[2] Visual inspection of forest plot suggests heterogeneity. This was corroborated by I-squared = 59%.
[3] Total drop-outs are only a proxy measure of adverse effects.

**Author(s):** Corrado Barbui, Wietse Tol, Jonathan Bisson
**Date:** 2012-04-19
**Question:** Should fluoxetine vs placebo be used in adults with PTSD?
**Bibliography:** Bisson review (submitted)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Fluoxetine | Placebo | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | **Quality** | **Importance** |
| **Symptom severity** (better indicated by lower values) | | | | | | | | | | | | |
| 7[1] | Randomized trials | No serious risk of bias | Serious[2] | No serious indirectness | Serious[3] | None | 754 | 313 | – | SMD 0.19 lower (0.39 lower to 0.01 higher) | ▢▢▢▢ LOW | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 6[1] | Randomized trials | No serious risk of bias | No serious inconsistency | Serious[4] | Serious[5] | None | 79/289 (27.3%) | 46/210 (21.9%) | RR 1.22 (0.73 to 2.04) | 48 more per 1000 (from 59 fewer to 228 more) | ▢▢▢▢ LOW | IMPORTANT |

[1] Bisson review (submitted).
[2] Visual inspection of forest plot suggests some degree of heterogeneity. I-squared = 45%.
[3] Confidence interval ranges from appreciable benefit associated with fluoxetine treatment to no beneficial effect.
[4] Total drop-outs are only a proxy measure of adverse effects.
[5] The CI ranges from no difference to substantial advantage for placebo.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | For tricyclic antidepressants, there is no evidence in terms of efficacy as measured with standard clinician-administered rating scales. However, there is evidence in terms of self-rated outcome measures suggesting that tricyclic antidepressants may have a beneficial effect in decreasing symptom severity in adults with PTSD. The confidence in estimate is LOW (fewer than 100 persons included in the analysis, very wide confidence interval ranging from substantial benefit to very little benefit). |
|---|---|
| | There is evidence suggesting that SSRIs as a class are associated with a small but statistically significant beneficial effect in adults with PTSD. The confidence in this estimate is MODERATE. For fluoxetine, the evidence suggests there is unlikely to be a clinically important difference between this SSRI and placebo. The confidence in estimate is LOW. |
| | In terms of functioning and presence of disorder, no evidence is available for tricyclic and SSRI antidepressants nor for fluoxetine specifically. |
| Harms | There is evidence suggesting that acute treatment with tricyclic antidepressants is not associated with more persons leaving the study early, a proxy measure of treatment acceptability. The confidence in estimate is LOW. |
| | There is evidence suggesting that acute treatment with SSRIs is not associated with more persons leaving the study early, a proxy measure of treatment acceptability. The confidence in estimate is LOW. Similarly, evidence suggests that treatment with fluoxetine is not associated with more persons leaving the study early, a proxy measure of treatment acceptability. The confidence in estimate is LOW. |
| | The safety of psychotropics in pregnancy and breastfeeding is not clearly established. For antidepressants, the risks of taking tricyclic antidepressants during pregnancy and when breastfeeding are better established than those of SSRIs and newer drugs. Antidepressants appeared not to be teratogenic, although SSRI exposure in late pregnancy may increase the risk of persistent pulmonary hypertension. |

| Value and preferences | |
| --- | --- |
| In favour | The possibility of lowering PTSD symptoms is an important value. |
| Against | In situations where people are exposed to potentially traumatic stressors, there is the preference to try to address the stressors before initiating biomedical treatment. This may lead to the preference for a stepped care model that may have a psychologically oriented intervention as a first step and, if still needed, antidepressants in a later step. Among psychologically oriented interventions, CBT and EMDR have shown to have a strong beneficial effect in decreasing symptom severity (see Q14). |

| Feasibility (including economic consequences) | Training is required to properly diagnose PTSD. |
| --- | --- |
| | In many low- and middle-income countries, continuous availability of psychotropic drugs in non-specialized health care is a challenge. |
| | Both generic tricyclic antidepressants and many generic selective serotonin re-uptake inhibitors are associated with low acquisition costs. |
| | Amitriptyline (as a representative of the tricyclic antidepressants) and fluoxetine (*not* as a representative of SSRIs) are included in the WHO list of essential medicines for the treatment of depressive disorders. |
| | Amitriptyline is included in the Interagency Emergency Health Kit (IEHK), a box with medicines and medical supplies designed to meet the expected primary health-care needs of people exposed to major humanitarian emergencies. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | Yes<br>**No X** |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

*Recommendation 16*

**Selective serotonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) should not be offered as the first line of treatment for posttraumatic stress disorder in adults.**

**SSRIs and TCAs should be considered if:**

**(a) stress management, CBT with a trauma focus and EMDR have failed or are not available**

or

**(b) if there is co-morbid moderate–severe depression.**

*Strength of recommendation: standard*
*Quality of evidence: low*

## Remarks
*Interactions with other drugs need to be considered and necessary precautions should be taken when prescribing to elderly populations and pregnant or breastfeeding women (see WHO (2010) mhGAP Intervention Guide module on moderate–severe depression).*

# 17. Posttraumatic stress disorder (PTSD): pharmacological interventions – children and adolescents

**Q17. For children and adolescents with posttraumatic stress disorder (PTSD), do antidepressants, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder, or adverse effects?**

## Background on the scoping question

Exposure to potentially traumatic stressors is common. Posttraumatic stress disorder (PTSD) is the most studied disorder after exposure to potentially traumatic events and can be associated with significant impairment in functioning.

Pharmacological treatments, especially antidepressants, are commonly prescribed for people suffering PTSD. However, there is currently no consensus on the effectiveness of pharmacological treatments between different clinical practice guidelines,[48] making this an important scoping question.

The question is limited to those pharmacological treatments that are most likely available now or in the next five years in non-specialized health care in low- and middle-income countries. There is a WHO model list of essential medicines for children and adolescents, and fluoxetine (*not* as a representative of SSRIs) is the only medicine included on this for the treatment of depressive disorders in children older than eight years.

## PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:**      Children and adolescents with PTSD, after the first month of a potentially traumatic event
- **Interventions:**  Antidepressants
- **Comparison:**    Treatment as usual or no treatment/waitlist
- **Outcomes:**
    - Symptom severity post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

---

[48] Forbes, D., Creamer, M., Bisson, J., Cohen, J.A., Crow, B.E., Foa, E., Friedman, M.J., Keane, T.M., Kudler, H.S., Ursano, R.J. (2010). A guide to guidelines for the treatment of PTSD and related conditions. *Journal of Traumatic Stress*, 23(5), 537-552.

## Details of commissioned systematic review

*NOTE: this systematic review was commissioned for a broader set of scoping questions, including pharmacological interventions for people suffering bereavement, PTSD and ASD. For this scoping question, the methodology of the review is presented for all studies, but only the results of studies relevant to children and adolescents with PTSD symptoms are discussed.*

## Types of studies

All double-blind, randomized, placebo controlled and comparative trials completed between October 2005 and October 2011 were considered in our primary and additional searches, covering 13 separate databases. Trials included in the NICE, Cochrane and ANCPTSD reviews were also considered.

Published and unpublished abstracts and reports were sought out in any language. Studies were not excluded on the basis of differences between them such as sample size or duration. Trials in which there was ongoing or newly initiated psychotherapy with a trauma focus or where the experimental medication served as an augmentation agent to ongoing pharmacotherapy were excluded. Trials in which there was ongoing supportive psychotherapy were allowed, provided it was not initiated during the course of the treatment. Open label trials were not considered.

## Types of participants

All studies of subjects with PTSD, ASD or grief reactions. There was no restriction on the basis of different diagnostic criteria for PTSD, duration or severity of PTSD symptoms. There was no restriction on the basis of co-morbid disorders, age or gender of participants.

## Types of interventions

Pharmacological treatments for children and adults with PTSD, ASD or a grief reaction, in which the comparator was a placebo (active or non-active) or other medication.

## Types of outcome measures

The primary outcomes of interest were clinician-administered PTSD symptom severity measures such as the Clinician Administered PTSD Scale (CAPS) and the Treatment Outcome PTSD Scale (TOP-8). Secondary outcomes of interest were remission rates, self-rated PTSD symptom scales such as the Impact of Event Scale (IES) and Davidson Trauma Scale (DTS) and measures of treatment response to co-morbid symptoms such as depression and anxiety (e.g. the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Hamilton Anxiety Scale (HAM-A) and the Covi Anxiety Scale (COV)). Measures of quality of life and functional disability such as the Sheehan Disability Scale (SDS) were also considered. The total number of participants who left the trial early due to any reason was used as a measure of treatment tolerability.

226

## Search strategy

We conducted a primary bibliographic database search of MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. This initial broad search was intended to identify not only the RCTs of interest but other study methodologies and journal reviews of pharmacotherapy for PTSD.

The comprehensive search term used was created by amalgamating the previous search strategies from the NICE, Stein and Australian Guideline reviews with an updated list of medications.

Specific additional searches were carried out to identify international studies in Japanese, Chinese, Spanish and Portuguese (no additional studies identified). In addition, we searched the National PTSD Centre's PILOTS Database, the Cochrane Library, the Controlled Trials Register, Web Of Knowledge, OpenSIGLE and Google Scholar using the term "post traumatic stress disorder" OR "PTSD" OR "post-traumatic stress disorder" OR "posttraumatic stress disorder" AND "treatment" OR "medication" OR "pharmacotherapy" AND "controlled". Reference lists of all selected studies and reviews were further scrutinized for any additional RCTs.

## Study selection

One reviewer transferred the initial search hits into EndNoteX4 software and duplicates were removed. Two reviewers then independently screened the titles and abstracts of RCTs identified from the search. Those that were clearly irrelevant were excluded and potentially relevant studies were then assessed for inclusion as full texts. Any discrepancies between reviewers' decisions were resolved by discussion and guidance from a third senior reviewer.

## Data extraction and risk of bias assessment

One reviewer extracted the details of the studies into a standardized table which was then checked by another reviewer. Details from each study were collected on:

- Study citation, year of publication, location, setting, number of centres, design, sample size, duration and length of follow-up, diagnostic criteria, inclusion and exclusion criteria;
- Characteristics of study participants including gender distribution, mean and range of age, disease severity, duration of PTSD symptoms, presence of co-morbid depression, proportion with combat-related trauma, number randomized into each group, number of drop-outs;
- Characteristics of interventions including mean and maximum doses;
- Outcome measures reported including whether the data represented an intention-to-treat (ITT) or completers-only sample. For ITT samples, the method of imputation was noted.

One reviewer input outcome data into the Cochrane Collaboration's Review Manager 5 software, which was then checked by another reviewer. Data from studies included in previous systematic reviews were extracted by one reviewer and independently cross-checked by a second reviewer for accuracy. Risk of bias was independently assessed for each trial by two reviewers using the domain-based evaluation method

recommended by the Cochrane Collaboration. This method considers the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias. Discrepancies between the two raters were resolved by discussion and arbitrated by a third senior rater. Masked study assessment (hiding details of publishing journal, author, etc.) was not undertaken, since it is unclear whether this reduces bias.

## Data analysis

Review Manager 5 software was used to synthesise data using meta-analysis and to provide forest plots for dichotomous and continuous data. Confidence intervals (CI) of 95% were used for all analyses.

Categorical outcome measures such as leaving the study early were analysed using relative risk (RR) calculations. For continuous data, standardized mean differences (SMD) were used.

The degree of heterogeneity between studies was calculated using the $I2$ statistic. Where the statistic was less than 30%, indicating a mild degree of heterogeneity, a fixed effects model was used. A random effects model was used when the statistic was greater than 30%.

Data were analysed from the ITT sample in the "once randomized always analysed" fashion where possible to avoid effects of bias from completers-only analyses.

## Narrative description of the studies that went into analysis

One study met the inclusion criteria (Robb et al., 2010, *Journal of Child and Adolescent Psychopharmacology*, 20:6, pp. 463-71). In this study children and adolescents (6–17 years old) meeting DSM-IV criteria for PTSD were randomized to 10 weeks of double-blind treatment with sertraline (50–200 mg/day) or placebo. The primary efficacy measure was the University of California, Los Angeles Post-Traumatic Stress Disorder Index for DSM-IV (UCLA PTSD-I). A total of 131 persons met entry criteria and were randomized to sertraline (n=67; female, 59.7%; mean age, 10.8; mean UCLA PTSD-I score, 43.8) or placebo (n=62; female, 61.3%; mean age, 11.2; mean UCLA PTSD-I score, 42.1).

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Pharmacological interventions | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Robb et al. (2010)<br>No data<br>No data<br>Robb et al. (2010) | |

## GRADE table

**Author(s):** Corrado Barbui, Wietse Tol

**Date:** 2012-06-26

**Question:** Should anti-depressants vs placebo be used in children and adolescents with PTSD?

**Bibliography:** Bisson review identified one RCT: Robb et al. (2010)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | SSRIs | Placebo | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | Quality assessment | | | | | | No. of patients | | Effect | | | |
| **Symptom severity** (better indicated by lower values) | | | | | | | | | | | | |
| 1[1] | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness[4] | Serious[5] | None | 67 | 61 | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | CRITICAL |
| **Prevention of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 1 | Randomized trials | Serious[2] | No serious inconsistency[3] | No serious indirectness | Very serious[5,6] | None | 51/67 (76.1%) | 0% | OR 1.02 (0.45 to 2.28) | – | ☐☐☐☐ VERY LOW | IMPORTANT |

[1] Robb et al. (2010): sertraline versus placebo.

[2] 131 patients randomized, but only 129 in the intention-to-treat population, with 30% dropping out in the sertraline sample. Allocation concealment unclear.

[3] Only one study in the analysis.

[4] Children and adolescents (6–17 years) with PTSD.

[5] Only one study in the analysis, with fewer than 200 patients.

[6] Confidence interval ranges from appreciable benefit to appreciable harm.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | The systematic review found only one study, which showed that sertraline was not effective when compared with placebo during 10 weeks of treatment. No evidence is available for the outcomes functioning and presence of disorder. It is therefore uncertain if pharmacological treatment may have a beneficial effect in children and adolescents with PTSD in terms of functioning and presence of disorder. |
|---|---|
| Harms | The systematic review found only one study, which showed that sertraline was a generally safe treatment in children and adolescents with PTSD. However, the evidence base is from one study only, and refers to acute treatment (10 weeks) with no long-term data. It is therefore uncertain how pharmacological treatment compares with placebo in terms of treatment acceptability in the longer term.<br><br>Evidence collected in children with depression highlighted safety and tolerability concerns associated with antidepressant exposure (see mhGAP evidence reviews conducted in 2009).<br><br>In adolescents with depression, in terms of suicide ideas/behaviour, the evidence is inconclusive and so it is not possible to determine if there is a clinically important difference between fluoxetine and placebo (see mhGAP evidence reviews conducted in 2009).<br><br>No data on the long-term consequences of psychotropic drug exposure in children and adolescents are available. |

| Value and preferences | |
|---|---|
| In favour | |
| Against | A widely held preference is that children and adolescents – still in development – should only be exposed to drugs if other effective treatment options have been tried, if the condition is sufficiently severe, if treatment is likely to lead to a substantial improvement in the condition, and if information about long-term consequences is available. |

| Feasibility (including economic consequences) | Training is required to properly diagnose PTSD in children and adolescents with due attention to any cultural variations that may exist.<br><br>In many low- and middle-income countries, continuous availability of psychotropic drugs in non-specialized health care is a |
|---|---|

challenge.

Training is required in the understanding and safe administration of all psychotropic medications.

Both generic tricyclic antidepressants and many generic selective serotonin re-uptake inhibitors are associated with low acquisition costs.

Fluoxetine is included in the WHO list of essential medicines for the treatment of depressive disorders in children above eight years only.

Amitriptyline (for adults) is included in the Interagency Emergency Health Kit (IEHK), a box with medicines and medical supplies designed to meet the expected primary health-care needs of people exposed to major humanitarian emergencies.

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

> ### *Recommendation 17*
> **Antidepressants should not be used to manage PTSD in children and adolescents.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: very low*

**Remarks**
*If there is concurrent moderate–severe depression, also use guidance for helping depressed children and adolescents as included in the WHO (2010) mhGAP Intervention Guide module on depression. There are alternatives to pharmacological treatment (see recommendation 15 on psychological interventions for PTSD in children and adolescents).*

# 18. Bereavement: universally applied structured psychological interventions – adults

**Q18. For bereaved adults *without* a mental disorder, do universally applied structured psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

*Bereavement* is referred to here as the event of a loss of a loved one. In this document, *grief* refers to the psychological reactions in response to bereavement. Loss of loved ones is a common occurrence in life, which for most people will not lead to mental disorder. For a small minority, bereavement and grief may be associated with prolonged symptomatology and impairment in functioning. This scoping question focuses on adults who do *not* meet criteria for a mental disorder, i.e. on interventions that are offered to all bereaved individuals independent of whether or not people score above certain threshold levels of symptoms.

Primary care practitioners often encounter bereaved individuals in their practice, with seemingly little consistency in applied interventions.[49] The increased popularity of "grief work" and bereavement interventions makes this a relevant scoping question.

The scoping question refers to "structured psychological" interventions, i.e. psychological interventions that go beyond general application of psychological principles that are part of health and social care, such as good communication and mobilizing and providing social support (cf. the mhGAP Intervention Guide (2010), p.6). Examples of structural interventions include psychotherapy or a grief counselling intervention involving a series of sessions that encompass psycho-education, efforts to improve coping skills, understanding of death and grief, talking about the deceased and expression of grief-related feelings.

The scoping question focuses on "universally applied" interventions, i.e. interventions applied to all bereaved individuals regardless of the existence of a mental disorder (i.e. delivery without identification).[50]

---

[49] Nagraj, S., Barclay, S. (2011). Bereavement care in primary care: A systematic review and narrative synthesis. *British Journal of General Practice*, DOI: 10.3399/bjgp11X549009.

[50] Advice for recently bereaved people meeting criteria for moderate or severe depression can be found in the depression module of mhGAP (p.10), which advises that antidepressants or psychotherapy should not be considered as first-line treatment of depression if there is recent bereavement or other major loss in the prior two months, but to consider discussion and support of culturally appropriate mourning and reactivation of social networks. This is consistent with the raised concerns about medicalization of normal grief responses (see Friedman, R.A. (2012). Grief, depression and the DSM-5. *New England Journal of Medicine*, 366(20), 1855-7). Also, there has been an ongoing discussion on a separate mental disorder category for prolonged grief disorder, traumatic grief disorder, or complicated bereavement disorder, etc. The category prolonged grief disorder (disabling grief occurring more than six months after the loss) is currently under consideration for inclusion in the ICD-11.

## PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Bereaved adults who do not meet criteria for a mental disorder
- **Interventions:** All universally applied psychological and psychosocial interventions
- **Comparison:** Treatment as usual or no treatment/waitlist
- **Outcomes:**
  - Symptom severity (mainly sub-threshold symptoms) post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## List of systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "bereavement" OR "grief" OR "mourning" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option. We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with adults (>18 years). In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Wittouck, C., Van Autreve, S., De Jaegere, E., Portzky, G., van Heeringen, G. (2011). The prevention and treatment of complicated grief: A meta-analysis. *Clinical Psychology Review*, 31, 69-78
COMMENT: this review covers both prevention and treatment studies. The prevention studies are relevant to the PICO question.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Currier, J.M., Neimeyer, R.A., Berman, J.S. (2008). The effectiveness of psychotherapeutic interventions for bereaved persons: A comprehensive quantitative review. *Psychological Bulletin*, 134(5), 648-661.
REASON FOR EXCLUSION: older than two years.

Currier, J.M., Holland, J.M., Neimeyer, R.A. (2010) Do CBT-based interventions alleviate distress following bereavement? A review of the current evidence. *International Journal of Cognitive Therapy*, 3(1), 77-93.
REASON FOR EXCLUSION: focused only on CBT interventions.

Forte, A.L., Hill, M., Pazder, R., Feudtner, C. (2004). Bereavement care interventions: a systematic review. *BMC Palliative Care*, 3(3), doi:10.1186/1472-684X-3-3.
REASON FOR EXCLUSION: older than two years.

Harvey, S., Snowdon, C., Elbourne, D. (2008). Effectiveness of bereavement interventions in neonatal intensive care: A review of the evidence. *Seminars in Fetal and Neonatal Medicine*, 13, 341-356.
REASON FOR EXCLUSION: older than two years, and focused on a specific sub-group of parents bereaved of a baby in neonatal care.

McDaid, C., Trowman, R., Golder, S., Hawton, K., Sowden, A. (2008). Interventions for people bereaved through suicide: A systematic review. *British Journal of Psychiatry*, 193, 438-443.
REASON FOR EXCLUSION: older than two years, and focused on a specific sub-group of people bereaved through suicide.

Nagraj, S., Barclay, S. (2011). Bereavement care in primary care: A systematic review and narrative synthesis. *British Journal of General Practice*, DOI: 10.3399/bjgp11X549009.
REASON FOR EXCLUSION: does not review evaluations of interventions, but UK primary care practices.

Rowa-Dewar, N. (2002). Do interventions make a difference to bereaved parents? A systematic review of controlled studies. *International Journal of Palliative Nursing*, 8(9), 452-457.
REASON FOR EXCLUSION: older than two years, and methodological limitations in retrieval of evidence.

Stroebe, M., Schut, H., Stroebe, W. (2007). Health outcomes of bereavement. *Lancet*, 370, 1960-1973.
REASON FOR EXCLUSION: older than two years, and review methodology not systematically described.

Szumilas, M., Kutcher, S. (2011). Post-suicide intervention programs: A systematic review. *Canadian Journal of Public Health*, 102(1), 18-29.
REASON FOR EXCLUSION: focused on a specific sub-group of those bereaved through suicide.

United Kingdom Department of Health. Bereavement Care Services: A Synthesis of the Literature. London, UK: DoH.
REASON FOR EXCLUSION: no formal meta-analysis conducted, wide inclusion criteria (also studies focusing on service need/provision issues) and databases searched.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Universal psychological interventions vs. no treatment/control | Symptom severity (mainly sub-threshold) | Wittouck et al. (2011) | Wittouck et al. (2011) is a recent thorough review comparing prevention with no intervention. |
| | | Functioning | No data | |
| | | Presence of disorder | No data | |
| | | Adverse effects | No data | |

## Narrative description of the studies that went into analysis

Wittouck and colleagues' (2011) study identified 14 randomized controlled trials (RCTs), through searching Web of Science and PsycArticles, focused on (a) prevention ($n_{studies}$=9) and (b) treatment of complicated grief ($n_{studies}$=5). As this scoping question concerns adults *without* a mental disorder, only the studies focused on prevention are discussed here. Treatment studies were defined as studies aimed at reducing symptoms of people with pronounced complicated grief.

The nine prevention studies contained preventive interventions ranging from one to 12 sessions. All studies were conducted in high-income countries (five in the USA, one UK, one Australia, one Netherlands, one not reported). These interventions included cognitive-behavioural (individual, family and group) interventions (n=4), writing therapy (n=3), information giving and emotional support (n=1) and brief psychotherapy (n=1). All studies used subjective outcome measures to assess complicated grief, which were shown reliable in all but one of the nine studies, and studies were included if they compared a grief intervention with a control condition or non-specific intervention (i.e. non-grief-focused). Sample size ranged from 42 to 276 participants.

*NOTE:* Currier et al.'s (2008) review was excluded because it was older than two years, in accordance with the WHO Handbook on Guidelines Development. This systematic review included a larger number of studies, and comes to a similar conclusion: "Overall, analyses showed that interventions had a small effect at posttreatment but no statistically significant benefit at follow-up. However, interventions that exclusively targeted grievers displaying marked difficulties adapting to loss had outcomes that compare favorably with psychotherapies for other difficulties. Other evidence suggested that the discouraging results for studies failing to screen for indications of distress could be attributed to a tendency among controls to improve naturally over time. The findings of the review underscore the importance of attending to the targeted population in the practice and study of psychotherapeutic interventions for bereaved persons" (p.648).

*NOTE:* Szumilas & Kutcher (2011) focuses on interventions with people bereaved through suicide. Given that this review focuses on a specific population sub-group it was not included in the GRADE table. It is noted, however, that this systematic review leads to similar conclusions as the other systematic reviews. It identified three RCTs, but only one of these compared treatment to a control group. The latter study evaluated a 10-week broad-spectrum intervention for parents bereaved of children through violent deaths, and found no effects with fathers. Regarding effects found with mothers, it concluded that, "The intervention appeared to be the most beneficial for mothers most distressed at baseline."

## GRADE table

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-02-24
**Question:** Should universal psychological or psychosocial interventions vs treatment as usual or no treatment/waitlist be used for bereaved adults who do not meet criteria for a mental disorder?
**Bibliography:** Wittouck et al. (2011)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Universal psychological or psychosocial interventions | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity: post-intervention** (better indicated by lower values) | | | | | | | | | | | | |
| 8[1] | Randomized trials | Serious[2] | No serious inconsistency | No serious indirectness | No serious imprecision | None | 442 | 334 | – | SMD 0.0 lower (0.19 lower to 0.19 higher) | ⊕⊕⊕⊝ MODERATE | IMPORTANT |
| **Symptom severity: follow-up** (better indicated by lower values) | | | | | | | | | | | | |
| 9[3] | Randomized trials | Serious[4] | No serious inconsistency | No serious indirectness | No serious imprecision | None | 440 | 329 | – | SMD 0.07 higher (0.08 lower to 0.21 higher) | ⊕⊕⊕⊝ MODERATE | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

| Prevention of disorder (better indicated by lower values) | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

| Adverse effects (better indicated by lower values) | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] A total of nine studies assessed the efficacy of preventive grief interventions (p.71 of Wittouck et al., 2011). Of these, eight comparisons were included in the analysis of effect immediately after the intervention (Figure 2 of Wittouck et al., 2011).

[2] Drop-out rates exceeded 30% in one study (O'Connor 2003); in two other studies drop-outs rates were nearly 30% (Kovac & Range, 2000; Sikkema, 2006). In addition, it is unclear if outcome assessment was performed by masked raters.

[3] A total of nine studies assessed the efficacy at follow-up of preventive grief interventions (p.71 of Wittouck et al., 2011 and Figure 2 of Wittouck et al., 2011).

[4] Drop-out rates exceeded 30% in two studies (O'Connor, 2003 and Range, 2000); in two other studies drop-outs rates were nearly 30% (Kovac & Range, 2000; Sikkema, 2006). In addition, it is unclear if outcome assessment was performed by masked raters.

# PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

## Evidence to recommendation table

| Benefits | There is evidence suggesting that universally applied psychological interventions have *no effect* on grief-related symptoms in bereaved adults. The confidence in estimate is MODERATE. <br><br> There is no systematic review of evidence on presence of disorder and functioning for universally applied psychological interventions in bereaved adults. |
|---|---|
| Harms | There is no systematic review of evidence of potential negative consequences from universally applied psychological interventions in bereaved adults. |

| Value and preferences | |
|---|---|
| In favour | Universally applied psychological interventions that involve the delivery of common-sense strategies in people with psychological symptoms (but no mental disorder) in response to bereavement (e.g. providing (a) emotional support through empathic listening with a respectful and non-judgemental attitude and (b) problem-solving) may be low-risk strategies in people who seek help for bereavement-related complaints. |
| Against | It is inappropriate to offer an intervention that has been subject to study but which lacks a positive evidence base. Interventions may contribute to medicalization. |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in more complex psychological interventions would require some resources, including supervision. <br><br> Psychological interventions require time to be delivered, which is important in the context of constrained human resources. |
|---|---|

239

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | **Yes X**<br>No |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | Yes<br>**No X** |

## Final recommendation by the guideline panel

> *Recommendation 18*
> **Structured psychological interventions should *not* be offered universally to (all) bereaved adults who do not meet the criteria for a mental disorder.**
>
> *Strength of recommendation: strong*
> *Quality of evidence: moderate*

**Remarks**
*General principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being) and the principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

# 19. Bereavement: universally applied structured psychological interventions – children and adolescents

**Q19. For bereaved children and adolescents *without* a mental disorder, do universally applied structured psychological interventions, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

*Bereavement* is referred to here as the event of a loss of a loved one. In this document, *grief* refers to the psychological reactions in response to bereavement. Loss of loved ones is a common occurrence in life, which for most children and adolescents will not lead to mental disorders. For a small minority, bereavement and grief may be associated with prolonged symptomatology and impairment in functioning. This scoping question focuses on children and adolescents who do *not* meet criteria for a mental disorder, i.e. on interventions that are offered to all bereaved individuals independent of whether or not people score above certain threshold levels of symptoms.

Primary care practitioners often encounter bereaved children and adolescents in their practice, with seemingly little consistency in applied interventions.[51] The increased popularity of "grief work" and bereavement interventions makes this a relevant scoping question.

The scoping question refers to "structured psychological" interventions, i.e. interventions that go beyond general application of psychological principles that are part of health and social care, such as good communication and mobilizing and providing social support (cf. the mhGAP Intervention Guide (2010), p.6). Examples of structural interventions include psychotherapy or a grief counselling intervention involving a series of sessions that encompass psycho-education, efforts to improve coping skills, understanding of death and grief, talking about the deceased and expression of grief-related feelings (e.g. through talk or drawings).

The scoping question focuses on "universally applied" interventions, i.e. interventions applied with bereaved individuals regardless of the existence of a mental disorder (i.e. delivery without identification).[52]

---

[51] Nagraj, S., Barclay, S. (2011). Bereavement care in primary care: A systematic review and narrative synthesis. *British Journal of General Practice*, DOI: 10.3399/bjgp11X549009.

[52] Advice for recently bereaved children and adolescents meeting criteria for moderate or severe depression can be found in the depression module of mhGAP (p.10), which advises that psychotherapy should not be considered as first-line treatment of depression if there is recent bereavement or other major loss in the prior two months, but to consider discussion and support of culturally appropriate mourning and reactivation of social networks. This is consistent with the raised concerns about medicalization of normal grief responses (see Friedman, R.A. (2012). Grief, depression and the DSM-5. *New England Journal of Medicine*, 366(20), 1855-7) Also, there is currently no consensus on the inclusion of a separate mental disorder category for prolonged grief disorder, traumatic grief disorder or complicated bereavement disorder, etc. The category prolonged grief disorder (disabling grief occurring more than six months after the loss) is currently under consideration for inclusion in the ICD-11.

# PART 1: EVIDENCE REVIEW

## Population/intervention/comparison/outcome (PICO)

- **Population:** Bereaved children and adolescents who do not meet criteria for a mental disorder
- **Interventions:** All universally applied psychological and psychosocial interventions
- **Comparison:** Treatment as usual or no treatment/waitlist
- **Outcomes:**
  - Symptom severity (mainly sub-threshold symptoms) post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

## List of the systematic reviews identified by the search process

The search was conducted in week 28 of 2011 in the following databases: Cochrane Database of Systematic Reviews, PubMed (clinical queries), the Campbell Collaboration, LILACS, psycINFO, Embase and PILOTS. As keywords we used "bereavement" OR "grief" OR "mourning" AND "systematic review". In databases that allowed specifically for selection of systematic reviews and meta-analyses (e.g. PubMed, psycINFO and Embase) we selected this option and used the keywords "bereavement" OR "grief" or "mourning". We included studies if they were systematic reviews of treatment studies published from 2001 onwards that included studies with children and adolescents. In addition, we searched for clinical practice guidelines through Google, the National Guideline Clearinghouse and NICE. Appraisal of quality of systematic reviews was conducted with the use of the Oxford Centre for Evidence-based Medicine's checklist.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Currier, J.M., Holland, J.M., Neimeyer, R.A. (2007). The effectiveness of bereavement interventions with children: A meta-analytic review of controlled outcome research. *Journal of Clinical Child and Adolescent Psychology*, 36(2), 253-59.

*EXCLUDED FROM GRADE TABLES AND FOOTNOTES*

Currier, J.M., Neimeyer, R.A., Berman, J.S. (2008). The effectiveness of psychotherapeutic interventions for bereaved persons: A comprehensive quantitative review. *Psychological Bulletin*, 134(5), 648-661.
REASON FOR EXCLUSION: meta-analysis of children, adolescents and adults together.

Forte, A.L., Hill, M., Pazder, R., Feudtner, C. (2004). Bereavement care interventions: a systematic review. *BMC Palliative Care*, 3(3), doi:10.1186/1472-684X-3-3.

REASON FOR EXCLUSION: meta-analysis of children, adolescents and adults together.

McDaid, C., Trowman, R., Golder, S., Hawton, K., Sowden, A. (2008). Interventions for people bereaved through suicide: A systematic review. *British Journal of Psychiatry*, 193, 438-443.
REASON FOR EXCLUSION: meta-analysis of children, adolescents and adults together, and focused on a specific sub-group of people bereaved through suicide.

Szumilas, M., Kutcher, S. (2011). Post-suicide intervention programs: A systematic review. *Canadian Journal of Public Health*, 102(1), 18-29.
REASON FOR EXCLUSION: meta-analysis of children, adolescents and adults together, and focused on a specific sub-group of people bereaved through suicide.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Psychological interventions vs. no treatment/control | Symptom severity (mainly sub-threshold) Functioning Presence of disorder Adverse effects | Currier, Holland & Niemeyer (2007) No data No data No data | Although older than two years, Currier, Holland & Niemeyer (2007) was the only identified systematic review and meta-analysis including children and adolescents only. |

## Narrative description of the studies that went into analysis

Currier, Holland & Niemeyer (2007) searched PsycINFO, PsychArticles, MEDLINE and Dissertation Abstracts and identified 13 studies meeting inclusion criteria (bereavement intervention vs no treatment, quantitative measures of treatment outcome). The meta-analysis included both randomized and non-randomized controlled studies, with little difference in estimation of effect between these two study types. Six (46%) of the included studies were journal articles and seven (54%) were unpublished dissertations. Twelve out of 13 studies used a group treatment modality (generally 8–9 sessions) and most treatments included psycho-education, efforts to improve coping skills, understanding of death and grief, talking about the deceased and expression of grief-related feelings (e.g. through drawing). Children were generally white, on average 10 years of age, and treatment started on average 1.5 years after the bereavement. Only one of the included studies screened for children showing adjustment difficulties related to grief. Around a third of the studies included measures specifically related to grief (n=4, 31%; only one used a well-established measure), the majority applied general measures of psychiatric symptoms or behavioural disorders. Most studies measured post-intervention, with virtual absence of longer-term follow-up.

## GRADE table

**Author(s):** Corrado Barbui

**Date:** 2012-02-24

**Question:** Should universally applied psychological or psychosocial interventions vs treatment as usual or no treatment/waitlist be used for bereaved children and adolescents who do not meet criteria for a mental disorder?

**Bibliography:** Currier (2007)

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Psychological or psychosocial interventions | Treatment as usual or no treatment/waitlist | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Quality assessment | | | | | No. of patients | | Effect | | | |
| **Symptom severity** (better indicated by higher values) | | | | | | | | | | | | |
| 13[1] | Observational studies[2] | Very serious[2,3] | No serious inconsistency[4] | Serious[5] | No serious imprecision | None | 0[6] | – | – | Cohen's d 0.14 higher (0 to 0.28 higher) | ⊕◯◯◯ VERY LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |

[1] From Table 1 of Currier (2007).

[2] Six of the 13 included studies are not randomized trials.

[3] In three studies drop-out rates exceeded 40% (Table 1 of Currier 2007). In addition, it is unclear if outcome assessment was performed by masked raters.

[4] Forest plot not available. However, it is reported that the effect sizes "appeared to resemble a homogeneous distribution".

[5] The Currier review included both children with and without a mental disorder.

[6] Unclear.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | There is evidence suggesting that universally applied psychological interventions have *no effect* on symptomatology in a mixed group of children and adolescents with and without specific grief-related distress. The confidence in estimate is VERY LOW. The GRADEd systematic review mentions that interventions that screened for distress and were implemented quickly after the bereavement had better effects than universally applied interventions.<br><br>There is no systematic review of evidence on the role of universally applied psychological interventions on overall functioning or mental disorder in bereaved children and adolescents. |
|---|---|
| Harms | There is no systematic review of evidence on potential negative consequences of universally applied psychological interventions in bereaved children and adolescents. |

| Value and preferences | |
|---|---|
| In favour | Universally applied psychological interventions that involve the delivery of common-sense strategies in people in response to bereavement (e.g. providing (a) emotional support through empathic listening with a respectful and non-judgemental attitude and (b) problem-solving) may be low-risk strategies in people who seek help for bereavement-related complaints. |
| Against | It is inappropriate to offer an intervention that has been subject to study but which lacks a positive evidence base. Interventions may contribute to medicalization. |

| Feasibility (including economic consequences) | Most staff in PHC in LMIC have not received extensive training in communication skills and basic emotional support. Any additional training in specific psychological interventions would require some resources, including supervision.<br><br>Psychological interventions require time to be delivered, which is important in the context of constrained human resources. |
|---|---|

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

*Recommendation 19*
**Structured psychological interventions should not be offered universally to (all) bereaved children and adolescents who do not meet the criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**Remarks**
*General principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being) and principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

*In cases where the child has lost a primary caregiver, the issue of protection and continued supportive caregiving, including socio-emotional support, should be addressed.*

# 20. Bereavement: benzodiazepines – adults

**Q20. For bereaved adults _without_ a mental disorder, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

_Bereavement_ is referred to here as the event of a loss of a loved one. In this document, _grief_ refers to the psychological reactions in response to bereavement. Loss of loved ones is a common occurrence in life, which for most people will not lead to mental disorder. For a small minority, bereavement and grief may be associated with prolonged symptomatology and impairment in functioning.

This scoping question focuses on adults who do _not_ meet criteria for a mental disorder.[53] Primary care practitioners often encounter bereaved individuals in their practice, with seemingly little consistency in applied interventions.[54] The popularity of prescribing benzodiazepines in bereaved persons without mental disorder makes this a relevant scoping question.

## PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:** Bereaved adults who do not meet criteria for a mental disorder
- **Interventions:** Benzodiazepines
- **Comparison:** Placebo/active pharmacological treatment
- **Outcomes:**
    - Symptom severity (mainly sub-threshold symptoms) post-intervention and at follow-up
    - Functioning/quality of life post-intervention and at follow-up
    - Presence of mental disorder post-intervention and at follow-up
    - Adverse effects (including tolerability).

---

[53] Advice for recently bereaved people meeting criteria for moderate or severe depression can be found in the depression module of mhGAP (p.10), which advises that antidepressants or psychotherapy should not be considered as first-line treatment of depression if there is recent bereavement or other major loss in the prior two months, but to consider discussion and support of culturally appropriate mourning and reactivation of social networks. This is consistent with the raised concerns about medicalization of normal grief responses (see Friedman, R.A. (2012). Grief, depression and the DSM-5. _New England Journal of Medicine_, 366(20), 1855-7). Also, there has been an ongoing discussion on a separate mental disorder category for prolonged grief disorder, traumatic grief disorder or complicated bereavement disorder, etc. The category prolonged grief disorder (disabling grief occurring more than six months after the loss) is currently under consideration for inclusion in the ICD-11.

[54] Nagraj, S., Barclay, S. (2011). Bereavement care in primary care: A systematic review and narrative synthesis. _British Journal of General Practice_, DOI: 10.3399/bjgp11X549009.

## Details of commissioned systematic reviews
**Two systematic reviews were commissioned to identify studies of benzodiazepines for bereaved adults:**

### (1) Pharmacotherapy for bereaved adults who do not meet criteria for a mental disorder (Bisson systematic review)
*NOTE: this systematic review was commissioned for a broader set of scoping questions, including pharmacological interventions for people suffering bereavement, PTSD and ASD. For this scoping question, the methodology of the review is presented for all studies, but only the results of studies relevant to bereaved adults are discussed. Note that this review goes beyond benzodiazepines.*

### Types of studies
All double-blind, randomized, placebo controlled and comparative trials completed between October 2005 and October 2011 were considered in our primary and additional searches, covering 13 separate databases. Trials included in the NICE, Cochrane and ANCPTMH PTSD reviews were also considered.
Published and unpublished abstracts and reports were sought out in any language. Studies were not excluded on the basis of differences between them such as sample size or duration. Trials in which there was ongoing or newly initiated trauma-focused psychotherapy or where the experimental medication served as an augmentation agent to ongoing pharmacotherapy were excluded. Trials in which there was ongoing supportive psychotherapy were allowed, provided it was not initiated during the course of the treatment. Open label trials were not considered.

### Types of participants
All studies of subjects with PTSD, ASD or grief reactions. There was no restriction on the basis of different diagnostic criteria for PTSD, duration or severity of PTSD symptoms. There was no restriction on the basis of co-morbid disorders, age or gender of participants.

### Types of interventions
Pharmacological treatments for children and adults with PTSD, ASD or a grief reaction, in which the comparator was a placebo (active or non-active) or other medication.

### Types of outcome measures
The primary outcomes of interest were clinician-administered PTSD symptom severity measures such as the Clinician Administered PTSD Scale (CAPS) and the Treatment Outcome PTSD Scale (TOP-8). Secondary outcomes of interest were remission rates, self-rated PTSD symptom scales such as the Impact of Event Scale (IES) and Davidson Trauma Scale (DTS) and measures of treatment response to co-morbid symptoms such as depression and anxiety (e.g. the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Hamilton Anxiety Scale (HAM-A) and the Covi Anxiety Scale (COV)). Measures of quality of life and functional

disability such as the Sheehan Disability Scale (SDS) were also considered. The total number of participants who left the trial early due to any reason was used as a measure of treatment tolerability.

## Search strategy

We conducted a primary bibliographic database search of MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. This initial broad search was intended to identify not only the RCTs of interest but other study methodologies and journal reviews of pharmacotherapy for PTSD.

The comprehensive search term used was created by amalgamating the previous search strategies from the NICE, Stein and Australian Guideline reviews with an updated list of medications.

Specific additional searches were carried out to identify international studies in Japanese, Chinese, Spanish and Portuguese (no additional studies identified). In addition, we searched the National PTSD Centre's PILOTS Database, the Cochrane Library, the Controlled Trials Register, Web Of Knowledge, OpenSIGLE and Google Scholar using the term "post traumatic stress disorder" OR "PTSD" OR "post-traumatic stress disorder" OR "posttraumatic stress disorder" AND "treatment" OR "medication" OR "pharmacotherapy" AND "controlled". Reference lists of all selected studies and reviews were further scrutinized for any additional RCTs.

## Study selection

One reviewer transferred the initial search hits into EndNoteX4 software and duplicates were removed. Two reviewers then independently screened the titles and abstracts of RCTs identified from the search. Those that were clearly irrelevant were excluded and potentially relevant studies were then assessed for inclusion as full texts. Any discrepancies between reviewers' decisions were resolved by discussion and guidance from a third senior reviewer.

## Data extraction and risk of bias assessment

One reviewer extracted the details of the studies into a standardized table which was then checked by another reviewer. Details from each study were collected on:

- Study citation, year of publication, location, setting, number of centres, design, sample size, duration and length of follow-up, diagnostic criteria, inclusion and exclusion criteria;
- Characteristics of study participants including gender distribution, mean and range of age, disease severity, duration of PTSD symptoms, presence of co-morbid depression, proportion with combat-related trauma, number randomized into each group, number of drop-outs;
- Characteristics of interventions including mean and maximum doses;
- Outcome measures reported including whether the data represented an intention-to-treat (ITT) or completers-only sample. For ITT samples, the method of imputation was noted.

One reviewer input outcome data into the Cochrane Collaboration's Review Manager 5 software, which was then checked by another reviewer. Data from studies included in previous systematic reviews were extracted by one reviewer and independently cross-checked by a second reviewer for accuracy. Risk of bias was independently assessed for each trial by two reviewers using the domain-based evaluation method recommended by the Cochrane Collaboration. This method considers the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other sources of bias. Discrepancies between the two raters were resolved by discussion and arbitrated by a third senior rater. Masked study assessment (hiding details of publishing journal, author, etc.) was not undertaken, since it is unclear whether this reduces bias.

## Data analysis
Review Manager 5 software was used to synthesise data using meta-analysis and to provide forest plots for dichotomous and continuous data. Confidence intervals (CI) of 95% were used for all analyses.
Categorical outcome measures such as leaving the study early were analysed using relative risk (RR) calculations. For continuous data, standardized mean differences (SMD) were used.
The degree of heterogeneity between studies was calculated using the I2 statistic. Where the statistic was less than 30%, indicating a mild degree of heterogeneity, a fixed effects model was used. A random effects model was used when the statistic was greater than 30%.
Data were analysed from the ITT sample in the "once randomized always analysed" fashion where possible to avoid effects of bias from completers-only analyses.

## Results
No RCTs of pharmacotherapy for grief reactions were identified.

## (2) Benzodiazepines for bereaved adults who do not meet criteria for a mental disorder (Lindsay Glynn systematic search)
*This review was commissioned to supplement the Bisson et al. review, as the Bisson et al. review only covered studies from 2005.*

## Literature search strategies
Databases searched include MEDLINE, CINAHL, Embase, PsycINFO, Cochrane and Scopus. Relevant articles from all search results were selected to ensure specificity. The reference lists from all relevant articles were hand-searched to locate additional articles, which were added to the final citation list. Supplemental searches in Google Scholar and practice guideline collections yielded no further results.
Terms such as bereavement-related depression, complicated grief, traumatic grief and prolonged grief disorder were noted as relevant topical terms in the literature in addition to the database-specific subject headings. These terms were not searched separately as they were

automatically addressed in searches using the keywords "grief" and "bereavement". Both subject heading searches and keyword searches were utilized to ensure exhaustive results.

Given the limited research in this subject area, no limits (i.e. study type, language, publication year) were applied to any database or article index search. While RCTs and systematic reviews are the preferred publication type, utilizing such limits would have eliminated relevant articles that outlined specific research in commentaries and letters that was not ultimately translated to a full research publication.

MEDLINE (PubMed)
Bereavement [MeSH] exp AND Benzodiazepines [MeSH] exp
benzodiazepines  AND (grief OR grieving OR bereavement OR personal loss)
The *Related Articles* feature was utilized to locate additional articles.

CINAHL
MH Antianxiety Agents, Benzodiazepine+ AND (MH Bereavement+ OR MH Grief+)
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)

Embase
Benzodiazepine Derivative/exp AND (bereavement/exp OR grief/exp)
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)

PsycINFO
DE Benzodiazepine/exp AND (DE Bereavement OR DE Grief)
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)

Cochrane
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss) in Title, Abstract, and keywords

Scopus
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)
*Cited By* feature was utilized to locate additional articles.

## Results
The search identified one study:

Warner, J., Metcalfe, C. & King, M. (2001). Evaluating the use of benzodiazepines following recent bereavement. *British Journal of Psychiatry*, 178(1), 36-41.

*INCLUDED IN GRADE TABLES OR FOOTNOTES*

Warner, J., Metcalfe, C. & King, M. (2001). Evaluating the use of benzodiazepines following recent bereavement. *British Journal of Psychiatry*, 178(1), 36-41.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Benzodiazepines vs. placebo | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | Warner (2001)<br>No data<br>No data<br>Warner (2001) | |

## Narrative description of the studies that went into analysis

Warner (2001) is a randomized double-blind, placebo controlled evaluation of diazepam after recent bereavement. Participants were randomized to either six-week supply of 2 mg diazepam – prescribed within two weeks of bereavement of a spouse or partner – or an identically packaged placebo up to three times daily. Thirty subjects were randomized. No evidence was found of an effect of benzodiazepines on the course of the first six months of bereavement.

## GRADE table

**Author(s):** Corrado Barbui, Wietse Tol
**Date:** 2012-05-08
**Question:** Should benzodiazepines vs placebo be used in bereaved adults who do not meet criteria for a mental disorder?
**Bibliography:** Bisson review; Lindsay Glynn systematic search

| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Benzodiazepines | Placebo | Relative (95% CI) | Absolute | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality assessment** | | | | | | | **No. of patients** | | **Effect** | | | |
| **Symptom severity** (better indicated by higher values) | | | | | | | | | | | | |
| 1[1] | Randomized trials | No serious risk of bias | No serious inconsistency[2] | No serious indirectness | Very serious[3] | None | 16 | 14 | – | MD 0.3 higher (6.2 lower to 6.7 higher) | ⬜⬜⬜⬜ LOW | IMPORTANT |
| **Functioning** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Presence of disorder** (better indicated by lower values) | | | | | | | | | | | | |
| 0 | No evidence available | | | | | None | 0 | – | – | MD 0 higher (0 to 0 higher) | | IMPORTANT |
| **Adverse effects** | | | | | | | | | | | | |
| 1[1] | Randomized trials | No serious risk of bias | No serious inconsistency[2] | Serious[4] | Very serious[3] | None | 4/20 (20%) | 1/15 (6.7%) | OR 3.5 (0.28 to 184) | 133 more per 1000 (from 47 fewer to 863 more) | ⬜⬜⬜⬜ VERY LOW | IMPORTANT |

[1] Warner (2001).
[2] Only one study contributed to this analysis.
[3] Only one trial with fewer than 50 patients. Wide confidence interval.
[4] Total drop-outs are only a proxy measure of adverse effects.

## PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

### Evidence to recommendation table

| Benefits | The evidence is inconclusive, and therefore it is not possible to determine if benzodiazepines are effective in bereaved adults who do not meet criteria for a mental disorder.<br><br>There is no evidence on the effect of benzodiazepines on functioning and presence of disorder. |
|---|---|
| Harms | The evidence is inconclusive, and therefore it is not possible to determine if benzodiazepines are harmful in bereaved adults who do not meet criteria for a mental disorder.<br><br>In addition to the evidence from randomized trials, data from observational and epidemiological studies highlighted a risk of tolerance and dependence. According to NICE UK, one of the key concerns about the use of benzodiazepines is that many people develop tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them (10–30% of chronic benzodiazepines users are physically dependent on them) and suffer a withdrawal syndrome when they stop taking them (50% of all users suffer withdrawal symptoms). The withdrawal syndrome includes anxiety, depression, nausea and perceptual changes.<br><br>There are also problems of abuse with benzodiazepines as they enhance and often prolong the "high" obtained from other drugs and alleviate their withdrawal effects.<br><br>The safety of psychotropic drugs in pregnancy and breastfeeding is not clearly established. In particular, exposure to benzodiazepines during the first trimester is associated with an increased risk of oral clefts, and exposure during the third trimester is associated with neonatal difficulties. |

| Value and preferences | |
|---|---|
| In favour | The possibility of decreasing acute symptomatology that prevents functioning at certain important times (e.g. in flight, organizing a funeral, etc.) and overall psychological distress is an important value. |
| Against | Providing medication for bereavement may contribute to the medicalization of normal psychological reactions and may contribute to dependence. |

| Feasibility (including economic consequences) | Training is required in the understanding and safe administration of all psychotropic medications. To avoid the risks of harm referred to above, training of primary care practitioners would be necessary on responsible use of benzodiazepines. |
| --- | --- |
| | In many LMIC, continuous availability of psychotropic drugs in non-specialized health care is a challenge. |
| | Benzodiazepines are associated with low acquisition costs. |
| | Diazepam (as a representative of the benzodiazepines) is included in the WHO list of essential medicines for the treatment of anxiety disorders. |
| | Diazepam is included in the Interagency Emergency Health Kit (IEHK), a box with medicines and medical supplies designed to meet the expected primary health-care needs of people exposed to major humanitarian emergencies. |

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
| --- | --- |
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

*Recommendation 20*
**Benzodiazepines should not be offered to bereaved adults who do not meet criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**Remarks**
*As mentioned in the remarks for recommendation 18 on psychological interventions for bereaved adults, general principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being) and the principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

# 21. Bereavement: benzodiazepines – children and adolescents

**Q21. For bereaved children and adolescents *without* a mental disorder, do benzodiazepines, when compared to treatment as usual, waiting list or no treatment, result in reduction of symptoms, improved functioning/quality of life, presence of disorder or adverse effects?**

## Background on the scoping question

*Bereavement* is referred to here as the event of a loss of a loved one. In this document, *grief* refers to the psychological reactions in response to bereavement. Loss of loved ones is a common occurrence in life, which for most people will not lead to mental disorder. For a small minority, bereavement and grief may be associated with prolonged symptomatology and impairment in functioning.

This scoping question focuses on children and adolescents who do *not* meet criteria for a mental disorder.[55] Primary care practitioners often encounter bereaved individuals in their practice, with seemingly little consistency in applied interventions.[56] The popularity of prescribing benzodiazepines in bereaved persons without mental disorder makes this a relevant scoping question.

## PART 1: EVIDENCE REVIEW

### Population/intervention/comparison/outcome (PICO)

- **Population:** Bereaved children and adolescents who do not meet criteria for a mental disorder
- **Interventions:** Benzodiazepines
- **Comparison:** Placebo/active pharmacological intervention
- **Outcomes:**
  - Symptom severity (mainly sub-threshold symptoms) post-intervention and at follow-up
  - Functioning/quality of life post-intervention and at follow-up
  - Presence of mental disorder post-intervention and at follow-up
  - Adverse effects (including tolerability).

---

[55] Advice for recently bereaved children and adolescents meeting criteria for moderate or severe depression can be found in the depression module of mhGAP, which advises that psychotherapy should not be considered as first-line treatment of depression if there is recent bereavement or other major loss in the prior two months, but to consider discussion and support of culturally appropriate mourning and reactivation of social networks. This is consistent with the raised concerns about medicalization of normal grief responses (see Friedman, R.A. (2012). Grief, depression and the DSM-5. *New England Journal of Medicine*, 366(20), 1855-7). Also, there is currently no consensus on the inclusion of a separate mental disorder category for prolonged grief disorder, traumatic grief disorder or complicated bereavement disorder, etc. The category prolonged grief disorder (disabling grief occurring more than six months after the loss) is currently under consideration for inclusion in the ICD-11.

[56] Nagraj, S., Barclay, S. (2011). Bereavement care in primary care: A systematic review and narrative synthesis. *British Journal of General Practice*, DOI: 10.3399/bjgp11X549009.

## Details of commissioned systematic reviews

**Two systematic reviews were commissioned to identify studies of benzodiazepines:**

### (1) Pharmacotherapy for bereaved children and adolescents who do not meet criteria for a mental disorder (Bisson systematic review)

*NOTE: this systematic review was commissioned for a broader set of scoping questions, including pharmacological interventions for people with bereavement, PTSD and ASD. For this scoping question, the methodology of the review is presented for all studies, but only the results of studies relevant to bereaved children and adolescents are discussed. Note that this review goes beyond benzodiazepines.*

### Types of studies

All double-blind, randomized, placebo controlled and comparative trials completed between October 2005 and October 2011 were considered in our primary and additional searches, covering 13 separate databases. Trials included in the NICE, Cochrane and ANCPTMH PTSD reviews were also considered.

Published and unpublished abstracts and reports were sought out in any language. Studies were not excluded on the basis of differences between them such as sample size or duration. Trials in which there was ongoing or newly initiated trauma-focused psychotherapy or where the experimental medication served as an augmentation agent to ongoing pharmacotherapy were excluded. Trials in which there was ongoing supportive psychotherapy were allowed, provided it was not initiated during the course of the treatment. Open label trials were not considered.

### Types of participants

All studies of subjects with PTSD, ASD or grief reactions. There was no restriction on the basis of different diagnostic criteria for PTSD, duration or severity of PTSD symptoms. There was no restriction on the basis of co-morbid disorders, age or gender of participants.

### Types of interventions

Pharmacological treatments for children and adults with PTSD, ASD or a grief reaction, in which the comparator was a placebo (active or non-active) or other medication.

### Types of outcome measures

The primary outcomes of interest were clinician-administered PTSD symptom severity measures such as the Clinician Administered PTSD Scale (CAPS) and the Treatment Outcome PTSD Scale (TOP-8). Secondary outcomes of interest were remission rates, self-rated PTSD symptom scales such as the Impact of Event Scale (IES) and Davidson Trauma Scale (DTS) and measures of treatment response to co-morbid symptoms such as depression and anxiety (e.g. the Hamilton Depression Scale (HAM-D), Montgomery-Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Hamilton Anxiety Scale (HAM-A) and the Covi Anxiety Scale (COV)). Measures of quality of life and functional disability such as the Sheehan Disability Scale (SDS) were also considered. Total number of participants who left the trial early due to any reason was used as a measure of treatment tolerability.

261

## Search strategy

We conducted a primary bibliographic database search of MEDLINE, Medline In-Process, Embase, HMIC, PsycINFO, ASSIA and CINAHL using the Ovid interface. This initial broad search was intended to identify not only the RCTs of interest but other study methodologies and journal reviews of pharmacotherapy for PTSD.

The comprehensive search term used was created by amalgamating the previous search strategies from the NICE, Stein and Australian Guideline reviews with an updated list of medications.

Specific additional searches were carried out to identify international studies in Japanese, Chinese, Spanish and Portuguese (no additional studies identified). In addition, we searched the National PTSD Centre's PILOTS Database, the Cochrane Library, the Controlled Trials Register, Web Of Knowledge, OpenSIGLE and Google Scholar using the term "post traumatic stress disorder" OR "PTSD" OR "post-traumatic stress disorder" OR "posttraumatic stress disorder" AND "treatment" OR "medication" OR "pharmacotherapy" AND "controlled". Reference lists of all selected studies and reviews were further scrutinized for any additional RCTs.

## Study selection

One reviewer transferred the initial search hits into EndNoteX4 software and duplicates were removed. Two reviewers then independently screened the titles and abstracts of RCTs identified from the search. Those that were clearly irrelevant were excluded and potentially relevant studies were then assessed for inclusion as full texts. Any discrepancies between reviewers' decisions were resolved by discussion and guidance from a third senior reviewer.

## Data extraction and risk of bias assessment

One reviewer extracted the details of the studies into a standardized table which was then checked by another reviewer. Details from each study were collected on:

- Study citation, year of publication, location, setting, number of centres, design, sample size, duration and length of follow-up, diagnostic criteria, inclusion and exclusion criteria;
- Characteristics of study participants including gender distribution, mean and range of age, disease severity, duration of PTSD symptoms, presence of co-morbid depression, proportion with combat-related trauma, number randomized into each group, number of drop-outs;
- Characteristics of interventions including mean and maximum doses;
- Outcome measures reported including whether the data represented an intention-to-treat (ITT) or completers-only sample. For ITT samples, the method of imputation was noted.

One reviewer input outcome data into the Cochrane Collaboration's Review Manager 5 software, which was then checked by another reviewer. Data from studies included in previous systematic reviews were extracted by one reviewer and independently cross-checked by a second reviewer for accuracy. Risk of bias was independently assessed for each trial by two reviewers using the domain-based evaluation method recommended by the Cochrane Collaboration. This method considers the following domains: random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessment; incomplete outcome data; selective reporting; and other

sources of bias. Discrepancies between the two raters were resolved by discussion and arbitrated by a third senior rater. Masked study assessment (hiding details of publishing journal, author, etc.) was not undertaken, since it is unclear whether this reduces bias.

## Data analysis

Review Manager 5 software was used to synthesise data using meta-analysis and to provide forest plots for dichotomous and continuous data. Confidence intervals (CI) of 95% were used for all analyses.

Categorical outcome measures such as leaving the study early were analysed using relative risk (RR) calculations. For continuous data, standardized mean differences (SMD) were used.

The degree of heterogeneity between studies was calculated using the I2 statistic. Where the statistic was less than 30%, indicating a mild degree of heterogeneity, a fixed effects model was used. A random effects model was used when the statistic was greater than 30%.

Data was analysed from the ITT sample in the "once randomized always analysed" fashion where possible to avoid effects of bias from completers-only analyses.

## Results

No RCTs of pharmacotherapy for grief reactions were identified.

## (2) Benzodiazepines for bereaved children and adolescents who do not meet criteria for a mental disorder (Lindsay Glynn systematic search)

*This review was commissioned to supplement the Bisson et al. review, as the Bisson et al. review only covered studies from 2005.*

## Literature search strategies

Databases searched include MEDLINE, CINAHL, Embase, PsycINFO, Cochrane and Scopus. Relevant articles from all search results were selected to ensure specificity. The reference lists from all relevant articles were hand-searched to locate additional articles, which were added to the final citation list. Supplemental searches in Google Scholar and practice guideline collections yielded no further results.

Terms such as bereavement-related depression, complicated grief, traumatic grief and prolonged grief disorder were noted as relevant topical terms in the literature in addition to the database-specific subject headings. These terms were not searched separately as they were automatically addressed in searches using the keywords "grief" and "bereavement". Both subject heading searches and keyword searches were utilized to ensure exhaustive results.

Given the limited research in this subject area, no limits (i.e. study type, language, publication year) were applied to any database or article index search. While RCTs and systematic reviews are the preferred publication type, utilizing such limits would have eliminated relevant articles that outlined specific research in commentaries and letters that was not ultimately translated to a full research publication.

MEDLINE (PubMed)
Bereavement [MeSH] exp AND Benzodiazepines [MeSH] exp
benzodiazepines  AND (grief OR grieving OR bereavement OR personal loss)

The *Related Articles* feature was utilized to locate additional articles.

CINAHL
MH Antianxiety Agents, Benzodiazepine+ AND (MH Bereavement+ OR MH Grief+)
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)

Embase
Benzodiazepine Derivative/exp AND (bereavement/exp OR grief/exp)
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)

PsycINFO
DE Benzodiazepine/exp AND (DE Bereavement OR DE Grief)
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)

Cochrane
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss) in Title, Abstract, and keywords

Scopus
benzodiazepine* AND (grief OR griev* OR bereavement OR personal loss)
*Cited By* feature was utilized to locate additional articles.

## Results
No RCTs of pharmacotherapy for grief reactions were identified.

## PICO table

| Serial no. | Intervention/comparison | Outcomes | Systematic reviews used for GRADE | Explanation |
|---|---|---|---|---|
| 1 | Benzodiazepines vs. no treatment/control | Symptom severity<br>Functioning<br>Presence of disorder<br>Adverse effects | No data<br>No data<br>No data<br>No data | |

# PART 2: FROM EVIDENCE TO RECOMMENDATION(S)

## Evidence to recommendation table

| Benefits | There is no evidence on the benefit of benzodiazepines for bereaved children and adolescents who do not meet criteria for a mental disorder with regard to symptom severity, presence of disorder or functioning. |
|---|---|
| Harms | There is no evidence on the harms of benzodiazepines for bereaved children and adolescents who do not meet criteria for a mental disorder.<br><br>In addition to the evidence from randomized trials, data from observational and epidemiological studies – mostly with adult populations – highlighted a risk of tolerance and dependence. According to NICE UK, one of the key concerns about the use of benzodiazepines is that many people develop tolerance to their effects, gain little therapeutic benefit from chronic consumption, become dependent on them (10–30% of chronic benzodiazepines users are physically dependent on them) and suffer a withdrawal syndrome when they stop taking them (50% of all users suffer withdrawal symptoms). With regard to children and adolescents, very few rigorous studies have been conducted but dependency risks have been similarly reported (Witek et al., 2005, *Psychiatric Quarterly*, 76).<br><br>The withdrawal syndrome includes anxiety, depression, nausea and perceptual changes.<br><br>There are also problems of abuse with benzodiazepines as they enhance and often prolong the "high" obtained from other drugs and alleviate their withdrawal effects. |

| Value and preferences | |
|---|---|
| In favour | |
| Against | Children and adolescents – still in development – should only be exposed to drugs if other effective treatment options have been tried, if the condition is sufficiently severe and treatment is likely to lead to a substantial improvement and if information about long-term consequences is available.<br><br>Providing medication for bereavement may contribute to the medicalization of normal psychological reactions and may contribute to dependence. |

| Feasibility (including economic consequences) | Training is required in the understanding and safe administration of all psychotropic medications. To avoid the risks of harm referred to above, training of primary care practitioners may be necessary on responsible use of benzodiazepines.<br><br>In many LMIC settings, continuous availability of psychotropic drugs in non-specialized health care is a challenge. |

265

## Judgements to inform the decision on the strength of the recommendation

| Factor | Decision |
|---|---|
| **Is there high- or moderate-quality evidence?**<br>*The higher the quality of evidence, the more likely is a strong recommendation.* | Yes<br>**No X** |
| **Is there certainty about the balance of benefits versus harms and burdens?**<br>*In the case of positive recommendations (a recommendation to do something), do the benefits outweigh harms?*<br>*In the case of negative recommendations (a recommendation not to do something), do the harms outweigh benefits?* | **Yes X**<br>No |
| **Are the expected values and preferences clearly in favour of the recommendation?** | **Yes X**<br>No |
| **Is there certainty about the balance between benefits and resources being consumed?**<br>*In the case of positive recommendations (recommending to do something) is there certainty that the benefits are worth the costs of the resources being consumed?*<br>*In the case of negative recommendations (recommending not to do something) is there certainty that the costs of the resources being consumed outweigh any benefit gained?* | **Yes X**<br>No |

## Final recommendation by the guideline panel

*Recommendation 21*

**Benzodiazepines should not be offered to bereaved children and adolescents who do not meet criteria for a mental disorder.**

*Strength of recommendation: strong*
*Quality of evidence: very low*

**Remarks**

*As mentioned in the remarks for recommendation 19 on psychological interventions for bereaved children and adolescents, general principles of care, as reported in the WHO (2010) mhGAP Intervention Guide (particularly principles on communication, mobilizing and providing social support, and attention to overall well-being) and principles of psychological first aid should be considered. Encourage participation in culturally appropriate mourning.*

*In cases where the child has lost a primary caregiver, the issue of protection and continued supportive caregiving, including socio-emotional support, should be addressed.*